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Abstract 
CD83 is well known as a surface marker for mature dendritic cells (DC). It is also 
expressed on activated T- and B-cells. Graft-versus-host disease (GVHD) is mediated by 
T cells and is a major complication of allogeneic haematopoietic stem cell transplantation 
(alloHSCT). CD83 represents an intriguing drug target for GVHD as our group has shown 
that anti-CD83 antibody (anti-CD83) prevents GVHD in a human peripheral blood 
mononuclear cell (PBMC) xenograft model and in a full murine alloHSCT model. It has the 
potential to preserve the desired graft-versus-leukaemia (GVL) effect in alloHSCT due to 
its preferential expression on activated DC rather than T cells.  In vitro, anti-CD83 lyses 
activated DC by natural killer (NK) cell mediated antibody dependent cellular cytotoxicity 
(ADCC). Since anti-CD83 should also target CD83+ B-cells, the antibody may affect 
humoral immunity. This thesis examines (i) a potential additional mechanism in which anti-
CD83 induces degradation of MHC II and CD86 on activated antigen presenting cells 
(APC) resulting in reduced T-cell activation; (ii) anti-CD83 mediated inhibition of thymus 
dependent humoral immune responses; and (iii) anti-CD83 mediated stimulation of thymus 
independent type 2 humoral immune responses. 
 
To investigate a potential non-ADCC mechanism for anti-CD83, HEK293T cells 
were transiently transfected with vectors encoding murine MHCII, the ubiquitin ligase 
MARCH1 which is associated with MHCII and CD86 degradation in APC, and CD83. The 
effects of anti-CD83 on MHCII and CD86 expression and on APC stimulated CD4 T-cells 
were also investigated. My results showed that CD83 antibody did not induce a significant 
reduction in MHCII expression in the transfected HEK293 cells. However, in primary 
murine splenocytes, anti-CD83 significantly reduced MHCII expression in APC but did not 
decrease CD4+ T-cell proliferation in both the allogeneic mixed lymphocyte reaction 
(alloMLR) and specific antigen presentation assays. Ubiquitination assays demonstrated 
that MHCII is ubiquitinated in splenocytes treated with anti-CD83 but there was no 
difference compared to negative control treatment.  
 
The effects of anti-CD83 on humoral immunity were investigated in human models. 
To characterize CD83 antibody mediated inhibition of human antigen specific B cell 
responses, carboxyfluorescein succinimidyl ester (CFSE)-labelled human PBMC were 
cultured with the recall antigen tetanus toxoid (TT). The mechanism of anti-CD83 was 
determined in alloMLR and cell depletion assays. Cytokine expression in antigen-specific 
T and B cell stimulation assays were assessed by Bio-plex, ELISA and flow cytometry. 
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CD83 expression on B cell subsets and kinetics of CD83 expression by B cells in human 
PBMC was also determined by flow cytometry. To determine if anti-CD83 can inhibit 
antigen specific B-cell responses in vivo, I used a TT vaccine to immunize SCID mice that 
had been pre-engrafted with human PBMC. In vitro, I found that anti-CD83 suppressed TT 
stimulated proliferation of CD4 T cells and B cells without depleting non-proliferating cells. 
Anti-CD83 inhibited immunoglobulin expression in the MLR by ADCC through NK cells. 
This mechanism was also suggested by the effects of NK cell depletion in anti-CD83 
treated TT stimulated cultures. Unexpectedly, depletion of DC and B cells did not abolish 
the effects of anti-CD83 on the proliferation of T- and B-cells although they were reduced 
in the absence of DC. Importantly, the levels of the autoimmune disease associated 
cytokines interferon-gamma (IFN-γ), granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and IL-17A were significantly reduced by anti-CD83. In vivo, anti-CD83 
inhibited the TT specific IgG response to TT vaccination without affecting circulating total 
human IgG levels. To investigate reports of increased murine IgG responses to anti-CD83, 
mice were immunized with TI-2 antigens: TNP-Ficoll and Pneumovax-23 in order to study 
the effect of anti-CD83 on TI-2 antibody responses. In vitro, dextran (αδ-dex) was used as 
a polyclonal B cell receptor stimulator to investigate proliferation and isotype switching in 
TI-2 responses. Sera from mice and culture supernatants were collected for ELISA 
analysis. Anti-CD83 substantially enhanced IgG responses to TNP-Ficoll immunization but 
only minimally enhanced Pneumovax-23 IgG responses. In vitro, anti-CD83 significantly 
increased B-cell proliferation in splenocytes, but decreased it in peritoneal cells (PC). 
Furthermore, total IgM, IgG1 and IgG3 levels were significantly higher in anti-CD83 treated 
splenocyte cultures, but were lower in the anti-CD83 treated PC cultures. This suggests 
that B-cell subsets may play a different role with anti-CD83, as the majority of B cells in PC 
are B-1 cells whereas splenocytes are predominantly B-2. 
 
In summary, the mechanism of action of anti-CD83 in preventing GVHD in fully 
murine alloHSCT is unknown and ADCC remains the likely mechanism in human systems. 
I found that anti-CD83 inhibits human B-cell responses and may have a potential clinical 
role in autoimmunity and graft rejection. I showed that anti-CD83 may have advantages 
over rituximab which is used currently in these conditions. Despite its minimal effect on 
Pneumovax-23 vaccination, my confirmation of its strong effects on TNP-Ficoll responses 
indicate that further work should be done to understand how anti-CD83 might be used to 
enhance responses to TI-2 vaccines. 
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Chapter 1: Literature Review 
 
1.1 CD83 
1.1.1 Introduction 
CD83 is a 45-KD, type-1 transmembrane glycoprotein belonging to the 
immunoglobulin (Ig) superfamily [1]. Human and mouse CD83 are well conserved with 
approximately 63% homology at the amino acid level [1]. CD83 is expressed at the surface 
of the most potent antigen presenting cells (APC), dendritic cells (DC) and is strongly 
upregulated during the maturation of DC [2, 3]. Other than DC, activation of monocytes 
and macrophages has also been reported to induce rapid surface expression of CD83. In 
contrast to DC, surface expression on those cell types is short term with CD83 completely 
vanishing from the surface after 8-24hrs [4]. In addition to mature DC expressing CD83, T-
cells, granulocyte-precursor cells, myelocytes, neutrophils and murine thymus epithelial 
cells express the CD83 surface molecule under steady state conditions [5]. Furthermore, 
CD83 expression was also detected on Hodgkin’s lymphoma cells [6] and Epstein-Barr 
Virus transformed lymphoblastoid cell lines [7]. In the mouse, thymic epithelial cells 
express CD83, which is required for CD4+ T-cell development [8, 9] as demonstrated by  
CD83-/- mice having a 68% reduction in CD4 single-positive thymocytes and a 75-90% 
reduction in peripheral CD4+ T cells [8]. Surface expression of CD83 is positively 
correlated with CD86 and major histocompatibility complex II (MHCII) expression in 
activated murine B-cells and DC [8, 10, 11]. The activation-induced surface expression of 
other co-stimulatory molecules such as CD80, CD40 or MHC-I is unchanged in CD83 
transgenic and CD83-deficient APC [10].  
 
Several lines of evidence suggest that CD83 regulates thymic T cell maturation and 
peripheral T cell activation in mice [8, 9, 12-19]. Breloer et al., 2007 first showed that CD83 
is expressed on murine B cells upon activation and is involved in the regulation of humoral 
immune responses [20]. They found that during an ongoing infection with Leishmania 
major or Trypanosoma cruzi, B cells and not DC are the dominant CD83 positive cell 
population in the lymph nodes draining the site of infection. A year later, Breloer et al. 
showed that CD83 functions as a negative regulator of activation, maturation and 
homeostasis [21]. CD83 expression is rapidly upregulated on B cells after either Toll-Like 
receptor 4 (TLR4) engagement by lipopolysaccharides (LPS) or B cell receptor (BCR) 
ligation [10]. BCR-engagement alone is sufficient to induce upregulation of CD83 whereas 
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addition of either IL-4 or anti-CD40 antibody (Ab) as costimulators induces increased and 
prolonged CD83 expression on B cells [10]. Kretschmer et al., 2011 reported that CD83 is 
a very sensitive and early activation marker of B cells that is upregulated not only upon B 
cell activation by TLR or BCR but also induced by the presence of activated T cells [22]. In 
another study, Kretschmer et al., 2009 showed that administration of CD83-specific Ab 
enhances Ig production in response to thymus independent type-2 (TI-2) antigen 
immunization [23]. However, a recent report by Uhde et al., 2013 found that CD83 
differentially regulates marginal zone (MZ) and follicular (FO) B cell responses by 
modulating BCR and TLR signalling [24]. In this case, CD83 functions as a general 
counter-regulator that dampens otherwise overwhelming immune responses. For example, 
CD83 directly inhibits BCR signalling leading to insufficient activation signals and reduced 
survival of follicular B cells and results in termination of B cell responses. On the other 
hand, CD83 enhances TLR-mediated IL-10 production in MZ B cells, DC and maybe other 
TLR-expressing cells and thereby increasing inflammatory immune responses [24]. 
 
1.1.2 Different forms of CD83 
Two isoforms of CD83 have been identified in vivo: a membrane bound form 
(mCD83) [2]  and a naturally occurring soluble form (sCD83) in man [25]. Each form has 
unique roles and functions in the immune system. mCD83 contains an extracellular Ig-like 
V domain at the N terminus, a short intracellular cytoplasmic domain of 39 amino acids, 
and one transmembrane domain [2]. sCD83 is thought to contain only the extracellular Ig-
like domain and may be generated by proteolytic cleavage of mCD83 from activated DC 
and B cells [25]. The presence of mCD83 on DC is correlated with increased stimulation of 
T cells [26-28], whereas sCD83 impairs DC-induced T cell activation [13, 18, 29]. 
 
1.1.2.1 Functions of mCD83 
 Functions of mCD83 are divided into extra-thymic and intra-thymic. Outside the 
thymus, it has been claimed that CD83 has a specific role during the induction of T-
lymphocytes [15, 30] and engagement with CD83 provides a signal that specifically 
supports the expansion of newly primed naïve CD8+ T-cells, enhancing the in vitro 
generation of cytotoxic T lymphocytes (CTL) [19]. Studies showed that the loss of CD83 
led to a strong reduction of the T cell stimulatory capacity of DC, suggesting mCD83 acts 
as an enhancer during T-cell activation [28, 31]. The most recent study by Pinho et al, 
2014 found that DC mCD83 enhances immune responses by boosting intracellular calcium 
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release in T lymphocytes [32]. Scholler et al., 2001 [15] and Yang et al., 2004 [16] have 
shown that CD83 is involved in the induction of anti-tumour immunity. In the thymus, 
mCD83 has an effect on the development of thymocytes [5]. The two functions are 
summarized in Figure 2-1 and 2-2. 
 
 
 
Figure 1-1: Summarized functions of membrane-bound CD83. CTL cytotoxic T-cells, 
mCD83 membrane bound CD83, MLR mixed leukocyte reaction. (Reprinted from Prechtel 
et al., 2007) [5]  
 
1.1.2.1.1 The effect of mCD83 on posttranslational processing of MHCII 
To date, CD83 ligands (CD83L) remain a mystery as no specific ligands have been 
identified. Further, the mechanism by which CD83 modulates the immune response is 
unknown. In 2001 Lechmann et al. reported that a CD83-like ligand may be present on DC 
and inhibit DC-mediated T cell stimulation by binding with the extracellular domain of 
CD83 [13]. While the ligands that bind to CD83 have not yet been characterized, 
numerous studies suggest that CD83 and the putative CD83L may play a role in 
intercellular communications involving DC, activated T and B cells [19, 21, 30]. Also, to 
identify CD83L, a recent study by Ramani et al., 2012 discovered homotypic binding of 
CD83 using a secreted protein microarray platform, but not other Ig proteins were spotted 
onto the arrays [33]. Tze et al., 2011 found that the transmembrane (TM) domain of CD83 
enhances MHCII and CD86 expression by blocking MHCII association with the ubiquitin 
ligase membrane associated RING-CH (MARCH-1). They demonstrated that CD83 
promotes surface display of MHCII by opposing its association with MARCH1 and 
ubiquitination provides a mechanistic explanation for the accelerated turnover of cell 
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surface MHCII and CD86 molecules in cells lacking the CD83 TM region. In the presence 
of IL-10 and LPS, MARCH1 mRNA remains high and due to these conditions CD83 TM 
provides a potent posttranslational mechanism to promote MHCII and CD86 display [34] 
(Figure 1-3).  In contrast, Kuwano et al. 2007 showed that CD83 deficiency did not disrupt 
MHCII folding, peptide antigen binding to class II molecules nor did it significantly alter 
class II ubiquitination [11]. It is possible that the difference between these two studies was 
due to the two different CD83 mutations used. Tze et al. showed that the N-ethyl-N-
nitrosourea (ENU) induced mutation in Anubis mice resulted in a CD83 gene product with 
no CD83 TM region but the cytoplasmic and extracellular domains (ECD) remained. There 
was weak but clear CD83 ECD protein expression in the intracellular compartment when 
activated by LPS. Lin et al., 2014 reported that synthetic soluble human CD83 ECD 
significantly downregulates MHCII and CD86 in human monocyte derived DC at 48hrs 
post-stimulation with LPS [35]. As human soluble CD83 inhibits murine immune responses 
same as it inhibits human immune responses [17], the soluble CD83 ECD protein product 
in Anubis mice, perhaps if secreted, may similarly inhibit the surface display of MHCII and 
CD86. Kuwano et al. 2007 used the methods of Fujimoto et al. where the deleted DNA 
removed half the Ig-like domain of the CD83 ECD and also the entire TM and cytoplasmic 
domains. Fujimoto ran a reverse transcribed polymerase chain reaction (PCR) and 
showed there was no CD83 gene present in CD83-/- mice. This suggests that there was no 
CD83 protein product that might retain some functional activity. 
 
As MHCII expression relates to antigen presentation, in chapter 4 of this thesis I 
investigated if anti-CD83 antibody binding to mCD83 decreased MHCII display, thus 
reducing antigen presentation. Anti-CD83 may block CD83 upregulation on DC during 
activation causing internalization (ie. downregulation) [36] for which there are many 
precedents (eg. CD71 [37]), or it might mimic the action of a ligand for CD83.   
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Figure 1-2: CD83 pathway regulates surface display of MHC II and CD86 on DC. CD83 
mRNA is induced by TLR signalling, and MARCH1 mRNA is induced by IL-10 and 
diminished by TLR signalling. CD83 TM binds to MARCH1, causing a reduction in 
MARCH1 association with the T TM segments of MHCII or CD86 and thus preventing 
ubiquitination of lysines in their cytoplasmic tails by the MARCH1 RING-CH domain, 
resulting in increased MHCII or CD86 surface display.  (Reprinted from Tze et al., 2011) 
[34] 
 
1.1.2.2 Functions of sCD83 
A soluble form of CD83 is released from DC and B lymphocytes either as a result of 
shedding from the cell surface or alternative splicing, during  differentiation and activation 
of these populations and the concentration of sCD83 is increased during DC maturation 
[25]. Lechmann et al., 2002 suggested that sCD83 might induce a maturation block in DC 
and therefore might control and down-modulate the immune response in vivo [38]. Due to 
its immune inhibitory function, sCD83 has great potential for the treatment of autoimmune 
diseases, preventing rejection in organ transplantations, and for immunotherapy [5]. Starke 
et al., 2013, who have shown that injection of sCD83 into NZB/W mice can suppress T and 
B cell activation and as a consequence the formation of autoantibodies [39]. Bock et al., 
2013 reported that sCD83 induces long-lasting allogeneic corneal graft tolerance in 
combination with a locally restricted immunosuppressive environment, mediated by the 
induction of regulatory T cells [40]. In addition, in experimental models sCD83 prevents 
cardiac [41], renal [42] and allograft rejection and the development of experimental 
autoimmune encephalomyelitis (EAE) [17]. 
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Figure 1-3: Summarized functions of soluble CD83. sCD83- soluble CD83, EAE-
experimental autoimmune encephalomyelitis. (Reprinted from Prechtel et al., 2007)  [5] 
 
 In summary, mCD83 and sCD83 play different roles in immune responses. The 
balance of mCD83 and sCD83 may be important for immune homeostasis. To date, no 
CD83 ligand has been identified and the molecular mechanism of mCD83-mediated 
immune stimulation and sCD83 mediated inhibition remain unclear. A study of the 
mechanism of action of anti-CD83 may provide additional insights into the role of CD83 in 
immunoregulation.  
 
1.2 The impact of anti-CD83 on graft-versus-host disease (GVHD) in haematopoietic 
stem cell transplantation (HSCT) 
1.2.1 Introduction 
HSCT was originally conceived more than 50 years ago as a treatment for injury 
from irradiation and later for blood cancers [43, 44]. HSCT is at the nexus between three 
promising areas of current clinical research: stem cell therapies, immune-modulating 
techniques and the individualization of cancer therapeutics [45]. Bone marrow is a rich 
source of hematopoietic stem cells [46, 47]. Furthermore, haematologic cells can initiate 
immune reactions that may complicate transplantation [47].  
 
 HSCT can be autologous (stem cells from the recipients themselves), syngeneic 
(stem cells from a genetically identical donor, eg. identical twin), or allogeneic (allo) (stem 
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cells from a genetically distinct donor). Autotransplantation was applied successfully to 
treat many other diseases and is now used more often than allotransplantation/alloHSCT. 
Because autotransplantation does not induce GVHD, it can be used in older patients. 
Although the mortality is considerably lower with autotransplantation and syngeneic 
transplantation than with allotransplantation, the absence of graft-versus-leukaemia (GVL) 
activity in autotransplantation reduces its effectiveness [47].  
 
 AlloHSCT became feasible in the early 1960s, after the identification of HLA 
(human leukocyte antigens), encoded by the major histocompatibility complex (MHC)) and 
the development of HLA typing [45, 47]. Allogeneic grafts initiate immune reactions related 
to their histocompatibility mismatch. The severity of the reaction depends on the degree of 
incompatibility, which is determined by a complex biology in which polymorphic MHC class 
I and class II HLA cell-surface glycoproteins bind small peptides from degraded proteins 
[47]. AlloHSCT is an effective adoptive cellular immunotherapy that was primarily used for 
haematologic cancers [46]. In alloHSCT, recipient T cells recognize foreign donor antigens 
and can reject the graft while donor T cells recognize recipient antigens and can cause 
GVHD and GVL effects [47]. The use of unrelated donors has increased, and the rates of 
success of such procedures have improved as better methods of gene definition (such as 
genotyping) and matching have been developed. These methods involve DNA typing to 
identify HLA alleles and determine the most closely matched donor. The use of a closely 
matched donor increases the chances of successful engraftment and also reduces the risk 
of GVHD while maintaining GVL [48]. 
AlloHSCT results in more cures and remissions than alternative treatments for 
advanced haematopoietic malignancies but also causes greater morbidity and mortality. 
About 40% of patients who undergo allogeneic transplantation die from complications 
related to transplantation, including GVHD, infections and recurrence of the malignancy 
[47]. Therefore it is critical to reduce the complications and improve the safety of 
transplantation. 
1.2.2 Complications 
 HSCT is associated with treatment-related mortality in the recipient. The major 
complications are failure to engraft, infection, veno-occlusive disease of the liver, 
mucositis, GVHD, immunosuppression and disease relapse [49]. 
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1.2.2.1 Graft-versus-Host Disease (GVHD) 
Despite improvements in our understanding of GVHD pathophysiology as well as 
the generation of new monoclonal antibodies, immunomodulatory chemotherapy, cellular 
therapeutics and supportive care, GVHD remains the major barrier to successful 
allogeneic HSCT. GVHD is divided into acute and chronic forms. Acute GVHD (aGVHD) 
develops within 2-10 weeks of allogeneic HSCT [50]. Clinically relevant grade II to IV 
aGVHD occurs in approximately 20% to 50% of patients who receive stem cells from an 
HLA-identical sibling donor and in 50% to 80% of those who receive stem cells from HLA-
mismatched sibling or from an HLA-identical unrelated donor. Dermatitis, hepatitis, and 
enteritis characterize aGVHD [51]. Chronic GVHD (cGVHD) occurs in less than 50% of 
long term survivors. It is a late developing and complex complication, the onset of disease 
is most frequently from 3-6 months after hematopoietic engraftment [51]. In approximately 
20% of the cases, there is no evidence of previous aGVHD [50]. In comparison with 
aGVHD, cGVHD is much more poorly characterized and understood. cGVHD can affect 
nearly any organ system and its manifestations typically resemble those of classical 
autoimmune diseases, such as lupus, Sjogren syndrome and systemic sclerosis [52]. 
. 
1.2.2.1.1 GVHD: pathogenesis, prophylaxis and treatment 
 GVHD, a potentially lethal complication of allogeneic HSCT, occurs when 
immunocompetent donor T cells attack the genetically disparate host cells [53]. The first 
description of GVHD was made by Billingham in 1966, where he postulated the three 
criteria that must exist for GVHD to occur after allogeneic transplantation [54]: 
(1) The recipient must be immunocompromised (immunosuppressed), so that he/she is 
incapable of mounting an effective immunologic reaction against the graft; 
(2) The donor and recipient must be antigenically different, so the recipient appears 
foreign to the graft; 
(3) The donor graft must contain immunologically competent cells.  
 
A widely accepted paradigm for the pathophysiology of aGVHD is based on the 
existence of three sequential phases (Figure 1-4): 
 Phase 1: Damage and cellular activation induced by preconditioning 
 Phase 2: Donor T-cell activation, proliferation and differentiation 
 Phase 3: Cellular and inflammatory effectors 
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Pharmacological prophylaxis against aGVHD is given to all patients undergoing 
allogeneic HSCT with T-cell-replete grafts. Prophylaxis is effective in preventing the 
development of aGVHD in 50-70% of patients receiving allogeneic grafts from HLA-
matched donors, but still allows for clinically significant GVL effects [55]. If aGVHD occurs, 
first-line treatment for aGVHD is comprised of high dose steroids with or without continued 
immunosuppression [56]. Failing this, patients will receive second-line therapy that may 
include higher doses of their initial treatment or one of many other novel therapeutics 
developed to reduce aGVHD, such as immunosuppressants [53, 57, 58], T cell depleting 
Ab [59, 60], TNF inhibitors [61-63], extracorporeal photopheresis (ECP) [64], 
mesenchymal stem cells [65] and regulatory T cells [66]. Regulating or controlling the 
cytokines which are involved in the development of aGVHD and cGVHD could potentially 
inhibit the development or reduce the severity of GVHD. These approaches include 
blocking pathways of inflammatory and T helper 1 and T cytotoxic  cytokines, involved in 
the initiation and augmentation of GVHD and GVL [67].   
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Figure 1-4: The three-phase model of aGVHD. Conditioning induces tissue damage and 
the release of a storm of pro-inflammatory cytokines that promote activation and 
maturation of APC (on which CD83 is upregulated) and the rapid amplification of donor T 
cells. Mononuclear phagocytes and neutrophils cause inflammation and are triggered by 
mediators such as LPS that leak through the intestinal mucosa. The inflammation recruits 
effector cells into target organs, amplifying local tissue injury with further secretion of 
inflammatory cytokines that together with CTL, leads to target tissue destruction (GVHD 
and GVL) [45, 46, 50, 68] 
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1.2.2.2 Graft-versus-leukaemia (GVL) 
 Potent GVL effects are an important benefit of alloHSCT in humans. Barnes et 
al.1956 first suggested a GVL effect in the 1950’s [69]. They observed that mice receiving 
syngeneic HSCT and injection of congenic leukemic cells after total body irradiation almost 
uniformly died from leukaemia, whereas mice receiving allogeneic transplants developed 
GVHD but had a lower incidence of leukemic deaths [69]. The GVL effect was confirmed 
by other investigators who observed increased risks of relapse in patients receiving T cell-
depleted grafts and in the recipients of a syngeneic transplant [70]. In most patients, an 
additional immune-mediated GVL effect is important to prevent relapse of leukaemia [71]. 
The GVL effect has been associated with the presence of GVHD. Relapse rates are 
significantly higher in patients who do not develop acute or chronic GVHD [72]. Cytokines 
are involved in the pathogenesis of GVHD and probably play a role in the GVL 
phenomenon [50]. The role cytokines play in the GVL effect is unknown, but could involve 
a direct anti-leukaemic effect, recruitment of accessory cells, and potentiation of the 
putative cellular mechanisms responsible for the anti-leukaemic effect [71].  
 
The most successful outcome of HSCT is infection free survival without GVHD 
while preserving GVL. aGVHD has be shown to be largely CD4 T cell-dependent in most 
fully MHC plus multiple minor antigen-mismatched murine models  [73, 74]. Studies using 
an EL4 (H-2b) leukaemia model showed that GVL effects against EL4 leukaemia are 
dependent on donor CD8+ T cells and independent of CD4 T cells [73, 75]. Clinical studies 
of HSCT recipients who received CD4-depleted bone marrow with an adjusted dose of 
CD8 T-cells demonstrated that CD8 T cells help to prevent graft rejection [76]. Murine 
transplant models have shown that CD8 T cell depletion without concomitant CD4 T cell 
depletion induced a high rate of leukaemia relapse in mice, thus demonstrating that CD8 T 
cells play an important role in GVL [77]. 
 
1.2.3 Conclusion 
The use of alloHSCT has expanded rapidly over the past decades and its role will 
continue to evolve as advances in conditioning, management of complications and 
expanding stem cell sources further widen its applicability to treating non-maglinant 
conditions such as those requiring gene replacement therapy [78] and autoimmune 
disease [79]. A successful outcome of HSCT involves engraftment, prevention of GVHD, 
eradication of leukaemia, and immune reconstitution. GVHD and GVL are always closely 
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linked; the severity of GVHD is inversely correlated with the probability of a relapse after 
allogeneic HSCT [80]. Mechanisms of GVHD have been studied extensively over recent 
years and while new anti-GVHD therapies have been developed GVHD remains a 
complication which is difficult to treat. Current treatments of GVHD mostly target phase 2 
of GVHD and focus on immunosuppression. However, while the therapy may be effective 
for GVHD prophylaxis it can impair the GVL effect. As a conclusion, understanding 
immunoregulatory networks in both murine and human systems is important for the 
development of novel GVHD therapeutics.  
 
We have shown that antibody-mediated targeting of CD83+ APC (rabbit polyclonal 
anti-CD83 antibody-RA83) prevents GVHD in a human PBMC xenograft SCID mouse 
model [81] and significantly delays GVHD (manuscript in preparation) in a full murine 
model of alloHSCT [82]. We also previously showed that CD83 antibody depletes 
activated DC and CD4 T cells by NK cell mediated ADCC [83]. We have since developed 
a humanized anti-huCD83 mAb [84, 85] which is formatted to be as effective as the 
polyclonal antibody, RA83, in ADCC lysis and in the hu-SCID mouse model of GVHD 
(unpublished data). These observations further support the importance of the study of the 
mechanism of action of anti-CD83 targeting DC, T and B cells. 
 
1.3 The impact of anti-CD83 in humoral immunity 
1.3.1 Introduction 
Although CD83 is best known as an activation marker for DC [2], it is also expressed 
on activated CD4 T cells and activated B-cells in mouse and man [86]. We have previously 
shown (unpublished) that anti-CD83 can deplete CD83+ cell lines such as the B cell 
lymphoma derived Raji cells, and that it has greater ADCC lysis capability than current 
therapeutic mAbs anti-CD20 rituximab and anti-CD52 alemtuzumab, which are both 
treatments for autoimmune diseases, such as rheumatoid arthritis. Also, in preliminary 
ADCC experiments using the 51Cr release assay, we showed that anti-huCD83 mAb can 
induce lysis of activated B cells, sparing resting B cells (unpublished data by Rebecca 
Baron). This in turn stimulated me to study the effects of anti-CD83 on humoral immunity 
via its actions on activated CD83+ DC, CD4 T cells and B and any potential therapeutic 
advantages anti-CD83 may have over pan-B cell depleting rituximab in autoimmune 
diseases and transplant rejection involving pathogenic auto- or allo-reactive antibodies, 
respectively. 
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 Immunity is defined as resistance to infectious diseases and involves an interactive 
network of lymphoid organs, cells, humoral factors, and cytokines. There are two 
fundamentally different types of immunity, innate and adaptive. Innate immunity provides 
the first line of defence and involves phagocytic cells such as neutrophils, monocytes and 
macrophages; cells that release inflammatory mediators (basophils, mast cells, and 
eosinophils), and NK cells [87]. Innate immunity is highly effective, despite the lack of 
specificity; microbial invasion is frequently controlled, and pathogens are often eliminated 
[88]. Adaptive immunity is the second line of defence and depends on the innate immune 
system for crucial information about the nature of the attacker [88]. Adaptive immunity 
relies on two major cell types: B lymphocytes and T lymphocytes, which lead the two 
broad classes of adaptive immunity: humoral and cell-mediated, respectively. The humoral 
immune response to antigens can be divided into thymus-dependent (TD) and thymus-
independent (TI) [89]. TI responses are further subdivided into type-1 (TI-1) and type-2 (TI-
2). A humoral immune response is initiated when naïve B cells are stimulated by a 
particular antigen, via the antigen specific BCR (and for TD responses by antigen specific 
T helper cells), to proliferate, and differentiate into memory B cells and Ab producing 
plasma cells [90]. Most pathogens elicit a humoral immune response that is characterized 
by an early rise of antigen-specific IgM Ab, followed by a subsequent rise in antigen-
specific affinity matured and class/isotype switched IgG, IgA and IgE antibodies [91]. 
Humoral immunity mediated by Ab is important for neutralization of viruses and bacterial 
toxins, thus limiting both the damage and spread of infection [90]. 
 
1.3.2 Elements of the adaptive humoral immune system 
DC, CD4 T cells and B cells are the key cellular elements involved in humoral 
immunity. Antigen-specific stimulation will increase CD83 expression on all these cells. 
Anti-CD83 that targets these cells would therefore be expected to affect multiple 
components of the humoral immune response, including antigen presentation by DC and B 
cells, T helper cell proliferation as well as B cell differentiation and antibody production. 
 
1.3.2.1 B cells 
 B cells are lymphocytes that play a key role in humoral immunity. A principal 
function of B-cells is to induce differentiation into plasma cells and memory B cells through 
a complex process involving antigen-specific CD4 Th cells. Plasma cells continuously 
secrete high affinity antigen-specific Ab and memory B cells can respond more rapidly to 
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future challenges by the same infectious organism [92]. Although it is well known that B 
cells require T-cell help to produce specific Ab to TD antigens, B cells can also initiate T 
cell responses by functioning as APC [93, 94]. However, B cells need to encounter their 
specific antigen and CD40L on activated CD4 T cells to activate their antigen presentation 
function [95, 96]. B cells are not only capable of presenting to T cells but also can affect T-
cell activation by mediating a number of costimulatory interactions. The costimulatory 
molecules CD80 and CD86, which are upregulated on the B-cell surface after activation, 
engage T-cell surface CD28, thereby promoting T-cell activation, amplifying proliferation, 
and inducing cytokine production [97]. The combined action of the T-cell cytokines and 
signals generated by the interaction of CD40L on the activated T cell with-CD40 on the 
antigen stimulated B cell induces antigen specific proliferation and differentiation [98]. 
 
B cells are generally divided into 2 subsets, B-1 and B-2 B cells. B-1 B cells are 
subdivided into B-1a and B-1b B cells in mice. B-2 B cells are Follicular (FO) B cells and 
Marginal Zone (MZ) B cells [99, 100]. Most of the observations about the B-1 cell subsets 
have been obtained in mice, and limited data are available on human B1 B cells [97]. B-1 
and MZ B cells are the first cell populations to encounter antigens acquired through the 
gut, peritoneum and blood stream. These two B-cell subsets have evolved to provide an 
innate-like defence against pathogens by responding rapidly to antigen stimulation [97] 
and also housekeeping removal of cellular debris [101]. Also, B1 cells and MZ B cells are 
particularly sensitive to TLR ligands and participate in TI immediate Ab responses [102, 
103], in which B-cell clones that are specific for TI antigens are enriched in the MZ 
compartment, as well as B1 compartment [104]. TD immune responses generally involve 
FO B cells.  
 
B-1 cells 
B-1 cells are the main producers of natural antibodies [105-109] that provide innate 
protection against bacterial infections in naïve hosts [97], but these cells are not commonly 
viewed as participating in antigen-stimulated Ab responses [110]. Natural antibodies are 
broadly reactive, autoreactive, and also repertoire skewed [100, 111-113]. In mice, B1 
cells are mainly found in the peritoneal and pleural cavities and the gut lamina propria 
[100, 107]. B-1a cells predominate in the peritoneal cavity (PC) and express low levels of 
CD5, but B-1b cells, which do not expressed CD5, are present at much lower frequencies 
in the PC [100, 114]. B-1a B cells and their plasma cell progeny produce natural 
antibodies, however, B-1a cells can produce specific Ab responses to certain antigens 
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such as phosphorycholine [104, 115, 116] and α1,3 dextran [117, 118].  B-1a cells up-
regulate Ab production in response to TLR stimulation [119-121].  B-1b B cells function 
independently without helper T cells, as the primary source for long-term adaptive Ab 
responses to polysaccharides and other TI-2 antigens during infection [122, 123].  
 
B-2 cells 
FO B cells, also known as conventional B cells, are the largest sub-population of B cells. 
They are the long-term main players in all effector functions that involve the germinal 
centre (GC) reaction, plasma cell production and memory B-cell generation [102]. FO B 
cells respond less well to LPS stimulation than do MZ B cells and B-1 cells [100]. MZ B 
cells represent approximately 15% of splenic B cells [100], capable of responding to all 
three major classes of antigens: TD, TI-1 and TI-2 [97]. MZ B cells are considered to be 
innate-like cells that can generate short-lived Ab responses in the absence of BCR ligation 
[99]. They are involved mainly in TI and innate-like immune responses [104, 124].  In TD 
responses, MZ B cells help to deliver protein antigen to FO B cells, and they may also be 
directly activated by TD antigens and receive T cell help [99, 102]. TD immune responses 
take longer to become established. Antigen-specific FO B cells will eventually overtake MZ 
B in the immune response [102]. TI-2 antigens typically stimulate splenic MZ B cells to 
differentiate into Ab producing plasmablasts in extrafollicular foci of the spleen [125, 126]. 
 
1.3.2.1.1 Ab Responses 
Creating immunological memory which generates long-lasting immunity is the main 
concept of vaccination [127]. Vaccination generates B cell memory, which provides 
protective Ab responses upon re-exposure to the same pathogens. Foreign proteins such 
as tetanus toxin are TD antigens, and they induce the generation of antigen-specific T 
cells (and memory T cells) that help FO B2 cell responses [128]. Certain bacterial products 
such as capsular polysaccharides induce Ab responses without T-cell help and are 
referred to as TI antigens [129]. TI antigens, which do not require specific T-cell help, 
induce weak and predominantly IgM-mediated responses, with inefficient induction of 
class/isotype switching, affinity maturation, and little or no booster effect after second 
exposure to the antigen [130]. Therefore, TI responses are considered to be IgM limited, of 
poor specificity and shortlived. 
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1.3.2.1.1.1 Thymus-dependent (TD) immune responses  
In the immune response to TD antigens, T cell help for B cells is essential for the 
regulation of B cell proliferation, production of Ig, Ig class switching, rescue of B cells from 
apoptotic death, germinal centre formation, and generation of B cell memory [131]. 
Bretscher and Cohn proposed that successful activation of resting B cells requires two 
signals: the first signal to the B cells is the result of antigen binding to membrane Ig (the 
BCR) and the second is supplied by Th cells [132]. Th-dependent activation of B cells is a 
continuous, dynamic process that relies on a series of intercellular signalling events 
between Th and B cells [133].  
 
In a classical TD immune response, professional APC, such as DC and 
macrophages that express high levels of MHC class II molecules, prime Th cell responses 
[134]. Once Th cells have been activated by professional APC, they can deliver help to B 
cells via a cognate interaction, such as CD40-CD40L interaction [134]. A variety of 
molecules are involved in TD immune responses. CD40 and its ligand are considered to 
be the most important pair of molecules in directly regulating TD B cells responses [135-
137]. In the absence of CD40 or its ligand CD40L (CD154), virtually all aspects of Th-cell 
dependent B cells responses are blocked [138, 139]. TLR ligands may facilitate Ab 
responses by enhancing Th-cell responses or by directly acting on B cells [134, 140, 141].  
 
The germinal center (GC) reaction is the basis of TD humoral immune responses 
against foreign pathogens [142]. GCs are the primary site of B cell affinity maturation and 
develop in the B cell follicles of secondary lymphoid tissues during TD antibody responses 
[127, 143, 144]. GCs are divided into light and dark zones (LZ and DZ, respectively) [145]. 
DZ consist almost entirely of B cells [145], in contrast, B cells in the LZ are interspersed 
among a network of follicular DC (FDC), which give this zone its “lighter” appearance 
[146]. FDC are not a subset of conventional DC. They are stromal in origin and develop 
from vascular mural cells [147], unlike conventional DC which are hematopoietic. FDC 
express high levels of CD35, CD21 and also adhesion molecules such as ICAMI and 
VCAM1 [148, 149]. LZ also contain T cells, mostly CD4+ and some CD8+ [150], as well as 
a small number of conventional DC [151, 152]. Activation markers such as CD83 and 
CD86 are found to be highly expressed in B cells in LZ compared to DZ [153]. It has been 
shown that IL-21 that is secreted by Th cells is also essential for normal GC development 
[154, 155]. GC size is closely correlated with the availability of follicular T helper (TfH) cells 
[156], and inhibition of TfH cells leads to inappropriate GC B cell selection and humoral 
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autoimmunity [157-159]. Weyand and Goronzy (2003) reported that rheumatoid synovitis 
is closely related to ectopic GC formation [160]. This study is further supported by Humby 
et al., 2009 where they demonstrated that ectopic GC-like structures are functional in 
rheumatoid synovitis and their presence also contributes to disease pathogenesis [161]. 
 
A significant feature that accompanies the response to a TD antigen is the 
development of memory cells. When memory  Th cells and memory B cells are 
subsequently exposed to the same TD antigen they respond rapidly, resulting in a 
secondary Ab response that occurs more quickly than the original primary response [162]. 
TD responses are slow but can elicit long-lasting (years) production of high affinity, class-
switched antibodies by plasma cells, and immune memory [163].  
 
1.3.2.1.1.2 Thymus-independent (TI) immune responses 
Classically, TI antigens do not generate B cell memory and the Ab responses 
therefore are short-lived [164]. In general, responses to TI antigens develop significantly 
more rapidly than TD responses and thus play a critical role in some contexts, such as 
bacteremia, a major cause of death in infectious disease [165].  
 
TI-1 antigens behave differently from TI-2 antigens due to intrinsic mitogenicity that 
stimulates B cells to produce Ab in a polyclonal manner, irrespective of antigen specificity 
[166, 167]. LPS, CpG, or poly-IC which elicits polyclonal B-cell activation via TLRs are 
examples of TI-1 antigens [97, 168]. TI-1 antigens such as LPS can also stimulate antigen-
specific B cells as well as non-specific B cells at higher doses [122]. TI-1 responding cells 
produce IgM, and some IgG2b, no memory, and little or no somatic mutation (affinity 
maturation and class/isotype switching) [169].  
 
TI-2 antigens are multivalent polysaccharides or other antigens with repetitive 
biochemical structures that can extensively crosslink multiple antigen-specific BCR 
molecules on the B cell plasma membrane. Thus, naturally occurring polymeric proteins, 
polysaccharides (eg, streptococcal and meningococcal carbohydrates [170]) and synthetic 
poly-haptenated modified polysaccharides (eg, 4-Hydroxy-3-iodo-5-nitrophenylacetyl-Ficoll 
(NIP-Ficoll), trinitrophenyl-Ficoll (TNP-Ficoll), and dinitrophenyl-Ficoll (DNP-Ficoll)) [131] 
induce TI-2 specific Ab responses [129].  Clinically important TI-2 antigens include 
bacterial capsular polysaccharides (CPS) [171]. CPS of Streptococcus pneumoniae, 
Haemophilus influenzae and Neisseria meningitidis are responsible for bacterial virulence 
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and antibodies to CPS provide protection against invasive infections of these bacteria 
[172]. However, CPS induce inadequate immune response in neonates and infants and 
also in the elderly [173]. 
 
 Even though TI immune responses do not require antigen-specific T cell help, the 
Ab response to TI-2 antigens is influenced by T cells [174-177]. However, the question of 
how T lymphocytes can influence B lymphocyte responses to TI-2 antigens is largely 
unanswered and identification of this process is a major research challenge. It has been 
reported that neither processing nor presentation by MHC class II molecules has been 
demonstrated for TI-2 antigens [131, 178]. Some studies demonstrated that CD1, which 
shows similarities to MHC I proteins [179] , may present TI-2 antigens such as 
polysaccharide to T lymphocytes [180-183]. Also, there is indirect evidence that T 
lymphocytes can be activated in the Ab response to TI-2 antigens via TLR [167, 184, 185]. 
Vos et al., 2000 suggested that T lymphocytes can be recruited directly by multivalent TI-2 
antigens without antigen presentation and TCR triggering by B lymphocytes [129].  
 
TI-2 responding B cells mainly produce IgM and some IgG3 in mice (or IgG2 in 
human), and they do not usually generate long-term memory cells (no secondary 
response) [186-188]. In another study by Perlmutter et al.,  they also showed that 
immunization of mice with TI-2 antigen, in contrast with TD antigens, stimulates a 
significant increase in serum levels of Ag-specific IgG3 [188]. However, several studies 
have demonstrated that TI-2 antigens can generate a second memory compartment (B-1b 
memory) that consists of either resting long-lived memory cells or long-lived memory bone 
marrow plasma cells [189]. An observation by Alugupalli et al., (2004) showed that B-1b 
cells can confer long-lasting TI immunity to immunodeficient mice [122]. The long-term 
immunity provided by B-1b cells appears similar to the immunity conferred by conventional 
memory B cells [190] but is generated and maintained in the complete absence of T cells. 
Nevertheless, the mechanism whereby they protect immunocompetent mice from bacterial 
infections is still uncertain. Another study by Taillardet et al. demonstrated that TI antigens 
can generate a bone marrow compartment of long-lived plasma cells that is sufficient to 
confer full protection against infection with live bacteria [191]. They suggested that TI 
immunologic memory involves both the B-1b and plasma cell compartment; although it is 
still unclear at present in which situation the B-1b cell memory compartment comes into 
play.  
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1.3.2.2 DC  
DC and B lymphocytes are professional APC capable of stimulating efficient T-cell 
responses [192, 193]. DC are the most potent APC for stimulating naïve T cells and are 
crucial in the initiation of antigen specific adaptive T- and B-cell immune responses that 
involve naïve T cell activation, expansion and differentiation to effectors [194, 195]. DC 
contributes to the stimulation of B cells, both in the lymph node T cell areas and in 
germinal centres [196, 197]. DC produce a number of cytokines and factors which are 
critical to the activation and differentiation of B cells [198]. DC capture and present 
unprocessed antigen to B cells and induce isotype switching both in vitro and in vivo [199]. 
DC are not a single cell type but consist of several distinct subsets [198, 200]. Many 
studies have shown that DC is involved in numerous diseases such as autoimmunity, 
allergy, transplantation, infection and cancer [198, 201].  
 
1.3.2.3 Natural Killer (NK) cells 
Natural killer cells are a separate lymphocyte lineage with the capacity to produce 
cytokines and kill target cells upon activation [202, 203]. NK cells have the morphology of 
lymphocytes but do not bear a specific antigen receptor. They recognise abnormal cells in 
two ways. First, they express Ig receptors (FcR) and bind Ab-coated targets leading to Ab-
ADCC which is a key mechanism of action of anti-CD83 antibodies [81, 83]. Second, NK 
cells have receptors on their surface for MHC class I. If on interaction with a cell, this 
receptor is not bound, the NK cell is programmed to lyse the target [204]. NK cells not only 
play an important role in innate immunity but are also important cells that shape and 
influence adaptive immunity and immunoregulation [205]. NK cells recognize abnormal or 
allogeneic cells using a repertoire of NK cell receptors that regulate their activation and 
effector functions [206, 207]. Alloantigen stimulation induces antigen-specific expansion 
and differentiation of NK cells [207]. Recent evidence suggests that NK cells might be able 
to eliminate autoreactive T cells in transplantation [208, 209]. In contrast, NK cell 
degeneration mediated by IL-21 that derived from autoreactive CD4+ T cells, can control 
excessive autoimmunity [210] 
 
1.3.2.4 CD4 T helper (Th) cells 
CD4 Th cells play critical roles in orchestrating adaptive immune responses. CD4 
Th cells are essential regulators of immune responses and inflammatory diseases by 
facilitating B cell responses, modulating innate immunity and regulating CD8+ T cell 
expansion [211-214]. After stimulation with processed antigen presented by APC, naïve 
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CD4+ T cells proliferate and differentiate into various effector subsets characterized by the 
production of distinct cytokines and by their distinct effector functions [215]. Besides the 
classical T-helper 1 (Th1) and T-helper 2 (Th2) subsets, other subsets have been 
identified in recent studies, including T-helper 17 (Th17), regulatory T cell (Treg), follicular 
helper T cell (Tfh), and T helper-9 (Th9) [216]. 
 
APC can drive CD4+ T-cell differentiation through cytokines and costimulation [217]. 
Th1 cells secrete IL-2, interferon-gamma (IFN-γ) and lymphotoxin-α (LT-α), whereas Th2 
cells produce IL-4, IL-5, IL-6 and IL-13 [218, 219]. IL-3, tumour necrosis factor-α (TNF-α) 
and granulocyte-macrophage colony-stimulating factor (GM-CSF) are secreted by both 
Th1 and Th2 cells [219]. Th1 cells enhance pro-inflammatory cell-mediated immunity and 
were shown to induce delayed-type hypersensitivity (DTH), B-cell production of opsonising 
isotypes of IgG, and mediate the response to some protozoa like Leishmania and 
Trypanosoma [220, 221]. Th2 cells promote non-inflammatory immediate immune 
responses and are essential in B cell production of IgG, IgA, and IgE [221, 222].  
 
Th17 cells mediate immune responses against extracellular bacteria and fungi 
[223]. The Th17 pathway has recently been shown to play a critical role in host defence, 
allergic responses and autoimmune inflammation [224]. Th17 cells produce many 
potentially pro-inflammatory cytokines and chemokines, including IL-17A, IL-17F, IL-22 as 
well as IL-6, GM-CSF and TNF-α [225, 226].   
 
Treg cells play a critical role in maintaining self-tolerance as well as in regulating 
immune responses [227]. Their main effector cytokines are IL-10 [228, 229], transforming 
growth factor-β (TGF-β) [230, 231]  and IL-35 [232]. Figure 1-5 summarizes the four CD4 
Th cell fates. 
 
CD4 Th cells are crucial in providing help to B cells in adaptive immunity and the 
generation of immunological memory [233, 234]. In recent years, TfH cells have emerged 
as specialized providers of T cell help to B cells, and are important for the formation of GC, 
affinity maturation, and to regulate germinal center B cell differentiation into most high-
affinity antibodies by plasma cells and memory B cells [144, 233, 235]. TfH cells express a 
number of cytokines that facilitate antibody production, including IL-4, IL-10 [236] and IL-
21 [237]. Dysregulation in the development or function of TfH cells could manifest as 
immunodeficiency, autoimmunity, and malignancy [235]. In systemic lupus erythematosus 
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(SLE) patients, an increase in TfH cells, IL-21+ CD4+ [238, 239] and also serum IL-21 have 
been detected [240]. The similar findings also observed in RA patients [241-244]. 
 
 
 
 
Figure 1-5: Summary of the four CD4 T helper cell fates: their functions, their unique 
products, their characteristic transcription factors, and cytokines critical for their fate 
determination. (Adapted from Zhu and Paul, 2008) [214]. 
 
1.3.2.5 Toll Like Receptors (TLRs) 
TLRs are pattern recognition receptors that recognize pathogen associated 
molecular patterns [245]  In humans and mice, there are 10-13 TLRs that recognize 
different components of bacteria and viruses, such as LPS, ssRNA and CpG-containing 
DNA [246]. Most TLRs signal via an adaptor protein called myeloid differentiation primary 
response gene 88 (MyD88), except for TLR3, which signals through TLR domain-
containing adaptor-inducing interferon-β (TRIF), and TLR4, which signal through both 
[141, 246]. TLR family members play critical roles in initiating innate inflammatory 
responses and promoting adaptive immune responses [247]. B lymphocytes express most 
known TLRs, in addition to their clonally-expressed BCR [248]. Over the last few years, 
research on TLR signalling in B cells has generated enormous interest due to its potential 
application in vaccine design and role in B cell-related diseases. TLR signalling not only 
promotes Ab responses, it is also involved in B-cell cytokine secretion, antigen 
presentation, Ig isotype switching and cell survival for long-lived plasma cells and memory 
B cells [246]. 
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1.3.2.6 Cytokines 
CD83 is expressed on cells that secrete cytokines, such as T and B cells, and to a 
lesser extent on macrophages. Anti-CD83 that binds CD83 expressed on these cells may 
affect cytokine production in antigen-specific humoral immunity, especially CD4 T cells, 
which are the main contributors in autoimmunity. Cytokines are produced from various 
sources during the effector phases of innate and adaptive immune responses. The central 
role of cytokines includes cell-to-cell communication, inflammatory response amplification, 
and immune response regulation [249]. Cytokines can induce or suppress their own 
synthesis, as well as the expression of other cytokines and their receptors, leading to 
antagonism or synergism of immune response [250, 251]. Cytokines also play a pivotal 
role in pathogenesis of autoimmune diseases. Excessive, reduced or aberrant cytokine 
responses can contribute to autoimmune inflammation (Figure 1-6) [252]. Th1 cells secrete 
predominantly IL-2, IL3, TNF-α, and most notably IFN-γ and control cell-mediated 
functions such as the activation of macrophages, while Th2 cells secrete IL-4, IL-5, and IL-
13 which leads to the stimulation of humoral immunity [253, 254]. 
 
IL-2 is a pleiotropic cytokine that promotes the growth of T-cells, augments NK 
cytolytic activity, induces the differentiation of Treg cells, and mediates activation-induced 
cell death [255]. IL-2 also controls inflammation by inhibiting Th17 differentiation [256]. 
Accordingly, IL-2 is an immunoregulatory cytokine which can act as an anti-inflammatory 
or pro-inflammatory molecule depending on the cytokine milieu after antigen stimulation 
[255] . 
 
IL-4 is a multifunctional cytokine that plays a critical role in the regulation of immune 
responses. It is mainly produced by Th2 cells, mast cells and NK cells [257]. It regulates 
the differentiation of antigen-stimulated naïve T cells [258]. These cells then develop to 
produce IL-4 and a number of other Th2-type cytokines including IL-5, IL-10 and IL-13 
[259, 260]. IL-4 induces the expression of MHCII molecules on macrophages and DC, and 
it also contributes to DC maturation and activation, and to B cell proliferation and activation 
[261]. IL-4 is linked tightly to the immunopathologies of allergy and asthma but is also 
required for immunity to parasitic infections [262-264]. Erb et al., 1997 reported that 
constitutive in vivo expression of IL-4 leads to the activation and/or expansion of 
autoreactive B cells and development of autoimmune-type disease [265]. This statement is 
consistent with the high incidence of IgG-type rheumatoid factor autoantibodies, (~70% of 
rheumatoid arthritis (RA) patient sera), which is often dominated by IgG4 and which is 
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induced by IL-4 in humans [266, 267]. In addition, increased production of IL-4 is also 
thought to be associated with the pathogenesis of SLE and it was demonstrated that IL-4-
producing cells frequently expressed activated T-and NK cell markers [268, 269]. 
 
IL-6 is a potent pro-inflammatory cytokine produced by APC such as DC, 
macrophages and B cells, and is critical for differentiation of B cells into plasma cells and 
for Ab production [270, 271]. IL-6 together with transforming growth factor-β (TGF-β) 
promotes differentiation of IL-17-producing Th17 cells but inhibits TGF-β induced Treg 
development [272, 273]. The imbalance of Th17/Treg may lead to onset and progression 
of autoimmune and chronic inflammatory diseases [274]. IL-6 is found in large amounts in 
the synovial fluid and serum of patients with RA [275]. IL-6 is involved in the immunological 
manifestations of RA, as illustrated by its effects on the B cells. IL-6-induced Ab production 
can be mediated indirectly by IL-21 produced by CD4+ T cells which in turn promotes B 
cell differentiation and increases Ab production [276]. Since IL-6 directly stimulates B-cell 
proliferation and B-cell differentiation to Ab-producing plasma cells, it may cause 
hypergammaglobulinemia and the production of autoantibodies in RA [277]. There are 
several pieces of evidence that IL-6 is also involved in other autoimmune diseases, 
including SLE [278-280], Castleman’s disease, and Crohn’s disease [281-283].  
 
IL-10 may be considered the most important anti-inflammatory cytokine in humans. It 
is produced by various cell populations, including macrophages and DC, B cells, mast 
cells and several subsets of T cells, such as Th2 cells, Treg, and Th17 cells [228, 284-
287]. IL-10 deactivates macrophages [288], and inhibits the secretion of Th1 cytokine IL-2 
and pro-inflammatory cytokines, such as TNF-α, IL-1, IL-6, IL-12, and IFN-γ, and controls 
differentiation and proliferation of macrophages, T- and B-cells [289-291]. The anti-
inflammatory effects of IL-10 are not mediated solely through effects on DC and 
macrophages, it also directly acts on pro-inflammatory Th17 cells [292]. Although IL-10 is 
an anti-inflammatory cytokine, autoimmune disease SLE seems to be associated with 
overproduction of IL-10 [293]. Compared to healthy individuals, IL-10 levels in SLE 
patients are significantly higher and there is a correlation of IL-10 levels with clinical 
disease activity [294]. 
 
 
IL-17 (also called IL-17A) is a pro-inflammatory cytokine produced by Th17 cells and 
is defined as a key mediator of chronic tissue inflammation [272, 295]. During immune 
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responses, IL-17 is often present at high levels in inflamed tissues [296]. IL-17 stimulates 
macrophages to produce various inflammatory cytokines, such as IL-1β and TNF-α [297]. 
These cytokines can further synergize with IL-17 to amplify GM-CSF secretion [298]. IL-17 
has been placed at the centre stage of autoimmune inflammation in recent studies. The 
expression of IL-17 has been detected in sera and target tissues of patients with RA, SLE, 
MS and asthma [299-302]. IL-17 is directly involved in the destruction of cartilage and 
bone in RA patients [303]. It has also recently been demonstrated that IL-17 regulates 
germinal-centre formation, as well as autoantibody production [304].  
 
 IL-21 is a member of the IL-2 cytokine family produced by activated T cells and NKT 
cells, but not by APC to regulate immune responses [305] [306]. The largest amounts of 
IL-21 are produced by TfH [237, 307] and Th17 cells [307-309]. In addition to T cells, B 
cells rely on IL-21 for survival and differentiation, supporting the production of Ab-forming 
cells with class-switched Ig isotypes [306]. IL-6 is a strong inducer of IL-21 [310]. IL-21 
together with TGF-β is able to induce differentiation of Th17 cells [308, 309, 311]. 
However, in vivo IL-6 plays a dominant role in Th17 differentiation, and only in the absence 
of IL-6 and following depletion of Tregs, is IL-21 involved in inducing Th17 cells [272]. 
These findings are further supported by studies that showed that when excess IL-6 is 
induced by immunization with autoantigen, the requirement for IL-21 in the induction of 
Th17 cells is overcome owing to excessive and continuous IL-6 production by the 
peripheral immune system [312, 313]. 
 
IFN-γ is produced by activated T lymphocytes, NK cells, B cells and professional 
APC [257]. IFN-γ orchestrates leukocyte attraction and directs growth, maturation, and 
differentiation of many cell types including monocytes, macrophages, DC, and T cells 
[314-316], in addition to enhancing NK cell activity [317] and regulating B-cell functions 
such as Ig production and class switching [315, 318]. The early host defence against 
infection is likely to utilise IFN-γ secreted by NK and professional APC. In adaptive 
immune responses, T lymphocytes are the major source of IFN-γ [257].  IFN-γ production 
is stimulated by IL-12 and IL-18 [319-323] and inhibited by IL-4, IL-10, and TGF-β [315]. 
IFN-γ produced by CD4+ T-cells can control many aspects of inflammation and 
immunoregulation. In general, it plays a much more important role as a pro-inflammatory 
molecule, promoting essentially all aspects of the Th1 immune response, while 
suppressing Th2 and Th17 responses [324-326]. IFN-γ has been associated with 
promoting autoimmune diseases due to its pro-inflammatory properties. The most notable 
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are RA [327], SLE [328, 329], multiple sclerosis (MS) [330, 331], and insulin-dependent 
diabetes mellitus (IDDM) [332-334]. 
 
GM-CSF is secreted in response to inflammatory stimuli such as LPS, IL-1 and TNF-
α by several different cell types, including endothelium, fibroblasts, muscle cells, 
macrophages, and by activated T cells [335]. There is a lot of evidence suggesting that 
GM-CSF is a pro-inflammatory cytokine [336-339]. El-Behi et al. (2011) [340] and Codarri 
et al. (2011) [341] also showed that production GM-CSF is critical for the pro-inflammatory 
functions of Th17 cells. Consistent with the concept of a pro-inflammatory action for GM-
CSF, anti-inflammatory glucocorticoids can suppress GM-CSF induction [342-344]. There 
is growing evidence showing that GM-CSF is involved in the pathogenesis of autoimmune 
disease. A recent study by Sonderegger et al., 2008 demonstrated that GM-CSF is 
essential for development of autoimmune myocarditis by promoting IL-6-dependent IL-17 
production and survival of autoimmune CD4+ T cells [345]. McQualter et al., 2001 also 
found that anti-GM-CSF treatment, either prophylactically or therapeutically, improved EAE 
disease, suggesting that GM-CSF may be a therapeutic target in MS [346].  
 
TNF-α is produced predominantly by activated macrophages and T lymphocytes 
[347]. TNF-α is a mediator of both innate and adaptive immune responses [257]. TNF-α 
induces production of IL-1, IL-6, TNF-α itself and chemokines via stimulation of 
macrophages [257]. TNF-α is not just a pro-inflammatory cytokine, it is also an 
immunoregulatory molecule that can alter the balance of Treg cells [348].  TNF-α is best 
known for its role in leading immune defences to protect a localized area from invasion or 
injury but is also determines the fate of target cells [349]. Excess levels of TNF-α 
contributes to pathogenesis of certain autoimmune diseases, including RA and Crohn’s 
disease [350]. TNF-α blockade reduces RA-associated inflammation [350-352], and has 
proven to be the most effective therapy for RA [350].  However, TNF-α blockade does not 
reverse the underlying mechanisms of autoimmunity and sometimes leads to adverse 
effects including development of additional autoimmune diseases such as SLE [353-355], 
type-1 diabetes [356, 357], vasculitis [358, 359], MS, psoriasis [360, 361], as well as 
lymphomas [362, 363]. As many adverse effects have been identified after TNF-α 
blockade treatment, they must be used with extra caution, perhaps finding an alternative 
approach will be a better option to treat TNF-α associated inflammation diseases. 
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Figure 1-6: The involvement of different T-cell subsets and the cytokines produced by 
them in the pathogenesis of autoimmune disorders. There are diverse subsets of effector 
and regulatory T cells, and balance in their activity is vital for an effective immune 
response that is proportionate to the inciting stimulus. Excessive, reduced, or aberrant 
cytokine responses contribute significantly to autoimmune inflammation that underlies 
several autoimmune diseases. Th1, Th17, Th22, and Th9 subsets (left panel-red) 
generally drive pathogenic effector responses, whereas Th2, Treg, IL-10 secreting 
regulatory T cell (Tr1), and TGF-β-secreting T cell (Th3) subsets (right panel-blue) mediate 
regulatory responses. T follicular helper cell (TfH) is a recently described T cell subset that 
plays a role in B cell activation in the lymphoid tissue. The primary cytokines secreted by 
various T cell subsets are shown in the figure. Also depicted are the properties displayed 
by various T cell subsets and/or cytokines (middle panel-purple) that come into play at 
different stages of an autoimmune disease. [Reprinted from Moudgil and Choubey, 2011] 
[252] 
 
Our understanding of the pathophysiology of B cell autoimmune disease had a major 
breakthrough when two distinct cytokine-secreting subsets were discovered in B-cells 
[364]. B lymphocytes polarized in the presence of Th1 cells were classified as B effector 1 
(Be-1) cells. Whereas, Th2 cells induced naïve B lymphocyte polarization to B effector 2 
(Be-2) cells [364]. Be-1 cells produce IFN-γ, IL-12 and TNF-α, while Be-2 cells produce 
cytokines such as IL-2 IL-4 IL-6 and TNF-α [364, 365]. B effector 1 cells amplify IFN-γ 
production by T cells, via a TNF-α mechanism [366]. Also, it has been shown that TNF-α 
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produced by B effector cells is necessary for sustained Ab production [367]. Consequently, 
this may lead to autoimmunity. 
 
In conclusion, dysregulation of cytokines produced either by T or B cells may 
contribute to several human autoimmune diseases, though possibly in different ways. T 
cell subsets and T cell cytokines can impact the differentiation of B cells and subsequent 
Ab production. Vice versa, B effector cells that produce autoimmune disease or transplant 
rejection associated cytokines, including cytokines IFN-γ, IL-6 and TNF-α may amplify 
these diseases. As we have shown that anti-CD83 can target B cells, this suggests that 
anti-CD83 may be able to reduce these cytokines and be used to treat autoimmune 
disease and transplant rejection. 
 
1.3.3 Autoimmune diseases and transplant rejection 
Autoimmunity results from a break in self-tolerance by humoral and/or cell mediated 
immune mechanisms which involves self-reactive T and/or B cells [368]. The role of B cells 
in autoimmune diseases involve secretion of autoantibodies, autoantigen presentation and 
reciprocal interactions with T cells and secretion of inflammatory cytokines [369]. The 
spectrum of autoimmune diseases includes a large variety of conditions such as RA, SLE, 
multiple sclerosis, type-1 diabetes, Crohn’s disease, Sjogren’s syndrome and systemic 
sclerosis, which all display different clinical features [370]. Rituximab is a chimeric 
murine/human mAb that binds to the pan-B-cell marker CD20 [371] and which is widely 
used for the treatment of B cell lymphoma, some autoimmune diseases and transplant 
rejection [372]. However, there have been infections noted in patients treated with 
rituximab, by viral, bacterial and fungal pathogens [373]. In addition, some B cells have 
immunoregulatory properties, and depletion of such B cells in animal models before 
disease induction has been shown to exacerbate autoimmunity [374]. Also rituximab 
therapy can exacerbate ulcerative colitis and psoriasis [374]. Clatworthy et al. found that 
transplant patients who received rituximab had a rate of acute rejection that was not only 
higher than the rate in the control group but also was higher than previously observed 
among patients who have not received induction therapy [375, 376]. This has in turn 
stimulated the search for new drugs in autoimmune disease and transplant rejection. Since 
autoimmune diseases involve DC, T and B cells and anti-CD83 targets activated forms of 
these cells, anti-CD83 may improve these conditions. 
 
 28 
 
Rheumatoid arthritis (RA) 
Rheumatoid arthritis is a complex condition that is well characterized by chronic 
inflammation of the joints followed by reduced mobility and joint destruction, finally leading 
to major disability [377]. In RA, several cytokines, e.g. IL-1, IL-6, IL-8, IL-12, IL-17, TNF-α, 
IFN-γ and GM-CSF, are involved in all aspects of articular inflammation and destruction 
[378]. In terms of disease initiation, it is often considered that the autoreactive T cell 
response in RA is biased toward Th1; however the evidence for such classification is 
circumstantial, mainly based on the presence of inflammatory cells in the lesion [379].  IL-
10 is a potent anti-inflammatory cytokine that has been shown to regulate endogenous 
pro-inflammatory cytokine production in RA synovial tissue [380]. The most common 
treatments in RA are blockade of TNF-α with etanercept, or with the anti-TNF-α mAb 
infliximab [368]. Although these treatments have been shown to be very effective, they do 
not work in all patients [381-383]. 
 
Systemic lupus erythematosus (SLE) 
Systemic lupus erythematosus is an autoimmune disease with a strong genetic 
background [384]. SLE is a heterogeneous systemic autoimmune disease characterized 
by uncontrolled production of autoantibodies to cellular antigens such as native, double 
stranded DNA [368, 385, 386]. As I mentioned earlier, serum levels of IL-10 are 
consistently high in patients with lupus, and they also correlate with the activity of the 
disease [387], which raises the possibility that blocking this cytokine could reduce the 
production of pathogenic autoantibodies. In an open trial of 20mg of a mouse anti-IL-10 
mAb administered daily in six lupus patients for 21 days, skin and joint symptoms 
improved in all the patients, and the improvement was maintained at the 6-month follow-up 
assessment [388]. Abetimus sodium has been used as specific method of reducing levels 
of anti-double-stranded DNA [389]. However, a large trial showed that abetimus sodium 
was not superior to placebo in an analysis of the primary outcome measure, although in 
post hoc analyses, the drug was superior to placebo in a subgroup analysis of lupus 
patients who had serum antibodies with high affinity for the drug [390]. 
 
Multiples sclerosis (MS) 
Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous 
system. MS impairs nerve cells in the brain and the spinal cord, affecting thinking and 
movement [391, 392]. The aetiology of MS is still unknown, but according to current data 
the disease is generally believed to be an immune-mediated disorder that occurs in 
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genetically susceptible people [393-395]. Experimental autoimmune encephalomyelitis 
(EAE) is an animal model of MS [260], which can be induced by immunization with self-
antigens derived from central nervous system (CNS) myelin [396]. According to studies 
derived from EAE, pathogenesis MS involves autoreactive peripheral activated CD4 T 
cells, MHCII expressed by both local glial APC and DC, pro-inflammatory cytokine 
secretion, such as IFN-γ and TNF-α, and chemokines which recruit additional non-specific 
inflammatory cells and specific anti-myelin antibody-forming B cells that amplify tissue 
injury [397-400]. For unknown reasons, the immune system sees the myelin sheath as a 
foreign antigen and attacks it. Therefore, unlike RA and SLE, B cells, but not 
autoantibodies, are pathogenic in MS. Zinser et al., 2004 showed that three injections of 
sCD83 prevented the paralysis associated with EAE almost completely in EAE mice, and 
animals also showed reduced disease symptoms [17]. This indicates that CD83 has a role 
in MS.  
 
Transplant rejection 
Transplant or graft rejection is a consequence of the recipient's immune response to 
non-self-antigens expressed by donor tissues. Graft rejection is the major barrier to 
successful transplantation. T cells are key initiators, effectors and regulators of graft 
rejection [401]. Although initiation of the adaptive immune response that results in allograft 
rejection is critically dependent on T cell recognition of alloantigen, many components of 
the immune system, including B cells, can subsequently contribute to the destructions of 
the transplanted tissue [401]. In renal transplantation, acute cellular rejection has been 
viewed as a T-cell dependent process, but B cells are required for allo-Ab production and 
may be also alloantigen presentation to T cells [402]. Furthermore, long-term survival of 
organ allografts remains limited by chronic rejection, a process distinct from acute 
rejection, in which B cells have been found to play a significant role [403]. 
 
 A complex of mediators, including cytokines, growth factors, chemokines and 
costimulatory molecules are involved in the microenvironment of the transplanted graft 
where the immune response determines the outcome of transplantation [404]. Cytokines 
are potentially involved in organ transplantation at four distinct levels: (1) organ harvesting 
from the donor; (2) transplant surgery; (3) acute alloimmune response; and (4) chronic 
rejection [405]. Cytokine production has been shown to be different between individuals 
and this may decide graft rejection or acceptance [404]. The role of cytokines in Th cell 
differentiation and graft rejection is summarized in Figure 1-7.  
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Figure 1-7: Transplant rejection. (a) The classical model. Naive helper T cells are induced 
by IL-12 to become Th1 or by IL-4 to become Th2 effector cells. Th1 cells secrete IFN-γ, 
which inhibits differentiation of Th2 cells and promotes cell-mediated immunity, leading to 
acute cellular rejection of transplants. Th2 cells secrete additional IL-4 and IL-10, which 
inhibit differentiation of Th1 cells and promote B-cell responses (humoral immunity), 
leading to antibody-mediated rejection of transplants and inhibiting cellular rejection of 
transplants. (b) Transplant rejection is associated in many ways with Th1 and Th2 
responses. In lymphoid organs in which immune responses are generated, Th1 and Th2 
cells are activated, leading to cell-mediated and humoral immune responses. The initial 
response gives rise to effector cells that attack the graft; the later response gives rise to 
immunoregulatory cells that suppress the attack on the graft. Because of the immune 
response, T cells and other cells in the graft secrete cytokines. The cytokines initially 
induce acute toxic injury, especially to blood vessels. If the graft is not destroyed, the blood 
vessels and other cells of the graft develop a state of resistance to toxic injury. (Reprinted 
from Holzknecht and Platt, 2000) [406]. 
 
 In addition to the cytokines mentioned in Figure 1-7, IL-6 and IL-17A have been 
reported to be involved in graft rejection. Itoh et al., 2010 showed that IL-17A accelerates 
allograft rejection by suppressing Treg cell expansion [407]. Also, IL-17A is temporarily 
increased in bronchoalveolar lavage fluid during acute rejection after lung transplantation 
[408]. IL-6 is a very important mediator of inflammation during allograft rejection. In renal 
transplant patients, delayed graft function was associated with high urine levels of IL-6, 
which declined once graft function recovered. Inhibition of IL-6 production could be one of 
the mechanisms by which steroids prevent allograft rejection as steroids are strong anti-
inflammatory agents [409]. IL-6 has also been implicated in acute and chronic cardiac 
rejection [410-414].  
cGVHD 
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 cGVHD is the most common non-relapse problem affecting long-term survival of 
alloHSCT recipients occurring in approximately 50% of transplant patients [415, 416]. As I 
mentioned earlier in Section 1.2.2.1, cGVHD has features resembling autoimmune 
disease. Although donor T cells play a central role in the development of cGVHD, several 
independent lines of evidence clearly demonstrate that B cells are involved in the 
pathogenesis of cGVHD [417], and autoantibodies can frequently be detected in patients 
with cGVHD [418-425]. In addition to antibody production, B cell antigen presentation, 
cytokine production, and immune regulation, which are thought to be involved in cGVHD 
[418, 426].  
 
 In clinical transplantation, therapies that deplete peripheral leukocytes, including T 
cells, are effective in preventing and reversing episodes of acute rejection and improving 
long-term graft and patient outcomes [427, 428]. At present, the most effective single 
therapeutic agents which prolong graft survival are calcineurin inhibitors, such as 
cyclosporine A and tacrolimus [429]. However, the major problem with the use of 
calcineurin inhibitors is they abrogate tolerance induction by costimulatory blockade, in 
association with inhibition of T cell apoptosis [430]. An additional problem with these non-
specific immunosuppressive agents is that they target all T cell subsets including Treg that 
regulate and control immune response [429]. Also, major toxicities of cyclosporine A 
include infection, renal impairment, thrombotic microangiopathy, and hypertension [431]. 
Based on the fact that B cells might possibly produce pathogenic antibodies in cGVHD, 
drugs that target B-cells may be an alternative for immune intervention in cGVHD. A 
number of studies have analysed the potential of rituximab in patients with cGVHD and 
several positive effects have been observed, mostly including reduction of skin 
manifestations of cGVHD [432-439]. However, among many of the responding cGVHD 
patients, rituximab failed to establish a complete recovery. There were also patients who 
were totally unresponsive to rituximab treatment [440]. Also, extensive depletion of all 
mature B cells with rituximab may affect the GVL response, as interaction between B and 
T cells proposed in cGVHD is similar to GVL [441] 
 
 In conclusion, inhibition of activated DC stimulated CD4 T responses and B cell 
responses to alloantigens are the key factors to prevent transplant rejection. A remedy 
which can target all three cell types, such as anti-CD83 antibody, may be a better strategy 
to prevent and treat transplant rejection in patients. 
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Chapter 2: Rationale and Aims 
 
2.1 Rationale 
Twenty years after its initial description, the CD83 molecule remains enigmatic. The 
data accumulated so far does not lead to a final model of peripheral CD83 function. CD83 
is not expressed exclusively on activated DC but is also expressed at low levels by 
germinal centre B cells and is inducible, following activation, on T and B cells. CD83 
upregulation and expression has a complex impact on B- and T-cell activation, survival 
and function. Therefore the understanding of the mechanism of action of CD83 antibody is 
an important step for the design of better immuno-modulatory drugs.  
 
Wilson et al, 2009 showed that Ab specific for the DC activation marker CD83 is a 
potential new therapeutic option for the control of GVHD in alloHSCT [81]. Their in vitro 
and in vivo studies showed that anti-CD83 not only limits the uncontrolled T cell 
proliferative response that characterizes GVHD but preserves the donor T-cell repertoire, 
potentially lifesaving anti-viral memory T-cells and anti-leukaemic effectors. In contrast to 
current GVHD prophylaxis, which depends on T-cell depletion of the graft before transplant 
or nonspecific immunosuppression post transplantation, which do not spare these vital 
components of the donor graft [442]. We also previously shown that anti-human CD83 
antibody depletes activated DC and CD4 T cells by NK cell mediated ADCC [83]. We have 
shown that in vivo, Ab-mediated targeting of CD83+ delays GVHD in murine allogeneic 
HSCT model. Murine CD83 antibodies RAM83 and MAM83 each conferred a survival 
advantage to allogeneic HSCT recipients (manuscript in preparation) (Figure 2-1). 
However, our experiment data showed that the addition of anti-mouse CD83 antibody to a 
killing assay did not enhance NK or complement-mediated cytotoxicity. Thus, in chapter 4 I 
have chosen to investigate the mechanism of action of anti-CD83, which will give us 
insights into how this Ab works and its impact on activated CD83+ APC particularly in 
GVHD. 
 
In addition, I am also interested in investigating the effects of anti-CD83 treatment 
on Ab responses. This may have utility in other conditions such as autoimmune disease, 
cGVHD, solid organ transplantation and allergy. Patients with RA can be treated 
successfully by B-cell depleting antibodies such as anti-CD20 mAb rituximab. There are 
reports indicating it is also effective in SLE, but the results of randomized controlled phase 
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3 trials have been disappointing. This may be due to sparing of other pathogenic cell 
targets such as CD4 T-cells. We have shown that anti-CD83 lyses activated CD4+ T-cells, 
DC and B cells, sparing resting T cells, DC and B cells. I investigated this finding to 
determine the effects of anti-CD83 on Ab responses in detail.  It is vital to determine if anti-
CD83 is safe and more effective than the current treatment so that it might become a 
treatment option for the above conditions in the future. 
 
 
 
Figure 2-1: CD83 antibodies RAM83 (polyclonal) and MAM83 (monoclonal) each 
conferred a survival advantage to murine allogeneic HSCT recipients. 
 
 
In summary, I hypothesized that CD83 may be a therapeutic target in clinical 
applications such as GVHD and humoral immunity (Figure 2-2). 
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Figure 2-2: CD83 is expressed on activated DC, activated T and B lymphocytes, activated 
macrophages and monocytes, a regulatory subset of NK cells, activated neutrophils and 
thymic epithelial cells. CD83 expressed on APC may play a crucial role in aGVHD. While 
CD83 expressed on T helper cells and B cells may affect adaptive humoral immune 
responses.  
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2.2 Hypotheses and Aims 
 
Hypothesis 1: Binding of anti-CD83 to CD83 induces increased MARCH1-mediated 
degradation of MHCII and CD86 on activated APC resulting in reduced T-cell 
activation and attenuated GVHD. 
 
Chapter 4: Binding of anti-CD83 to CD83 induces degradation of MHCII and CD86 on 
activated APC resulting in reduced T-cell activation and attenuated GVHD 
Aim 1: To ascertain the in vitro effects of anti-CD83 on MHCII and CD86 expression 
Aim 2: To determine if binding of anti-CD83 to CD83 promotes MARCH-1 mediated 
ubiquitination of MHCII 
Aim 3: To determine the effects of anti-CD83 on alloproliferation of T-cells stimulated by 
APC 
Aim 4: To determine the effect of anti-CD83 on antigen specific T-cell proliferation 
 
 
Hypothesis 2: Anti-CD83 Affects Humoral Immune Responses 
 
Chapter 5: Anti-CD83 mediated inhibition of human humoral immune responses  
Aim 1: To characterize anti-CD83 mediated inhibition of B cell responses to stimulation (in 
vitro). 
Aim 2: To define the kinetics of CD83 expression by B cells on stimulation (in vitro). 
Aim 3: To characterize the effects of anti-CD83 treatment on human B cell responses in 
vivo (xenograft model). 
 
Chapter 6: Anti-CD83 mediated stimulation of murine antibody responses  
Aim 1: To characterize CD83 expression by murine B cell subsets and the effects of CD83 
deficiency on responses to TI-2 and TD immunization. 
Aim 2: To investigate the effect of anti-CD83 treatment on antigen specific antibody 
responses to TI and TD immunization of immunocompetent mice. 
Aim 3: To investigate in vitro TI-2 responses and class switching induced by anti-CD83 
treatment. 
 
 
 
 36 
 
Chapter 3: General Materials and Methods 
 
3.1 Preparation of polyclonal rabbit anti-mouse CD83 (RAM83) Ab  
mCD83-FC transfectant was a gift from Dr. Martina Jones (AIBN-UQ). mCD83-FC protein 
was then purified by chromatography using a HiTrap Protein A column (Bio-Rad). 
Immunization of rabbits with mCD83-FC protein was done by South Australian Health and 
Medical Research Institute (SAHMRI), South Australia. After repeated immunizations with 
mCD83–FC, the rabbit was given a final boost with mCD83–FC and the sera collected 10 
days later. The Ig fraction was then purified by chromatography using a HiTrap Protein A 
column (Bio-Rad). Cross-reactive Ig within the purified fraction was then depleted by 
passage over human IgG (Intragam, CSL Bioplamsa, Parkville Australia) which was bound 
to a NHS-activated High Performance column (GE Healthcare) and rabbit antibody 
reactive to the human IgG Fc component of the CD83 fusion protein was removed from 
rabbit IgG collected from the protein A column. The non-absorbed Ig fraction was then 
used as rabbit anti-mouse CD83 in all experiments described in chapter 4 and 6. The 
specificity of RAM83 was analyzed by ELISA. Briefly 96-well plates were coated with 
CD83-mFC (1 μg/ml) then following blocking (1% BSA in PBS), incubated with rabbit Ig (1 
μg/ml) diluted in 1% BSA in PBS. Following washing, wells were incubated with Goat anti-
rabbit IgG-HRP (1:5000 dilution in 1% BSA in PBS), then following further washing, 
developed with SIGMAFASTTM OPD (o-phenylenediamine dihydrochloride) (Sigma-
Aldrich). OD was measured at 490 nm using an ELISA reader (Bio-Rad). 
 
3.2 Preparation of monoclonal anti-mouse CD83 (MAM83) Ab 
Anti-mouse CD83 transfectants were provided by AIBN-UQ. The Ig fraction was then 
purified by chromatography using a HiTrap Protein A column (Bio-Rad). The Ig fraction 
was then eluted with 0.1M Glycine pH 2.7 (Sigma-Aldrich) and neutralized immediately 
with 400μl of 1M pH 9.0 Tris-(hydroxymethyl)-aminomethane (Sigma-Aldrich) per ml of 
eluted antibody.  Antibody collected was termed MAM83. 
 
3.3 Anti-human CD83 Ab 
Three anti-human CD83 antibodies were used: affinity purified rabbit polyclonal anti-
human CD83 (RA83, Wilson et al., 2009 [81]) and human IgG1 mAbs specific for CD83 
(3C12.C and 3C12.Ckif, which are improved versions of 3C12, which is described by 
Jones et al., 2010 [84]). Polyclonal antibody RA83 is effective at ADCC lysis [81, 83], as 
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are the two other mAbs (Therese Seldon, 2011) [85]. 3C12.C is an antigen affinity matured 
version of the original 3C12 and has undergone preclinical development as a potential 
prophylactic for GVHD (Therese Seldon, 2011) [85]. 3C12.Ckif has further enhanced 
ADCC efficacy due to a modification of the oligosaccharide side chain of the mAb heavy 
chain Fc region which confers higher affinity for the ADCC inducing CD16a Fc receptor on 
NK cells [443]. 
 
3.4 Mice 
All animal work was approved by the University of Queensland Animal Ethics Committee 
(AEC approval numbers: 124/11 and 149/11) (Appendix A and B). SCID mice, BALB/c (H-
2d) and C57BL/6 (H-2b) were purchased from the Animal Resources Centre (WA, 
Australia) or from UQ Biological Resources (UQBR). OTI and OTII (C57BL/6 (H-2b) 
background) were obtained from Dr Ray Steptoe at Diamantina Institute, University of 
Queensland, Australia. CD83anu/anu mice were bred in house. All mice were housed under 
specific sterile conditions and acclimatised for at least 3 days prior to experimental work. 
 
3.5 Conditioning and Transplantation 
Anti-Asialo GM1 (aASGM1) antibody was injected intraperitoneally (i.p) into SCID mice 
and total body irradiation at 275cGy was delivered on the day before engraftment using 
137Cs irradiator (Gammacell40). 30 x 106 Human PBMC was injected i.p into SCID mice on 
the day of transplantation [81].  
 
3.6 Immunization 
BALB/c or C57BL/6 were immunized i.p. with 25 μg of trinitrophenyl (TNP)-Ficoll or 4-
hydroxy-3-iodo-5-nitrophenyl-acetyl (NIP)-Ficoll [TI type 2 antigen), in PBS or 25 μg of 
alum-precipitated TNP–KLH (TD antigen). All antigens were obtained from Biosearch 
Technologies. Serum samples were collected before immunizations and on day 7, day 14 
and day 21 after the immunization with TI or TD antigen. SCID mice were immunized with 
200µl of TTvac (Equivac T vaccine, Pfizer) or KLH-adjuvant (1:20 ratio of CFA/IFA). 
 
3.7 Determination of serum immunoglobulins by ELISA 
For human ELISA assays, Nunc Immuno plates (Thermo Fisher Scientific, USA) were 
coated with 2µg/ml of purified mouse anti-human IgM or IgG monoclonal antibody (BD, 
USA) 5µg/ml of TT and 20µg/ml KLH. For murine ELISA assays, Nunc Immuno plates 
were coated with 5 μg/ml of TNP-BSA or NIP-BSA (Biosearch Technologies, USA). Mouse 
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serum was incubated on plates in a dilution ranging from 1:1000 to 1:51200 for total IgG, 
IgM and IgG1, for IgG2a, IgG2b and IgG2c, 1:100-1:2,000 for IgG3, 1:200 to 1:6400, and 
1:50 to 1:1600 for IgA.  In between all steps, plates were washed at least three times and 
bound antibodies were detected with corresponding HRP-conjugated goat anti–mouse or 
anti-human IgM, IgG (both from Jackson Laboratories), IgG1, IgG2a, IgG2b, IgG2c, IgG3 
and IgA (all from SouthernBiotech) antibodies. Colorimetric reaction was produced by final 
incubation with SIGMAFASTTM OPD (o-phenylenediamine dihydrochloride) (Sigma-
Aldrich). OD was measured at 490 nm using an ELISA reader (Bio-Rad).  
 
3.8 General Cell Culture 
HEK293T cells or CD40L L cells were grown in Dulbecco's Modified Eagle Medium 
(DMEM) while human PBMC, KM-H2, Raji and murine cells were cultured in RPMI 1640, 
both containing 10% of fetal bovine Serum (FBS) supplement, Hepes (10mM) and 100 
units/ml of penicillin and 100 units/ml of streptomycin (all from Gibco Life Technologies) 
and incubated at 37°C in 5% CO2.   
 
3.9 Thawing of Cells 
Frozen cells were rapidly thawed in a 37°C water bath and immediately placed into 9 ml of 
pre-warmed medium DMEM or RPMI containing 10% FBS. Following centrifugation at 500 
xg for 5 min, supernatant was removed and cells resuspended in 1 ml of appropriate 
medium prior to counting. 
 
3.10 Transformation and Transfection (Chapter 4) 
Vectors were obtained from Tze et al., 2011[34] (List of transformed vectors are MARCH-
1, Flag-hCD4-IAb WT, Flat-hCD4-IAb KR, CD83 WT and CD83 Chimera 2) and were 
transformed using the protocol as described in E.coli Competent Cells Quick Protocol 
(Promega). Before transfection, plasmids DNA were quantitated. DNA required per well in 
6-well plate was 4ug. Groups of plasmid DNA that transfected into HEK293T cells was as 
below: Sample 1: March 1-V5 (4ug); Sample 2: Flag-hCD4-IAb WT (4ug); Sample 3: Flag-
hCD4-IAb WT (2ug), March 1-V5 (2ug); Sample 4: Flag-hCD4-IAb KR (2ug), March 1-V5 
(2ug); Sample 5: Flag-hCD4-IAb WT (0.4ug), March 1-V5 (1.6ug), CD83 WT (2ug) and 
Sample 6: Flag-hCD4-IAb WT (0.4ug), March 1-V5 (1.6ug), CD83 Ch2 (2ug). 
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Figure 3-1: Schematic of chimeric proteins comprising the indicated segments from CD83, 
human CD4 (hCD4), and mouse class II I-Aβb (IAb).  
 
HEK293T cells were transfected using LipofectamineTM 2000 (Invitrogen) protocol and 
analysed by flow cytometry 24hr after transfection. HEK293T cells were transfected with 
the vectors encoding Flag-hCD4 IAb WT (containing the MHC II I-Aβb TM and cytoplasmic 
regions and the hCD4 extracellular domain) or KR (K255R missense mutation in the Flag-
hCD4-IAb cytoplasmic tail which prevents ubiquitination of MHC II), MARCH1-V5, CD83 
WT, or CD83 chimera 2 where TM segment is substituted with that from hCD4 (Figure 3-
1). 
 
3.11 Immunoprecipitation and immunoblotting-Ubiquitination (Chapter 4) 
To detect ubiquitination, the proteasome inhibitor MG-132 (Calbiochem, Millipore) was 
added at a final concentration of 20 µM 3hrs before the cells were harvested to reduce the 
degradation of ubiquitin-conjugated proteins. Cells were harvested and washed once with 
PBS. Cells were lysed in a buffer containing 1% SDS, 2 mM dithiothreitol (DTT), and the 
protease inhibitor mixture followed by denaturation at 100 °C for 5 min. This mixture was 
then diluted 10 fold in buffer containing 0.55% IGE-PAL, 55.55 mM Tris (pH 8.0), 11.1 mM 
MgCl2, and protease inhibitor mixture. MHCII complexes were isolated by 
immunoprecipitation using anti-MHCII antibody (Y-Ae; Santa Cruz Biotechnology) 
immobilized on protein G Agarose beads (Pierce, Thermo Scientific) and analysed by 
immunoblotting. Samples were fractionated by 4-12% SDS-PAGE. The membranes were 
blocked with TBST buffer (20mM Tris-HCl, pH 7.4, 150mM NaCl, and 0.05% Tween) and 
blocking buffer (5% skim milk/TBST) then stained with anti-ubiquitin antibody (P4D1; 
Santa Cruz Biotechnology), followed by detection using a chemiluminescent HRP 
substrate kit (Pierce, Thermo Scientific).  
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3.12 Human peripheral blood mononuclear cells (PBMC) 
PBMC were purified from freshly collected blood from healthy donors (ethic no. 1407-AP, 
Appendix C). 17ml of Peripheral blood were diluted with 18ml of 1xPBS and under-layed 
with 15ml of Ficoll (GE Healthcare). Mononuclear cells were then obtained by density 
gradient centrifugation at 1,600rpm for 30 mins at room temperature with no brake. The 
separated mononuclear cells were recovered from the buffy coat interface and 
resuspended in 1xPBS. Mononuclear cells were then washed once with 1XPBS and 
pelleted by centrifugation at 500 x g for 10 mins at room temperature with low brake. Cells 
were then resuspended in 10% FBS RPMI in 50x106 cells/ml. 
 
3.13 Mixed Lymphocyte Reaction (MLR) 
In the murine model, stimulator splenocytes were harvested from BALB/c mice on the day 
prior to the MLR. Mouse CD11c Positive Selection Kit (EasySep, STEMCELL 
Technologies,USA) or CD11c+ microbeads (Miltenyi, CA, USA) or T-cell depleted kit 
(EasySep, STEMCELL Technologies, and USA) were used to isolate DC or APC 
populations from murine splenocytes using manual separation columns as per 
manufacturer procedures (Miltenyi, CA, USA). The purity of the cell preparation was 
evaluated by flow cytometry and was consistently greater than 80% of CD11c+ and 5-10% 
CD19. Cells were cultured overnight with 10% FBS/RPMI (Gibco Life Technologies) and 
activated with LPS (2ug/ml; Sigma-Aldrich) and 200ug/ml Ovalbumin (only in specific 
experiments when stimulators were obtained from C57BL/6 mice) (Sigma-Aldrich, MO, 
USA) in the presence of CD83 antibodies (RAM83 or MAM83), IgG control RANeg and 
IgG2a control Isotype (20ug/ml). On day 0, T cells were isolated from spleens of C57BL/6 
mice or OTI (CD8 T-cells) and OTII (CD4 T-cells) mice using the Mouse T cell Enrichment 
Kit (EasySep, STEMCELL Technologies, and USA). Purified T-cells were labelled with 
carboxyfluorescein succinimidyl ester (CFSE) (5uM) (Molecular Probes®-Life 
Technologies, USA)  for 15mins in 37°C and 5x105 CFSE labelled T-cells were co-cultured 
with 5x104 activated stimulators for 4 days in the presence of CD83 antibodies. The 
proliferation of T-cells was measured by CFSE dilution using flow cytometry. In the human 
model, the allogeneic mixed lymphocyte reaction (alloMLR) was performed with fresh or 
frozen human PBMC as stimulators or responders. 1X106 of two different human PBMC 
were cultured together with RPMI containing 10% of FBS without irradiation of stimulator in 
the ratio of 1:1 in 24-well plate. 
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3.14 Isolation and activation of peritoneal cavity and splenocytes (Chapter 6) 
5ml of 10% FBS RPMI 1640 media was injected into the peritoneal cavity (PC) of 
euthanized BALB/c mice using a 18-gauge needle. The mouse abdomen was massaged 
gently before the lavage fluid containing peritoneal cells was withdrawn using sterile 
pasteur pipette. Additional 3-5 ml media was used to wash the PC to prevent loss of 
peritoneal cells. The spleen was harvested and splenocytes were crushed and filtered 
through 70 µm of cell strainer (BD, USA). 2 ml of red blood cell lysis buffer was added to 
the crushed splenocytes and lysis was stopped by adding 20ml of fresh culture media 
containing (RPMI 1640 supplemented with 10% FBS, Hepes (10mM) and 100 units/ml of 
penicillin and 100 units/ml of streptomycin). Cells were pelleted by centrifugation at 500 X 
g for 5 mins at 4°C and resuspended in fresh culture media. Cells were then labelled with 
CFSE at concentration of 2.5 µM for 15 mins at 37°C and then quenched, spun at 500 X g 
for 5 mins and resuspended in culture media. 1x106 CFSE-labelled cells were added to 
each well of a 48-well plate and stimulated with dextran-conjugated anti-IgD antibody (αδ-
dex) (5ng/ml) (Fina BioSolutions LLC, USA) and IL-5 (150 U/ml) (PeproTech, USA)  in the 
presence of anti-CD83 or its controls at 37°C in 5% CO2 for 6 days or 8 days. At day 6, 
cells were surfaced stained and proliferation assessed by CFSE dilution by flow cytometry. 
The supernatant of cells was collected at day 8 for analysis of cytokine production by 
ELISA analysis. 
 
3.15 Cell depletion assays 
CD11c DC, CD56 NK cells and CD19 B cells were depleted according to the 
manufacturer’s instructions (Miltenyi Biotec). 
 
3.16 B cell Stimulation and Proliferation (Chapter 5) 
For experiments investigating antigen specific B cell stimulation, CFSE-labelled human 
PBMC were cultured with RPMI containing 10% of FBS and stimulated with TT (10 µg/ml) 
in the presence of anti-CD83 (RA83 or 3C12.Ckif), rituximab (anti-CD20) or control 
antibody (RANeg or human IgG1 Isotype) (1µg/ml) for 6 days. In the CD83 kinetics study, 
human PBMC are labelled with CFSE (1µM) and cultured with anti-IgG+anti-IgM (2µg/ml), 
CD40L transfected cells or LPS (2µg/ml) for six days. Proliferation was assessed by CFSE 
dilution by flow cytometry. 
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3.17 Intracellular cytokines staining (ICS) (Chapter 5) 
CFSE-labelled human PBMC were cultured with RPMI containing 10% of FBS and 
stimulated with TT (10 µg/ml). On day 6 of culture, cells were cultured at 37°C in 5% CO2 
with 20 ng/mL phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) plus 1 μM ionomycin 
(Sigma-Aldrich or Molecular Probes) for 6 hr. After 2 hr, monensin (GolgistopTM BD) was 
added at a final concentration of 10 μg/mL for the last 4 hr of culture. Finally, cells were 
surface-stained, fixed and permeabilised for ICS. 
 
3.18 PBMC supernatant cytokine assay (Chapter 5) 
PBMC (2×106 cells/mL) were stimulated with TT (10ug/ml) for 6 days. The 6 day culture 
supernatants were assayed for cytokine secretion (IFN-γ, TNF-α, IL-2, IL-4, IL-5, IL-13, IL-
10) by 8-plex as directed by manufacturer using a Bio-plex system (Magpix, Bio-Rad).  
 
3.19 Antibodies and Flow Cytometry 
Cellular phenotypic analysis in the murine model was performed by flow cytometry using 
fluorescently labeled rat anti-mouse antibodies (except where stated) as follows: CD4 
Pacific Blue (PB) (RM4-5, IgG2a), CD8 allophycocyanin (APC) (53-6.7, IgG2a), MHC class 
II (I-A/I-E) pacific blue (PB) (M5/114.15.2, IgG2b), CD86 PE-cy7 (GL1, IgG2a), CD83 
allophycocyanin (APC)(Michel-19, IgG1 ), CD19 allophycocyanin-cyanine dye (APC-Cy7) 
(1D3, IgG2a), CD19 (PE) (1D3, IgG2a), CD43 (FITC)(S7, IgG2a), CD23 (PE-Cy7)(B3B4, 
IgG2a), CD21 (APC-Cy7)(7E9, IgG2a), CD5 (V450)(53-7.3, IgG2a), B220 (PE)( RA3-6B2, 
IgG2a). Human cellular phenotypic analysis was performed by flow cytometry using 
fluorescently labeled mouse anti-human antibodies (except where stated) as follows CD4 
Pacific Blue (PB) (RPA-T4, IgG1), CD4 (APC-h7) (RPA-T4,IgG1), CD11b (APC-Cy7) 
(ICRF44,IgG1), CD14 (PE-Cy7) (M5E2,IgG2a), CD19 (PB) (SJ25-C1,IgG1, Invitrogen), 
CD20 (PB) (IgG1), CD27 (APC) (M-T271,IgG1), CD43 (FITC)(1G10,IgG1), CD45 
(APC)(2D1,IgG1), CD83 (FITC)(HB15e,IgG1)/ (PE)(HB15e,IgG1)/ (PE-Cy7)(HB15e,IgG1)/ 
(APC)(HB15e,IgG1), HLA-DR (FITC)(G46-6,IgG2a)/(APC)(G46-6,IgG2a), CD86 (PE)(2331-
FUN1,IgG1). Unless stated, all antibodies were purchased from Becton-Dickinson (BD 
Pharmingen, San Jose, CA or eBioscience) as were appropriate isotype controls.  Cells 
were washed in MACs buffer containing PBS, 2mM EDTA, 0.5% BSA and 0.09% sodium 
azide. 50,000 or more events were collected using a BD LSRII (BD, San Jose, CA) or 
CYAN ADP Analyser (DAKO) and analyzed using Flowjo (Flowjo 8.8.7). 
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3.20 Statistical analyses 
For normally distributed data, differences between groups were analysed with paired 
Student’s t-test; for non-normally distributed data, differences were analysed by the 
nonparametric Mann Whitney or Wilcoxon Signed Rank tests.  The normality tests used 
were: KS normality test, D'Agostino & Pearson omnibus normality test, or Shapiro-Wilk 
normality test. In chapter 4, all the statistical analysis was done using raw MFI data, the 
fold change of MFI is only for presentation purposes. All data involving comparisons 
across time between treatment and control were analysed by 2-way ANOVA. Other 
comparisons were made by 1-way ANOVA. Results were expressed as means or means ± 
SEM, and unless otherwise stated, were considered statistically significant at P < 0.05. All 
statistical tests were performed using Prism 5.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44 
 
Chapter 4: Binding of anti-CD83 to CD83 induces degradation 
of MHCII and CD86 on activated APC resulting in reduced T-
cell activation and attenuated GVHD 
 
4.1 Introduction 
We have shown that CD83 antibody treatment delays GVHD in a murine model of 
allogeneic HSCT (manuscript in preparation). Based on studies done by another lab 
member, we concluded that the mechanism of action was not NK-mediated ADCC killing 
of CD83+ DC. We were interested to determine the mechanism of action of anti-CD83 in 
delaying GVHD. Kuwano et al., 2007 reported that CD83 expression might affect MHCII 
antigen expression within the thymus and periphery. Their study showed that CD83 
deficiency reduced MHCII cell surface expression by 25%-50% on splenic B cells and DC, 
thymic epithelial cells and peritoneal macrophages [11]. A recent study reported that the 
TM segment of CD83 is essential to stabilize surface display of MHCII and CD86 by 
regulating their rate of cell surface turnover [34]. However, the exact correlation of these 
phenomena to the modulation of T-cell proliferation by CD83 remains largely 
undetermined. Thus, we determined that it was vital to understand the interaction between 
CD83 and MHC class II. I therefore hypothesized that CD83 antibody may block CD83 TM 
from binding and hence downregulate the surface expression of MHCII and CD86 on APC 
and as a consequence reduce stimulation of allogeneic CD4+ T-cell proliferation.  
 
Ubiquitination has been shown to play a critical role in fine-tuning the regulation of 
MHCII antigen presentation, with significant roles in antigen receptor internalization and 
turnover of MHCII at the cell surface [444]. It has been reported that transgenic 
overexpression of MARCH VIII/c-MIR in mouse splenic APC leads to internalization of 
surface CD86 and MHCII, and subsequent lysosomal degradation [445]. Furthermore, 
deletion of the E3 ubiquitin ligase, MARCH-1 promoted an increase of surface MHCII 
levels in mouse B cells [446]. Another study reported that down-regulation of MARCH I is a 
key event in MHC class II up-regulation at the surface of LPS-activated DCs [447]. In 
addition, Tze et al., 2011 found that the CD83 TM domain opposes the effects of MARCH-
1 and promotes MHCII surface display. Adding this evidence together, I hypothesized that 
binding of anti-CD83 to CD83 induces increased MARCH1-mediated degradation of MHC 
II and CD86 on activated APC by ubiquitination.  
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4.2 Aims 
Aim 1: To ascertain the in vitro effects of anti-CD83 on MHCII and CD86 expression 
Aim 2: To determine if binding of anti-CD83 to CD83 promotes MARCH-1 mediated 
ubiquitination of MHCII 
Aim 3: To determine the effects of anti-CD83 on alloproliferation of T-cells stimulated by 
APC 
Aim 4: To determine the effect of anti-CD83 on antigen specific T-cell proliferation 
 
 
4.3 Results 
 
Aim 1: To ascertain the in vitro effects anti-CD83 on MHCII and CD86 expression 
4.3.1 CD83 antibody treatment of activated murine APC (DC & B cells) 
4.3.1.1 Rationale 
According to the study by Tze et al., CD83 TM is essential to stabilize surface display of 
MHCII and CD86. I wanted to determine if binding of anti-CD83 would disrupt the stability 
of MHCII and CD86 surface display, and hence reduce the expression of MHCII and CD86 
on splenocytes. 
 
4.3.1.2 Experimental design 
To determine if CD83 antibody treatment affects MHCII and CD86 expression, the mouse 
CD11c positive selection kit or T-cell depletion kit was used to isolate APC populations 
from murine splenocytes. The purity of CD11c and T-cell depletion was consistently 
greater than 80%. 4x106 T-cell depleted or enriched DC murine splenocytes were cultured 
in 10% RPMI and activated with 2ug/ml LPS overnight in the presence of CD83 or control 
antibodies in 6 well plates. Analysis of cellular phenotype was performed by flow cytometry 
using fluorescently labelled rat anti-mouse antibodies (Section 3.19). 
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Figure 4-1: Experimental design of anti-CD83-treatment of LPS-activated stimulators 
overnight. RAM83-Rabbit anti-mouse CD83 polyclonal antibody; RANeg-control for 
RAM83; MAM83- murine anti-murine CD83 monoclonal antibody, IgG2a ; Isotype- IgG2a 
Isotype control for MAM83. 
 
 
4.3.1.2 Results 
(i) Upregulation of MHCII, CD86 and CD83 by LPS activation 
(A) 
 
 
 
 
 
 
 
 
LPS 
No LPS 
CD11c 
DC 
CD19 
B cells 
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(B) 
 
 
Figure 4-2: (A) Confirmation of LPS-induced upregulation of cell surface MHCII, 
CD83 and CD86 on DC and B cells. Representative cytometry histograms show 
upregulation of MHCII, CD86 and CD83 in DC and B-cells with LPS treatment. (B) 
Summary of fold change of MFI of LPS treatment relative to no LPS (1.0). The solid 
horizontal lines are the means obtained from at least eleven independent experiments. 
**p<0.01, ***p<0.001. Statistical analysis: paired student t-test (the analysis was done using 
raw MFI data, the fold change of MFI is only for presentation purposes) 
 
LPS activation significantly upregulated MHCII, CD86 and CD83 expression on 
CD11c+ DC and CD19 B cells. Anti-CD83 treatments were considered successful only 
when MHCII, CD86 and CD83 were upregulated during the experiments.  
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(ii) MHCII and CD86 expression of DC and B cells treated with anti-CD83 
(A) 
 
             
 
 
  
 
 
(B) 
 
 
RAM83 
RANeg 
MAM83 
Isotype 
Top panel: CD11c DC, bottom panel: CD19 B cell 
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Figure 4-3: Anti-CD83 induces downregulation of MHCII but not CD86. (A) 
Representative cytometry histograms show surface expression of MHC II and CD86 on 
CD11c DC and B-cells cultured with polyclonal (RAM83), monoclonal CD83 (MAM83) Ab 
or their controls. (B) The summary graphs show the fold change of MFI due to anti-CD83 
treatment relative to their controls (1.0).  The solid horizontal lines are the means from at 
least eleven experiments. *p<0.05, ***p<0.001. Statistical analysis: 2-tails paired student t-
tests. 
 
MHCII expression by CD11c DC was decreased 12% (p<0.05, n=11) by RAM83 
treatment. There was no statistically significant difference in CD86 expression by 
CD11c+MHCII+ DC treated with RAM83 or RANeg. Similar findings were observed in B-
cells where MHCII expression was significantly downregulated (p<0.05, n=9). MAM83 
significantly decreased MHCII expression by CD11c+ DC by approximately 20% (p<0.001, 
n=11). In B-cells, the expression level of MHCII was downregulated more than 25% 
(p<0.05, n=9). Treatment with MAM83 did not decrease CD86 expression on either DC or 
B cells. In summary, MHCII, but not CD86, was significantly downregulated by CD83 
antibody treatment. 
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Aim 2: To determine if binding of anti-CD83 to CD83 promotes MARCH-1 mediated 
ubiquitination of MHCII. 
4.3.2 MHCII and CD83 expression following HEK293T cells transfection 
4.3.2.1 Rationale 
Tze et al., 2011 reported that in the presence of IL-10 and LPS, the TM domain might 
antagonise MARCH-1-MHC II association and ubiquitination and hence promote MHCII 
surface display [34]. In contrast, Kuwano et al. 2007 showed that CD83 deficiency did not 
appear to alter class II ubiquitination [11]. Therefore, we do not know whether MHCII 
ubiquitination is CD83 dependent. It is important to investigate the role of CD83 on MHCII 
display and ubiquitination as it affects antigen presentation. If it is true as reported in Tze 
et al., 2011, an antibody directed against CD83 as a therapy to prevent GVHD may work 
by the antibody blocking CD83 from binding to March-1 thereby decreasing the surface 
display of MHC class II by promoting MHCII degradation via the ubiquitination pathway 
(Figure 4-4). I modified Tze et al. diagram below (Figure 4-4 (A)) by adding CD83-ab and a 
large red cross to denote my hypothesized anti-CD83 inhibiting the interaction of CD83 TM 
with MARCH1 (Figure 4-4 (B)). 
 
 
 
 
Figure 4-4: Proposed mechanism of CD83 antibody-mediated GVHD attenuation. 
CD83 antibody prevents CD83 TM from binding to MARCH1, allowing IL10 to induce 
MARCH1 transcription, despite TLR signalling, driving ubiquitination, and degradation of 
MHCII and CD86 on activated APC (DC & B cells), thereby reducing T cell activation by 
activated APC and thus attenuating GVHD [34]. 
 
 
 
No ubiquitination & no degradation ubiquitination & degradation 
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4.3.2.2 Experimental design 
HEK293T cells were transfected with vectors encoding Flag-hCD4 IAb WT (containing the 
MHC II I-Aβb TM and cytoplasmic regions and the hCD4 extracellular domain) or KR 
(K255R missense mutation in the Flag-hCD4-IAb cytoplasmic tail which prevents 
ubiquitination of IAb/MHC II), MARCH1-V5, CD83 WT, or CD83 chimera 2 where the 
CD83 TM segment is substituted with that from hCD4. All vectors were obtained from [34]. 
Successful V5 tagged March1 transfection was confirmed by immunoblot analysis for the 
V5 tag. The expression of hCD4 (surrogate for MHCII/IAb) and CD83 were analysed by 
flow cytometry 24hrs after transfection. Transfected HEK293 cells were then treated with 
anti-CD83 mAb MAM83 or isotype control. The effects of MAM83 on CD83 expression and 
on MHCII expression were assessed by flow cytometric staining with APC-CD83 and PB-
anti-human CD4.  
 
4.3.2.3 Results 
 
Figure 4-5: Western-blotting showed the MARCH1 was transfected into the HEK293 cells. 
 
 Immunoblotting of anti-MARCH1 flag-tagged V5 confirmed that MARCH1 had been 
successfully transfected in HEK293 cells (lane 1 and 3, Figure 4-5). Transfected HEK293 
cells with MHCII alone showed no expression (lane 2, Figure 4-5) of MARCH1, which 
further validated the transfection. 
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Figure 4-6 and 4-7: Representative histograms show flow cytometric analysis of cell 
surface expression of Flag-hCD4-IAb and CD83 24hrs following transfection of cells. 
(Transfected vectors groups: 1: March 1-V5; 2: Flag-hCD4-IAb WT; 3: Flag-hCD4-IAb WT, 
March 1-V5; 4: Flag-hCD4-IAb KR, March 1-V5; 5: Flag-hCD4-IAb WT, March 1-V5, CD83 
WT; 6: Flag-hCD4-IAb WT, March 1-V5, CD83 Ch2) 
 
All vector groups were successfully transfected into HEK293 cells (Figure 4-6 and 
4-7). This validated the method and constructs by Tze et al. (2011). MHCII (hCD4) 
expression was lower in cells co-transfected with MARCH-1 (compare 3, 5 6 with 2, 4 in 
Figure 4-6), as expected because MARCH1 ubiquitinated- MHCII and hence decreased its 
surface display.  Also as expected, MHCII expression was higher for the transfectant with 
the KR missense mutation in the Flag-hCD4-IAb cytoplasmic tail (4) (Figure 4-6) because 
the mutated MHCII will not bind to and become ubiquitinated by MARCH1. Among all 
groups, only transfected group 5 was relevant and used for the study and to test the 
ubiquitination of MHCII by anti-CD83. 
Figure 4-6 Figure 4-7 
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Figure 4-8: Group 5- HEK293T cells were transfected with the indicated vectors 
encoding Flag-hCD4 IAb WT, March1-V5, and CD83WT and treated with anti-CD83 
MAM83 and its control 24hrs after transfection. CD83 and MHCII expression were 
analysed 24 hours after treatment (ie, 48hrs after transfection). The results of repeated 
experiments are summarized in Figure 4-9. 
 
 
 
Figure 4-9: The figure shows the ratio of expression (MFI) of MHCII by transfected 
cells treated with anti-CD83 for 24hrs (48hrs after transfection) relative to isotype 
control antibody treatment (1.0). The data shown are obtained from four independent 
experiments. Statistical analysis: Difference between MAM83 and isotype control was 
analysed by the Mann Whitney test. (NS, not-significant). 
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The results illustrated that the expression of CD83 was very unstable between 24 
and 48hrs after transfection. Moreover, MHCII expression was very low particularly after 
48hrs. This instability of expression might be related to the transient nature of the 
transfection method (Figure 4-8). Even though my results showed that addition of MAM83 
into the culture did not significantly change MHCII expression on the cell surface (Figure 4-
9), the transient nature of this experiment does not allow comprehensive assessment of 
the effect of anti-CD83 on MHCII. 
 
In summary, the expression levels of MHCII and CD83 were unstable after each 
transfection particularly at 48hrs, and were variable between transfections. It was 
concluded that this is not a good method to investigate the effects of anti-CD83 on MHCII. 
As a result, subsequent experiments employed primary murine cells and stable human cell 
lines expressing CD83, MHCII and CD86. 
 
4.3.3 MHCII ubiquitination assay on LPS-activated murine APC (cultures treated with 
anti-CD83) 
4.3.3.1 Experimental Design 
T-cell depleted splenocytes from BALB/c mice were activated with LPS (2 ug/ml) and 
treated with CD83 or control antibody overnight and then lysed. Anti-MHCII 
immunoprecipitates were resolved on 4-12% SDS-PAGE gel, and analysed by 
immunoblotting with anti-ubiquitin. (Details in Chapter 3, section 3.11) 
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4.3.3.2 Results 
 
 
 
 
 
Figure 4-10: (A) Expression of ubiquitinated MHCII (1-5) following treatments as 
shown of murine T-cell depleted splenocytes. (B) Independent replicate experiment 
of (B) (1-6). Lane 1: no treatment; Lane 2: LPS only; Lane 3: LPS+RANeg; Lane 4: 
LPS+RAM83; Lane 5: LPS+Isotype control of MAM83; Lane 6: LPS+MAM83. Red arrows 
= ubiquitinated MHCII [448, 449]. 
 
 
 
(A) 
(B) 
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Changes in MHCII ubiquitination of T-cell depleted splenocytes treated with anti-
CD83 polyclonal Ab RAM83 were not consistently different from RANeg control treatments 
(Ub band 1-5) between the two replicate experiments. However, cells treated with anti-
CD83 mAb MAM83 had more highly ubiquitinated MHCII compared to the control (eg, Ub-
3 in (A)). The replicate experiment clearly demonstrates MHCII ubiquitination of MAM83 
treated cultures was higher at bands Ub-1 and Ub-6 (Figure 4-10 (B)).  Data from results 
section 4.3.1 showed that MAM83 has a greater effect in decreasing MHCII expression 
compared to RAM83. This is consistent with greater ubiquitination induced by MAM83 
compared to RAM83.  
 
4.3.4 Human HLA-DR and CD86 expression in KM-H2 and Raji cell lines 
4.3.4.1 Rationale 
I have shown that anti-CD83 significantly downregulated MHCII but not CD86 expression 
by murine APC. I also investigated whether this downregulation of MHCII is linked to 
MARCH-1 mediated ubiquitination. To investigate if these findings translate from mouse to 
man, I treated CD83+MHCII+CD86+ human cell lines with human CD83 antibodies RA83 
and 3C12.C. In humans, the MHC is also called the human leukocyte antigen (HLA). MHC 
class II molecules are encoded in humans by the HLA-DP, -DQ, and -DR genes. They are 
only expressed on cells actively involved in the immune response. HLA-DR is 
constitutively expressed on professional antigen-presenting cells like dendritic cells, B 
cells, and monocytes/macrophages. Its expression is further up-regulated upon activation. 
HLA-DR is the broadest description of the antigen. In this study, only HLA-DR had been 
studied. The cell lines selected (KM-H2 and Raji) spontaneously express CD83, HLA-DR 
and CD86 on the cell surface (Figure 4-11 (A)).  
4.3.4.2 Experimental design 
Human HLA-DR and CD86 expression levels were analysed at different time points, 
following splitting of the cell lines. Surprisingly, expression levels varied with time. The best 
time range at which anti-CD83 could be given was considered to be 8-24hrs after 
subculture (Figure 4-12).  CD83 or control antibodies were added to the cells and cultured 
overnight. HLA-DR and CD86 expression was analysed by flow cytometry staining with 
mouse anti-human APC-HLA-DR and PE-CD86 antibodies. 
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4.3.4.3 Results 
(A) 
 
 
 
 
                                                                                  
  (B) 
 
 
Figure 4-11: (A) and (B) KM-H2 and Raji cells constitutively express CD83, HLA-DR and 
CD86 on the cell surface. 
 
Figure 4-11 (A) shows the differences in expression of CD20 (rituximab), CD52 
(campath-1) and CD83 (3C12.C) in Raji cell lines. KM-H2 and Raji cells constitutively 
express CD83, HLA-DR and CD86 on the cell surface (Figure 4-11 (A) and (B)).  They 
were used to investigate the effect of anti-CD83 on MHCII and CD86 expression in this 
study. 
Anti-human CD83 mAb 3C12 
binds CD83 expressed by KM-H2 
cells, Jones et al., 2010 [83] 
CD20/CD52/CD83-FITC 
KM-H2 Cells Raji 
Cell
s 
Unpublished data 
by Rebecca Baron 
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Figure 4-12: Cell surface HLA-DR expression (MFI) versus time for KM-H2 and Raji 
cell lines. (n=2-3 experiments) 
 
 
 
 
Figure 4-13: Fold change of MFI of HLA-DR and CD86 due to RA83 (A) and 3C12.C 
(B) treatment relative to control antibody treatment (1.0) (dotted line). n=5-6 
experiments. Statistical analysis: Wilcoxon signed rank test. 
 
(A)  
(B) 
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Cell surface expression of HLA-DR was stable between 2-48hrs in KM-H2 cells as 
opposed to 2-24hrs in Raji cells (Figure 4-12). The best time to give anti-CD83 is 24hr 
before the expression of HLA-DR dropped. Human CD83 antibodies RA83 and 3C12.C did 
not downregulate HLA-DR (MHCII) and CD86 in either human cell line. Although there was 
a trend of reduced HLA-DR expression in Raji cells incubated with RA83, it was not 
statistically significant (Figure 4-13). As there was no significant effect of CD83 antibodies 
on either human cell line, follow-up ubiquitination assays were not done.  
 
Aim 3: To determine the effects of anti-CD83 on alloproliferation of T-cells 
stimulated by APC (murine) 
 
4.3.5 CD4 and CD8 T-cell alloproliferation 
4.3.5.1 Rationale 
We tested the effects of anti-CD83 treatment in vitro on alloproliferation of both CD4 
T-cells and CD8 T-cells. Of particular interest are any differential effects between CD4 and 
CD8 T cells because these cells play different roles in GVHD, immunity to infection and 
GVL. 
4.3.5.2 Experimental design 
To investigate T-cell alloproliferation as a consequence of anti-CD83 treatment, 2x105 LPS 
activated BALB/c APC (“stimulators”) were cultured with 3x105 CFSE-labelled C57BL/6 
purified T cells (“responders”) in the presence of anti-CD83 or control antibody for four 
days. T cell alloproliferation as measured by CFSE dilution was analysed by flow 
cytometry. Phenotypic analysis was performed by flow cytometry using fluorescently 
labelled rat anti-mouse antibodies (except where stated) as follows: rat anti-mouse CD4 
Pacific Blue (PB) (RM4-5, IgG2a), rat anti-mouse CD8 allophycocyanin (APC) (53-6.7, 
IgG2a). Figure 4-14 summarizes the experimental design. 
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Figure 4-14: Experimental design for assessing the effects of anti-CD83 antibody on  
CD4 and CD8 T cell proliferation. 
 
4.3.5.3 Results 
 
Figure 4-15: The cytometry histograms show alloproliferation of CD4 and CD8 T-
cells after 4 days of culture with stimulator cells and antibody. (a+b = 100%,  a = % 
proliferation) 
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 (A) 
 
 
 
 (B) 
 
 
Figure 4-16:  Percentage of alloproliferation of CD4 or CD8 T-cells with CD83 
antibodies (A) RAM83 and (B) MAM83 and controls. Statistical analysis: RAM83 vs 
RANeg: differences between groups were analysed with paired Student’s t-test (n=7); 
MAM83 vs Isotype: differences were analysed by the Mann Whitney test (n=4)  
 
We observed a small reduction in CD4+ and CD8+ T-cell proliferation in RAM83 
treated-cultures but these were not statistically significant (Figure 4-16 (A)). MAM83 
treatment did not affect CD4+ nor CD8+ T-cell proliferation (Figure 4-16 (B)). In conclusion, 
neither RAM83 nor MAM83 significantly reduced CD4 T-cell alloproliferation in the MLR, 
despite the anti-CD83 induced reductions in MHCII expression as observed in Figure 4-3. 
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Aim 4: To determine the effect of anti-CD83 on antigen specific T-cell proliferation. 
4.3.6 Specific antigen stimulated CD4 and CD8 T-cell proliferation 
4.3.6.1 Rationale 
In the previous section, I investigated T-cell alloproliferation and in this section I extend the 
studies to investigate antigen specific T-cell proliferation. In allo-stimulation the stimulator 
and responder cells are from genetically distinct strains of mice. For antigen specific 
stimulation, stimulators (C57BL/6) and responders (transgenic OTI or OTII C57BL/6) are of 
the same strain. OT-I mice carry a transgenic CD8 T-cell receptor (TCR) for the MHC 
class I–restricted OVA peptide aa 257–264. OT-II mice carry a transgenic CD4 TCR 
specific for the MHC class II–restricted OVA peptide aa 323–339. I hypothesized that 
CD83 antibody would reduce antigen specific CD4 T cell proliferation but not antigen 
specific CD8 T cell proliferation. 
 
4.3.6.2 Experimental Design 
To investigate antigen specific T-cell proliferation, 5x104 C57BL6 APC (T cell depleted 
splenocytes) were activated with 2 µg/ml LPS and pulsed with 200 µg/ml ovalbumin (OVA) 
in the presence of anti-CD83 or its control overnight and co-cultured with 5x105 transgenic 
mouse OVA specific OTI CD8 or OTII CD4 T cells for four days. T-cell proliferation as 
measured by CFSE dilution was analysed by flow cytometry. Phenotypic analysis was 
performed by flow cytometry using fluorescently labelled rat anti-mouse antibodies (except 
where stated) as follows: rat anti-mouse CD4-PB (RM4-5, IgG2a), rat anti-mouse CD8-APC 
(53-6.7, IgG2a). Figure 4-17 summarizes the experimental design. 
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Figure 4-17: Experimental design for assessing the effects of anti-CD83 on specific 
antigen stimulated CD4 and CD8 T-cell. OTI CD8 and OTII CD4 T cells were cultured 
separately in the assay. 
 
4.3.6.3 Results 
(A) 
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 (B) 
 
 
Figure 4-18: (A) Representative cytometry histograms show proliferation of CD4 and 
CD8 T-cells after 4 days of culture with APC, OVA and CD83 or control antibodies. 
(B) Fold change of proliferation of CD4 and CD8 T-cells due to CD83 antibody 
(RAM83 or MAM83) treatments relative to their controls (1.0). Statistical analysis: 2-
tailed paired student’s t-test. 
 
The addition of the polyclonal CD83 antibody RAM83 and monoclonal MAM83 
antibody reduced OVA stimulated proliferation of CD4+ T-cells but it was not statistically 
significant. Anti-CD83 treatment did not affect CD8+ T-cell responder proliferation. In 
summary, anti-CD83 treatment did not reduce CD4 T–cell proliferation stimulated by 
specific antigen presented by autologous APC. CD8 T-cell responses were unaffected 
which is important for the maintenance of immunity to infection and GVL in alloHSCT. In 
conclusion, in mice, anti-CD83 does not show significant effects on APC induced CD4 T 
cell proliferation. In conclusion, we found no strong evidence to support the hypothesis that 
anti-CD83 treatment reduces CD4 T cell proliferation in vitro in murine models.  
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4.4 Discussion 
 
Traditional GVHD therapies have targeted T cells, yet APC particularly DC have 
long been considered to be critical in the pathogenesis of GVHD. Their depletion or 
blockade may prevent GVHD by stopping T cells from being sensitised to host antigens. 
This laboratory has previously shown that a rabbit anti-human CD83 polyclonal antibody 
(RA83) depletes activated human DC by NK cell-mediated ADCC [83] and attenuates 
GVHD in a xenogeneic model of GVHD whilst retaining T cells with GVL and anti-viral 
immune capabilities [81]. We have also confirmed that CD83 antibody treatment delays 
GVHD in murine allogeneic HSCT models in the context of pre-transplant conditioning and 
haematopoietic reconstitution (manuscript in preparation). Rabbit polyclonal anti-mouse 
CD83 antibody (RAM83) conferred a survival advantage to allogeneic HSCT recipients. 
However, we were unable to show that RAM83 depletes activated mouse DC by NK cell 
mediated ADCC. 
 
An aim of my project is to investigate a possible alternative mechanism of action of 
CD83 antibody in murine alloHSCT recipients: that binding of antibody to CD83 on the 
surface of APC causes a reduction in the expression of MHCII and/or CD86, thereby 
reducing APC-mediated stimulation of T-cells. Data published by Tze et al. (2011) using 
HEK293 cells transfected with CD83, MHCII and MARCH-1 constructs suggested that 
anti-CD83 binding might induce increased ubiquitination and consequent proteosomal 
degradation of MHCII and CD86. Nevertheless, using the same method and constructs, 
my results showed that anti-CD83 did not reduce MHCII expression. Contrary to this 
finding, in primary murine splenocytes, I found that MHCII, but not CD86, was significantly 
downregulated in anti-CD83 treated cultures of murine APC. The reduction of MHCII 
induced by anti-CD83 antibody treatment was approximately 20% in both DC and B cells 
(Figure 4-2 and 4-3) which is small though statistically significant. Also, the expected 
consequential reduction in CD4 T cell proliferation in both the alloMLR and specific antigen 
stimulation assays did not occur, suggesting that it may not be biologically important. 
Kretschmer et al., 2008 showed that reduced CD83 expression on DC did not alter the 
antigen-specific response in OTII T cells [450]. Kuwano et al. 2007 also demonstrated that 
CD83-/- APC induced T cell proliferation more effectively than wild-type APC in vitro 
assays. This phenomena may reflect an increase in functional engagement between APC 
and T cells in the absence of CD83 as a result of increased class II turnover and/or 
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possibly the generation or presentation of more immunogenic peptides [11]. Collectively, 
this may explain why there was no reduction of CD4 T cell proliferation in my experiments.  
 
Additionally, I did not find any clear difference for ubiquitination of MHCII in anti-
CD83 treated cultures of primary APC or in HEK293 transfectants. There were also no 
significant changes in MHCII/HLA-DR and CD86 expression in human anti-CD83 treated 
human cell lines. Since only one study by Tze et al., 2011 had reported this mechanism so 
far and there is no additional evidence to support their findings, we cannot confirm the 
MHCII downregulation induced by anti-CD83 is by ubiquitination and degradation of 
MHCII. 
 
 In conclusion, there is no evidence to suggest that binding of anti-CD83 to CD83 
induces degradation of MHCII and CD86 on activated APC resulting in reduced T-cell 
activation and attenuated GVHD. The mechanism of action of anti-CD83 in the murine 
alloHSCT/GVHD model remains unknown.  
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Chapter 5: Anti-CD83 mediated inhibition of human humoral 
immune responses  
 
5.1 Introduction 
The adaptive immune system involves a tightly regulated interplay between APC, T 
and B cells. The responses include antigen specific B and T cell proliferation when these 
cells bind unprocessed or processed antigen presented by DC and other APC, generation 
of immunological memory, and regulation of host immune homeostasis [87, 204, 451, 
452]. B cells and their progeny are central to the adaptive humoral immune system as they 
express Ig which are the key antigen-specific effector molecules that arise to protect the 
host against pathogens. B cells can also play a pathogenic role in human disease and 
have recently become important drug targets for treatment of some hematologic 
malignancies and autoimmune diseases. The therapeutic mAb rituximab, specific for the 
pan-B cell surface marker CD20, has been approved for the treatment of B cell 
malignancies (eg, non-Hodgkins lymphoma) and some autoimmune diseases mediated by 
autoreactive antibodies, such as rheumatoid arthritis. However, rituximab induces long-
term depletion of all B cells including memory B cells which may compromise immunity to 
infections in patients [372, 453], and reduce responsiveness to vaccination [454]. 
 
CD83 is upregulated and expressed on the plasma membrane during maturation of 
DC. It is also expressed on activated CD4 T cells and activated B cells in mouse and 
human. CD83 is involved in the regulation of B cell maturation, homeostasis and function 
[10, 23, 455, 456] but the mechanism is not understood at the molecular level. CD83 
expression is reached maximally within an hour after TLR4 engagement by 
lipopolysaccharide (LPS) or BCR ligation [10, 20, 86]. CD83 is considered to be a negative 
regulator and is involved in the down-modulation of B cell responses [21]. Breloer et al. 
(2007) showed that overexpression of CD83 suppresses Ig production during infection as 
well as after immunization with T-cell-dependent and T cell independent model antigens 
[20] . Furthermore, CD83 mAb treated C57BL/6 mice had strongly increased antigen-
specific IgG responses to immunization with a model TI-2 antigen (see chapter 6) [20]. All 
of this strongly suggests that CD83 is involved in the regulation of B cell function in 
humoral immune responses. Figure 5-1 summarizes the CD83+ cells and pathways 
involved in adaptive humoral immune responses. 
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Figure 5-1: CD83 expressing cells involved in adaptive humoral immune response. 
Humoral immune response is initiated when B cells are stimulated through BCR by a 
particular antigen, followed by its differentiation into plasma cell. Plasma cells release 
high-affinity antibodies that opsonize antigens and promote their removal by macrophages. 
Professional APC such as DC, are activated by antigens through engagement of surface 
pattern recognition receptors (PPR). Intracellular and extracellular antigens are processed 
into peptide by DC and loaded onto MHCII antigens presented CD4+ T cells. T-helper 
cells, Th2 cells activate B cells to produce Ab [90]. B cells can also act as APC to stimulate 
CD4 T cells by processing and presenting internalized Ag on MHCII molecules to primed 
CD4 T cells [457]. DC: dendritic cell, TCR: T cell receptor, BCR: B cell receptor. 
 
In the human system, our group has shown that anti-CD83 depletes activated DC 
and CD4 T cells by NK cell mediated ADCC [83] and may be a therapeutic option for the 
control of graft-versus-host disease (GVHD) in haematopoietic stem cell transplantation 
[81] . In this chapter, I hypothesized that anti-CD83 also affects adaptive humoral immune 
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responses and may have additional therapeutic indications, such as in RA, SLE and in 
allergy.  
 
In this study, I used two different types of CD83 antibodies: affinity purified rabbit 
polyclonal anti-human CD83 (RA83, Wilson et al., 2009 [81]) and human IgG1 mAbs 
specific for CD83 (3C12.C and 3C12.Ckif, which are improved versions of 3C12, Jones et 
al., 2010 [84]). Others in our group have shown that 3C12.Ckif is more effective than 
3C12.C in inducing NK cell ADCC of activated primary B cells (submitted for publication 
[85]). Unlike rituximab which depletes both activated and resting B cells, 3C12.Ckif did not 
deplete resting B cells. 
 
5.2 Aims 
Aim 1: To characterize anti-CD83 mediated inhibition of B cell responses to stimulation (in 
vitro). 
Aim 2: To define the kinetics of CD83 expression by B cells on stimulation (in vitro). 
Aim 3: To characterize the effects of anti-CD83 treatment on human B cell responses in 
vivo (xenograft model). 
 
5.3 Results 
Aim 1: To characterize anti-CD83 mediated inhibition B cell responses to 
stimulation. 
5.3.1 The in vitro effects of anti-CD83 on antigen specific B and T helper cell 
proliferation. 
5.3.1.1 Rationale 
In preliminary ADCC experiments using the 51-Cr release assay, others in our group 
showed that 3C12.Ckif can induce lysis of purified activated B cells, but not resting B cells. 
Also, anti-CD83 inhibited human total IgM and IgG expression in vitro by resting and allo-
stimulated PBMC and, in vivo, by human PBMC xenografted SCID mice (unpublished data 
by Rebecca Baron; manuscript in preparation). B cell and usually, CD4 T cell proliferation 
is required for the upregulation of Ig expression by B cells [204, 457]. Given the above 
results and that B and T helper cell responses to antigen always involve proliferation [458], 
I tested if anti-human CD83 antibody also inhibits antigen stimulated B and T helper cell 
proliferation in vitro. 
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5.3.1.2 Experimental Design 
To determine if anti-CD83 can modulate the stimulation of antigen specific 
proliferative responses, CFSE-labelled human PBMC were cultured with the recall antigen 
TT (10 ug/ml) in the presence of anti-CD83 (RA83 or 3C12.Ckif), rituximab (human IgG1 
anti-CD20 mAb) or control Ab (RANeg or human IgG1 Isotype) (1ug/ml) for 6 days. The 
proliferation of CD4 T-cells and CD19 B cells was analysed by flow cytometry after 
staining the cells with fluorophore conjugated mouse anti-human mAbs PB-CD19 and 
APC-H7-CD4. 
5.3.1.3 Results 
(A) Rabbit polyclonal anti-CD83 (RA83) 
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(B) Monoclonal anti-CD83 (3C12.Ckif) 
 
 
 
(C) Summary of CD4 T-cell and CD19 B-cell proliferation (% of total live cells) 
 
(D) CD19 B-cell population 
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Figure 5-2: Anti-CD83 inhibited TT-responsive CD4+ T- and CD19+ B-cell 
proliferation. (A) and (B) Representative flow cytometry plots show the effect of anti-
CD83 and rituximab on proliferation of CD4 T-cells and CD19 B cells from the same donor. 
Proliferated cells = CFSEdim gated as shown. CD4+ and  CD19+ cells were gated from live 
cells (representative flow plots in Appendix D). (C) The bar charts show TT responsive 
proliferated CD4 T-cells and CD19 B cells (% of total live cells). (D) CD19 B cell 
population, after 6 days of culture with polyclonal or monoclonal anti-CD83, rituximab and 
controls. The bar charts represent the resting CD19 B cells in anti-CD83 or rituximab 
treated cultures relative to control Ab (1.0). (C) and (D) Results are presented as mean (± 
SEM) of at least 7 experiments/donors. *p<0.05, **p<0.01  ***p<0.001. Statistical analysis: 
(C) 2-tailed Wilcoxon signed rank test; (D) 2-tailed paired student’s t-test (passed normality 
test; Gaussian distribution) 
 
TT significantly increased the CD4 T-cell and CD19 B cell proliferation (presumed to 
be TT specific memory T and B cells). RA83, 3C12.Ckif (Figure 5-2) and 3C12.C IgG1, but 
not 3C12.C IgG4, (Appendix E) suppressed TT stimulated proliferation of CD4 T cells and 
CD19 B cells without affecting non-proliferating T and B cells. Rituximab depleted almost 
all CD19 B cells and did not inhibit TT stimulated CD4 T-cell proliferation (Figure 5-2).  
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5.3.1.4 Outcomes 
From the data collected, we concluded that: 
 These results show for the first time that anti-CD83 treatment inhibits the antigen 
specific proliferative response to TT. This is consistent with our group’s earlier 
observation that anti-CD83 lyses activated B cells but not resting B cells. In 
contrast, rituximab depleted nearly all B cells. 
 
 My experiments also showed that anti-CD83 inhibits the CD4 T-cell proliferaive 
response to TT, whereas rituximab failed to do this. This may be an important 
advantage of anti-CD83 in the clinic because activated CD4 T cells are major 
contributors of inflammatory cytokines (TNF-𝛼, IFN-𝛾, IL-17/IL-23, IL-27, and IL-21 
[370, 459-461]) in inflammatory autoimmune diseases. See section 5.34 for 
experiments evaluating the effects of anti-CD83 on cytokine expression.  
 
 Even though B cells are MHCII+ CD86+ APC, the failure of rituximab to inhibit TT-
stimulated CD4 T cell proliferation is a clear demonstration that other APC fulfil this 
role, such as CD83+ DC. 
 
5.3.2 The role of DC, B and NK cells in anti-CD83 mediated inhibition of antigen-
specific B cell and T-helper cell proliferation 
5.3.2.1 Rationale 
As shown above, anti-CD83 inhibits antigen-specific B and T-helper cell proliferative 
responses. The possible mechanisms may involve NK cells (as ADCC effectors) [83] and 
DC (as CD83+ ADCC targets [81, 83] that present antigen to B and T-helper cells. I 
therefore expected that removal of NK cells or DC from PBMC would reduce the inhibitory 
effects of anti-CD83 on antigen-specific B and T cell proliferation.  I also investigated the 
effect of B cell removal on T helper cell proliferation as B cells can present processed 
antigen to and stimulate T cells [95]. 
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5.3.2.2 Experimental Design 
CFSE-labelled B or DC or NK cell depleted (method see section 3.15) human 
PBMC were cultured with TT (10 ug/ml) in the presence of CD83 (RA83 or 3C12.Ckif), 
rituximab (anti-CD20) or control Ab (RANeg or Herceptin (h IgG1 Isotype) (1ug/ml) for 6 
days. The proliferation of CD4 T-cells and CD19 B cells was analysed by flow cytometry 
after staining the cells with fluorophore conjugated mouse anti-human mAbs PB-CD19 and 
APC-CD4. 
5.3.2.3 Results 
 Addition of TT significantly increased CD4 T cell proliferation in both whole PBMC 
and in B cell depleted PBMC (Figure 5-3 (A) (i) and (ii)) but, as expected, not in CD11c DC 
depleted PBMC (Figure 5-3 (A) (iii)) and unexpectedly, not in NK cell depleted PBMC 
(Figure 5-3 (A) (iv)). Addition of TT also increased CD19 B cell proliferation in whole 
PBMC (Figure 5-3 (B) (i)) and as expected, in CD11c DC and NK cell depleted PBMC 
(Figure 5-3 (B) (ii) and (iii)). 
 
Removal of B cells did not affect the anti-proliferative effects of RA83 and 3C12.Ckif 
on CD4 T cells in TT-stimulated cultures (Figure 5-3 (A) (vi) and (x)). Accordingly, I 
conclude that B-cells do not act as APC in these experimental conditions. As mentioned 
previously, the failure of rituximab to inhibit TT-stimulated CD4 T-cell proliferation (Figure 
5-3 (A) (xiii) clearly showed that other APC, most likely CD83+ DC fulfil this function.  
 
When CD11c+ DC were depleted, it reduced TT-responsive CD4 T-cell proliferation 
in the cultures, and to a lesser extent, B-cell proliferation. Despite that, anti-CD83 
continued to suppress both CD4 T-and B-cell proliferation in the absence of CD11c+ DC 
(Figure 5-3 (A) (vii) & (xi) and (B) (v) & (viii)). Overall, I conclude that CD83+ CD11c+ DC 
and B-cells were not the only APC in these experiments. 
 
As expected, in NK-depleted cultures, anti-CD83 did not inhibit TT-responsive CD4 
T-cell proliferation (Figure 5-3 (A) (viii) and (xii)). This is consistent with the known NK cell 
mediated ADCC mechanism of action to deplete CD83+ DC and/or activated CD83+ CD4 
T-cell. However, B-cell proliferation continued to be dampened by anti-CD83 in the 
absence of NK cells (Figure 5-3 (B)(vi) and (ix)).  This may be due to other possible non 
NK/ADCC mechanisms occurring in this experiment. 
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 In conclusion, the mechanism by which anti-CD83 depletes activated CD4 T-cells is 
not confirmed in this experiment, although NK cells have been previously shown to deplete 
activated CD4 T cells in alloMLR [83]. In the absence of CD11c+ DC and B-cell, anti-CD83 
treatment nevertheless reduced CD4 T-cell proliferation. These results indicate that anti-
CD83 may target to other CD83+ APC to inhibit TT responsive CD4 T-cell. 
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(A) CD4 T-cell proliferation 
 
 
 
 
 
 
 
 
 
 
 
 
 
(i) (ii) (iii) (iv) 
(v) (vi) (vii) (viii) 
(ix) (x) (xi) (xii) 
(xiii) (xiv) (xv) 
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(B) CD19 B-cell Proliferation 
 
 
 
 
 
 
 
Figure 5-3: The graphs show the effect of anti-CD83 and rituximab on (A) CD4 T-cell 
and (B) CD19 B-cell proliferation in DC, B- or NK-cell depleted or whole PBMC. 
Results are presented as symbols and lines from at least 5 experiments/healthy donors 
(each represented by distinct symbols). *p<0.05, **p<0.01. Statistical analysis: 2-tailed 
paired Wilcoxon signed rank test (did not pass normality test). 
 
 
(i) (ii) (iii) 
(iv) (v) (vi) 
(vii) (viii) (ix) 
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5.3.3 Mechanism of anti-CD83 in inhibiting Ig production 
5.3.3.1 Rationale 
We had previously shown that anti-CD83 inhibited human total IgM and IgG 
production more than 30-fold and 4 fold respectively by both resting and allo-stimulated 
PBMC in vitro (unpublished data by Rebecca Baron). Munster et al., 2004 reported that 
rabbit anti-human CD83 polyclonal Ab (RA83) depletes CD83+ DC by NK cell-mediated 
ADCC [83]. Therefore, I hypothesized that the inhibition of Ig production is also by Ab-
dependent NK cell mediated ADCC lysis of CD83+ cells. The alloMLR is a unique ex vivo 
method to study a drug's action on the initial events resulting in T-cell activation and 
proliferation, modelling to the initial stages of tissue and organ destruction by T-cell 
responses in transplant rejection and GVHD [462]. AlloMLR is also used to test the 
capacity of PBMC to initiate a naive immune response. Using this approach, I evaluated 
the contribution of NK cells in ADCC by using anti-human CD16 mAb (3G8 (murine IgG1)). 
3G8 blocks CD16 signalling [463] in the cultures. CD16 is expressed on NK cells as well 
as macrophages and granulocytes. CD16 (Fcγ receptor III) is a receptor expressed on NK 
cells that facilitates ADCC by binding to the Fc portion of various antibodies, including 
IgG1 and IgG3 [463, 464]. CD56dim CD16bright NK cells represent at least 90% of all 
peripheral blood NK cells [465, 466] . 
 
Human IgG1 isotype efficiently fixes complement and also induces ADCC to kill 
target cells in vitro, whereas human IgG4 is inactive [467, 468]. I also compared IgM/G 
production in the presence of RA83, 3C12.C IgG1 (both are already known to induce NK 
cell ADCC lysis of CD83+ cells ([83] and also unpublished data) and 3C12.C IgG4 (known 
not to support NK cell mediated ADCC).  
5.3.3.2 Experiment design 
To determine whether anti-CD83 mediated inhibition of Ig production involves NK 
cell-mediated ADCC, 2-way alloMLR cultures were treated with anti-CD83 (RA83 or 
3C12.C IgG1), or their controls (RANeg or 3C12.C IgG4)(2ug/ml) in the presence of the 
function blocking anti-CD16 (3G8) and murine IgG1 isotype control (20 µg/ml) for 7 days. 
Supernatants of the cultures were collected and production of IgG and IgM were analysed 
by ELISA. 
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5.3.3.3 Results 
 
(A)  
 
 
(B) 
 
 
 
Figure 5-4: Anti-CD83 inhibited Ig production by NK-mediated ADCC. (A) Anti-CD83 
RA83 did not suppress human total IgG and IgM secretion in CD16 blocked alloMLR 
cultures. (B) 3C12.C IgG1 did not inhibit human IgM secretion in CD16 blocked alloMLR 
cultures. Data are presented as means (± SEM) of n=6 experiments/6 pairs of donors. 
*p<0.05, **p<0.01. Statistical analysis: 2-tailed paired student’s t-test (passed normality 
test; Gaussian distribution). 
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Polyclonal and monoclonal anti-CD83 inhibited IgM/IgG production in 2-way 
alloMLR cultures (Figure 5-4 (A) and (B)). When the cultures were treated with anti-CD16 
mAb 3G8, anti-CD83 induced inhibition of IgM and IgG production were significantly 
impaired. In the absence of 3G8, 3C12.C IgG4 had no effect on IgM secretion compared 
to 3C12.C IgG1 (total human IgG expression could not be assayed due to the presence of 
added human IgG4). These experiments indicate that the primary mechanism is CD16-
mediated ADCC. From the results obtained, I conclude that anti-CD83 inhibits Ig 
production by inducing CD16 mediated ADCC lysis of activated cells, including DC, T or B 
cells, probably via NK cells although other CD16+ effectors such as 
monocytes/macrophages cannot be excluded by these experiments.  
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5.3.4 Cytokine expression in antigen-specific B and T-helper cell stimulation 
5.3.4.1 Rationale 
Cytokines are important mediators of immunity, inflammation, cell proliferation and 
differentiation  [469]. Cytokines produced by the major subsets of CD4 T cells such as 
Th1, Th2, Th17 and iTreg  are critical for their fate determination and some of their 
functions [214]. Inflammatory cytokines including TNF-α, IFN-γ, IL-17a are associated with 
autoimmune diseases, such as RA, SLE and MS [330, 350, 470-476]. IL-21 also has a role 
in the pathogenesis of autoimmune disease [477]. A series of autoimmune animal models 
showed that IL-21 is strongly linked with autoimmunity and appeared to be a common 
modulator of the adaptive immune response towards self-tissue in diseases like RA, SLE, 
MS and type-1 diabetes [478-484]. My data above showed that proliferation of CD4 T and 
B cells was inhibited by anti-CD83. It is important to determine whether cytokine 
expression is also altered. If the inflammatory cytokines are reduced by anti-CD83, it may 
lead us to a better treatment in autoimmune diseases. 
 
5.3.4.2 Experimental Design 
CFSE-labelled human PBMC were cultured with TT (10 ug/ml) in the presence of 
anti-CD83 (RA83 or 3C12.Ckif), rituximab (anti-CD20) or control Ab (RANeg or herceptin 
(human (h) IgG1 Isotype) (1ug/ml) for 6 days. On day 6 of culture, supernatants were 
collected. These supernatants were used to analyse secreted cytokines using the Bio-Plex 
Pro™ human cytokine 8-plex immunoassay (IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, TNF-α and 
GM-CSF) (Bio-Rad) and ELISA kits for IL-17A (eBioscience, Human IL-17A (homodimer) 
ELISA Ready-SET-Go!®), IL-6 and  TNF-α (BD ELISA kit) and IL-21 (Biolegend, Human 
IL-21 ELISA MAX™ Deluxe). 
 
On day 6, the cells were washed and replenished with fresh media (RPMI with 10% 
FBS) and further cultured at 37°C in 5% CO2 with 50 ng/ml PMA plus 1µM ionomycin for 
6hrs. After 2hrs, monensin was added at a final concentration of 10µg/ml for the last 4hrs 
of culture. Finally cells were stained and ICS was carried out and analysed by flow 
cytometry. The following monoclonal antibodies were used: mouse anti-human fluorophore 
conjugated mAbs PB-CD19 and APC-H7-CD4, APC-IFN-γ (Biolegend), APC-TNF-α, APC-
IL-4, APC-IL-10, APC-IL-17a, Alexafluor 647 IL-21 (BD Bioscience).  
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5.3.4.3 Results 
(A) Bio-plex and ELISA analysis 
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(B) Intracellular cytokine staining (ICS) 
(i) Cytokines expressed by CD4 T-cells 
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(ii) Cytokines expressed by proliferating (CFSEdim) and non-proliferating (CFSEbright) 
T-cells 
 
 
 
Figure 5-5: Anti-CD83 reduced some of the pro-inflammatory cytokine expression in 
TT antigen-stimulated cultures. (A) The bar charts show the Bio-plex and ELISA 
analysis data for cytokines secreted into 6-day TT-stimulated PBMC cultures. (B) (i) The 
bar charts show the percentage of CD4 T cells that express each cytokine as a percentage 
of total CD4 T cells. (To show gating, representative flow cytometry plots for cytokines 
expressed by total CD4 T cells are shown in supplementary data in Appendix F). (ii) The 
summary graphs show the fold change of % of CFSEdim and CFSEbright CD4 T cells 
expressing each cytokine due to CD83 treatment relative to control Ab (1.0). The 
proportions of cytokine expressing cells were expressed as a % of total CD4 T cells in both 
Fig.5-5 B (i) and (ii). The solid horizontal lines are the means from at least 5 
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experiments/donors. (A) and (B)(i) Data are presented as mean (± SEM) of n= at least 6 
experiments/donors.  *p<0.05, **p<0.01. Statistical analysis: 2-tailed paired Wilcoxon 
signed rank test (did not pass normality test) 
 
 In Bio-plex and ELISA analysis (Figure 5-5 (A)), TT-stimulation significantly 
increased the secretion of IL-2 and IFN-γ. There was also a trend towards elevation in IL-
10, IL-17A and GM-CSF secretion but did not reach significance. Importantly, anti-CD83 
significantly decreased the secretion of pro-inflammatory cytokines such as IFN-γ in TT-
stimulated cultures. The secretion of IL-2 was also inhibited in 3C12.Ckif treated culture. 
Interestingly, the secretions of IL-4 and TNF-α were unaffected by anti-CD83 treatment. 
 
In ICS (Figure 5-5 (B)), the percentage of IFN-γ, IL-17A and IL-10 expressing CD4 
T cells were reduced by anti-CD83 especially the 3C12.Ckif monoclonal Ab. This finding 
was consistent with Bio-plex and ELISA analyses. IL-21 expression was very low in ICS 
and below the detection limit in ELISA analysis.  
 
Cytokines expressed by proliferated (CFSEdim) and non-proliferated (CFSEbright) 
CD4 T-cells were analysed separately [485] (Figure 5-5 (B)(ii)). Proliferated CD4 T cells 
represent those that have undergone antigen specific stimulation [485], and the non-
proliferated may be non-reactive resting CD4 T cells [486] or non-specific bystander cells. 
CD83 mAb 3C12.Ckif significantly reduced the expression of all the cytokines studied, 
except TNF-α, in CFSEdim CD4 T-cells. This reflects the strong inhibition of TT stimulated 
CD4 T-cell and the greatly reduced numbers of proliferated CD4 T-cells in anti-CD83 
treated cultures (see Figure 5-2 (C)). In the RA83 treated cultures, expression of all the 
cytokines was also reduced but also did not reach significance for IL-4, IL-10 and IL-21. 
  
Since there were no significant changes in cytokine expression (except IL-10) by 
CFSEbright CD4 T-cells in TT stimulated cultures treated with anti-CD83, we concluded that 
the observed reductions in secretion of the cytokines induced by anti-CD83, including IFN-
γ and IL-17A (Figure 5-5 (A)) were mainly contributed by proliferated CD4 T-cells (ie. TT 
antigen specific) CD4 T-cells. 
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5.3.5 CD83+ B cell subsets in human PBMC  
5.3.5.1 Rationale 
In some autoimmune diseases, autoantigen specific B cells are considered to be 
pathogenic as they release autoantibodies that cause damage to target tissues [487]. B-1 
cells represent a small subset compared to the numerically dominant B2 subset of 
conventional B cells [101]. In mice, the majority of B-1 cells reside in peritoneal and pleural 
cavities and a small number is also found in the spleen [488]. B-1 cells constitute a distinct 
B cell lineage that expresses “natural antibodies” that are protective against microbial 
pathogens. “Natural antibodies” are IgM and are poly-reactive (bind to multiple antigens) 
and self-reactive. However, class switched B-1 cells that express self-reactive antibodies 
are potentially pathogenic. Increased numbers of B-1 cells have been reported in patients 
with Sjogren’s syndrome, SLE and RA [169]. In 2011, Griffin et al. reported that circulating 
CD11b+ B-1 cells are markedly increased in SLE patients [489]. Here I investigated which 
B cell subsets in human PBMC express CD83, either spontaneously or after LPS 
stimulation, in an attempt to determine if anti-CD83 might have a role in the treatment of 
such autoimmune diseases. 
5.3.5.2 Experimental Design 
To determine which and when human B cell subsets express CD83, frozen or fresh 
human PBMC were cultured overnight with or without LPS (2ug/ml) in 10% FBS/RPMI. B 
cell subsets were analysed by flow cytometry. Surface phenotype of B cell subsets (PB-
CD20, FITC-CD43, APC-CD27, APC-cy7-CD11b) is adapted from Griffin et al., 2011 [489]. 
5.3.5.3 Results 
In this sample of six to seven healthy donors, naïve B cells (CD20+CD43-CD27-) 
were the major B cell subset in PBMC followed by memory B cells (CD20+CD43-CD27+)  
(Figure 5-6 (A)). All B cell subsets express CD83 after overnight culture with or without 
LPS treatment. There was no difference in CD83 expression in B cell subsets in LPS 
treated cultures except an increase in naïve B cells. The numbers of CD11b- B-1 cells 
exceeded the CD11b+ B-1 cells subset two-fold, but together they accounted for less than 
2.5% of all circulating B cells. Nevertheless, a higher proportion of the CD11b+ B-1 subset 
expressed CD83 than any other subset, regardless of LPS stimulation (Figure 5-6 (B)). As 
CD11b+ B-1 cells are increased in SLE patients [489] anti-CD83 targeting of CD83+ 
CD11b+ B-1 cells may be an potential therapeutic option for SLE patients.  
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(A) 
 
 
(B) 
 
 
Figure 5-6: (A) B cell subsets identified in human PBMC (% of total B cells). (B) 
CD83 expression on B cells after 24hrs culture with or without LPS treatment (% of 
cells in each subset that express CD83). Mean (± SEM) of 6/7 donors. Surface 
phenotype: naïve B cells (CD20+CD43-CD27-), memory B cells (CD20+CD43-CD27+) and 
B-1 cells (CD20+CD43+CD27+) Others (CD20+CD43+CD27-). *p<0.05, **p<0.01, ***p<0.001. 
Statistical analysis: One way Anova with Bonferroni post-test. (Representative flow 
cytometry plots are shown in Appendix G). 
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Aim 2: To define the kinetics of CD83 expression by B cells on stimulation (in vitro) 
5.3.6 Kinetics of B cell CD83 expression  
5.3.6.1 Rationale 
Section 5.3.5 showed that even after 24 hours of culture in the absence of B cell 
activators, most (approximately 73%) B cells do not express CD83. However, CD83 
expression is rapidly upregulated by B cells when activated, but its expression on B cells is 
not sustained (unpublished data by Rebecca Baron). B cell CD83 expression can be 
stimulated using anti-IgG/M, CD40L, anti-IgD conjugated to dextran (αδ-dex) or LPS. Anti-
IgM activates all naïve and IgM expressing memory B cells while anti-IgG activates IgG-
switched memory B cells (both via the B cell receptor, BCR). αδ-dex is an efficient and 
potent polyclonal B cell activator [177] that also acts via the BCR. CD40L is a polyclonal 
activator which acts via CD40 expressed on B cells. LPS is also a polyclonal B cell 
activator but acts through TLR-4. It is well known that healthy human B cells express very 
low levels of TLR-4 and therefore may not respond well to LPS. However, a recent report 
showed that human B cells responding to antigen plus T cell help, as mimicked by anti-IgM 
+ anti-CD40, have increased potential to upregulate surface TLR4, but the final level of 
TLR4 expression is highly dependent on the cytokine environment [490]. These stimuli 
also induce B cell proliferation and immunoglobulin expression but the experiments here 
are designed to characterize the kinetics of CD83 expression. It is important to determine 
the best time when anti-CD83 treatment can intervene following B cell activation. 
5.3.6.2 Experimental Design 
Freshly isolated human PBMC were labelled with CFSE (0.5uM) and cultured with 
anti-IgG/IgM (2ug/ml) or LPS (2ug/ml) or irradiated CD40L transfected L cells (L 
cell/PBMC ratio 1:20) for up to six days. CD83 expression and proliferation were measured 
by flow cytometry after staining with mouse anti-human PB-CD19, APC-h7-CD4 and APC-
CD83. For short-term kinetics experiments (<48hr), freshly isolated human PBMC were 
cultured with anti-IgG/IgM (2ug/ml), LPS (2ug/ml), anti-CD3/CD28 (1ug/ml), αδ-dex (10 
ng/ml) or CD40L-L cells (L cell/PBMC ratio 1:20). B cell CD83 expression was assessed at 
0, 6, 12, 18, 24, 36 and 48hrs after stimulation. 
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5.3.6.3 Results 
(A) Long term Kinetics of B cell CD83 expression  
 
(i) 
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Figure 5-7: (A) (i) Flow cytometry plots show the kinetics of CD83 expression by 
CD19 B cells on days 1, 2, 4 and 6. (ii) Summary of % of CD19 B cells expressing 
CD83 at time points shown in PBMC cultures treated with Nil, anti-IgG/IgM, LPS or 
CD40L. (iii) Summary of proliferated (CFSEdim) and non-proliferated (CFSEbright) 
CD83+ CD19 B cells at days 4 and 6.  Data represent mean (± SEM) (n=3 experiments 
or donors). 
 
CD83 was upregulated substantially by B cells treated with CD40L and anti-IgG/IgM 
on day 1 and 2 compared to Nil and LPS treated PBMC cultures. No B and T cell 
proliferation was observed until after day 2 under any treatment conditions. Substantial B 
cell proliferation was seen on day 4 in CD40L and anti-IgM/G and, to a lesser extent, LPS 
treated cultures. However, B cell CD83 expression had been downregulated to basal 
levels on day 4 and 6 in all treatment conditions except CD40L treatment. For Nil, LPS and 
anti-IgM/G stimulated cultures, there were substantially more non-proliferating CD83+ B 
cells at all-time points compared to CD83+ proliferating B cells. Perhaps they were naïve B 
cells that could not proliferate without help from CD4 T cells. As such help is mediated 
mostly via upregulated CD40L on activated CD4 T cells, this is consistent with the much 
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higher number of CD83+ proliferating cells in CD40L stimulated cultures (Figure 5-7 (A) 
(iii)). 
 
The purpose of this experiment was to determine the point in the sequence of 
events following B cell activation that anti-CD83 treatment can intervene. As I found above 
that CD83 expression was already decreasing after day 1, and proliferation did not occur 
until after day 2, earlier time points 0, 6, 12, 18, 24, 36 and 48hrs after stimulation were 
assessed in the following experiment. 
 
(B) Short term Kinetics of DC and B cell CD83 expression  
 
 
 
Figure 5-8: Summary of % CD19 B cells and DC expressing CD83 at time points 
shown in PBMC cultures treated with Nil, LPS, TT, CD40L, anti-CD3+anti-CD28, anti-
IgG/IgM or αδ-dex. Data represent mean (± SEM) (n=2 for DC and 3 for B cells). 
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 CD83 expression on B cells was rapidly upregulated within 6hrs of stimulation 
(compared with close to zero at 0hr (Appendix H). The expression of CD83 by B cells was 
substantially elevated (> 80%) and relatively stable in cells treated with CD40L and anti-
CD3/CD28 for 24 hr before it started slowly dropping. Anti-CD3/anti-CD28 stimulate T cells 
in a manner that partially mimics stimulation by APC [491]. Anti-CD28 co-stimulation 
increased CD4 T cell expression of CD40L, which in turn promote B cell proliferation and 
Ig secretion [492]. This explains why anti-CD3/CD28 and CD40L stimulation had similar 
CD83 expression profiles on B cells. However, CD83 expression on B cells dropped after 
only 6hrs and 12hrs on stimulation with anti-IgM/G and LPS respectively. The expression 
of CD83 on on αδ-dex stimulated B cells reached only half that of CD40L or anti-CD3/28 
stimulated cells, but the level was sustained for 36 hr. CD83 expressed on B cells was 
upregulated the least following TT-stimulation. This is presumably due to the antigen 
specific nature of the stimulation as only TT specific memory B cells are expected to 
respond. TT-specific memory B cells were reported present at a relatively constant 
frequency (1 in 80000 (0.00125%) of whole PBMC, or 1 in 400 of total memory B cells) 
[493]. CD83 expression on B cells returned to basal level at 48hr in LPS, anti-IgG and TT 
stimulations.  
 
 The expression of CD83 on DC was elevated maximally (approximately 50%) within 
6hrs of LPS activation. In CD40L stimulation, maximal CD83 expression on DC was at 
12hrs. Contrary to B cells, CD83 expressed on DC dropped to basal level at 48hrs of 
CD40L stimulation.  
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Aim 3: To characterize the effects of anti-CD83 treatment on human B cell 
responses in vivo (xenograft model). 
5.3.7 Kinetics of B cell CD83 expression in vivo (human PBMC xenografted SCID 
mice) 
5.3.7.1 Rationale 
Our overall aim is to test if anti-CD83 can be used to inhibit antigen-specific B cell 
responses (eg, to self-antigens in autoimmune disease, or to alloantigen in transplantation) 
without depleting all B cells (which could compromise immunity to infections. See Section 
1.3.3 for discussion of rituximab). We have shown this is possible in vitro (Rebecca 
Baron’s work and my work above in Section 5.3.1). It is important to show it in vivo. I 
tested this in human PBMC-xenografted SCID mice. A previous study by another lab 
member had shown that anti-CD83 treatment given immediately prior to xenografting 
depleted nearly all B cells and consequently reduced circulating human total Ig and TT-
specific antibodies in PBMC xenografted and TT vaccinated SCID mice. Anti-CD20 mAb 
rituximab can do the same (unpublished data by Rebecca Baron). As most B cells in 
resting human PBMC do not express CD83 ex vivo (see Sections 5.3.5-6) we suspected 
that CD83 was upregulated on many B cells in SCID mice due to an experimental artefact 
of xenografting, raising the possibility that this in vivo model may require modification to 
address the aim. To address this we hypothesized that pan-B cell depletion might be 
reduced if anti-CD83 was administered after xenotransplantation, at a time to be 
determined. In order to choose the best timing for anti-CD83 treatment, I studied the 
kinetics of human B cell CD83 expression in vivo. 
 
Does xenografting human PBMC upregulate CD83 expression by B cells? 
5.3.7.2 Experimental Design 
Anti-Asialo GM1 Ab (aASGM1) was injected intraperitoneally (i.p) into SCID mice 
one day before transplantation in order to deplete murine NK cells which compromise 
human engraftment [494]. 30 x 106 Human PBMC was injected i.p into SCID mice on the 
day of transplantation. Mice were sacrificed on days 1, 2, 4, 10 and 14 post-transplant and 
peritoneal washings were collected for analysis by flow cytometry [495].  
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Figure 5-9: Experimental design of kinetics of B cell CD83 expression post-transplant in 
SCID mice. 
 
5.3.7.3 Results 
 
Figure 5-10: Kinetics of human B cell CD83 expression in vivo. The graph 
represents the percentage of all human B cells that express CD83 at the time points 
shown. Results are presented as mean (± SEM) (n=3 mice for each time point). 
 
Approximately 37% of human B cells recovered from the peritoneal cavity 
expressed CD83 24 hours after transplantation. This dropped to approximately 7% at 
48hrs and continued to decrease at later times.  This early peak in CD83 expression may 
be a transplantation artefact that compromises the model because anti-CD83 treatment at 
the time of transplantation is likely to deplete all these B cells. A better approach may be to 
delay anti-CD83 treatment and immunization until CD83 expression levels have fallen 
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back to baseline levels. In this context, for the next in vivo study, I chose day 3 post-
transplant for anti-CD83 administration followed by immunization with a recall antigen (TT) 
and a neoantigen (KLH). 
 
5.3.8 Human Ab responses in SCID mice treated with anti-CD83 and vaccinated 3 
days after human PBMC transplantation 
5.3.8.1 Experimental Design 
aASGM1 was injected i.p into SCID mice to deplete NK cells and total body 
irradiation using a 137Cs irradiator (Gammacell40) at dose 275 cGy was delivered on the 
day before PBMC transplantation to further immunosuppress the mice (based on a 
previous lab member’s work, we could not get a naïve antigen specific response (KLH) in 
xenografted non-irradiated SCID mice. I decided to irradiate the mice because Sandhu et 
al. (1994) claimed this gives a KLH responses [496]). 30 x 106 human PBMC were injected 
i.p. into SCID mice on the day of engraftment. Anti-CD83 RA83 or control RANeg were 
given i.p. on day 3, four hours before TT (Equivac® T) or KLH (mixed with complete 
freund’s adjuvant (CFA) and incomplete freund’s adjuvant (IFA) in a ratio of 1:20 (v/v) 
[496]) immunizations. Mice were immunized with TT or KLH in separate cohort. The mice 
were sacrificed at day 13 and serum was collected via cardiac puncture. TT specific and 
KLH specific antibodies and total IgG/M were measured by ELISA. To confirm the 
engraftment of human PBMC, peritoneal cavity washings and spleen were collected, 
stained and analysed by flow cytometry. 
 
 
 
Figure 5-11: Experimental design to test Ab responses to immunization and the 
effect of anti-CD83 (RA83) treatment. Antigens: TT or Keyhole limpet hemocyanin 
(KLH). RANeg= negative control Ab. 
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5.3.8.2 Results 
 
 
 
Figure 5-12: The graphs show the percentage of engrafted human CD4 T and CD19 
B cells of total human CD45+ cells in the peritoneal cavity and spleen in SCID mice 
on day 13 post-transplant. n=6/combined data from 2 independent donors/experiments, 
3 mice each. *p<0.05, Statistical analysis: 2-tailed paired Wilcoxon signed rank test (did 
not pass normality test). 
 
 Human PBMC was successfully transplanted into SCID mice. In PC washings, the 
percentage of CD19 B cells was significantly decreased in anti-CD83 treated mice 
although the treatment was given 3 days after administration. However, the percentage of 
B cells in PC on day 13 post-transplant were very low (<2.5% of human CD45+ cells) in 
both control and anti-CD83 treated mice. This may due to recovery of B cells from PC 
washings were low. There was no difference in engrafted B cells in the spleen of mice 
treated with anti-CD83  orcontrol. Unexpectedly, CD4 T cells were increased in spleen in 
anti-CD83 treated mice compared to controls.  
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Figure 5-13: Total IgG and TT specific serum IgG levels in xenografted mice 
immunized with TT and treated with CD83 or negative control Ab. Data represent 
means (± SEM) (n=6/group). *p<0.05. Statistical analysis: 2-tailed paired student’s t-test 
(passed normality test; Gaussian distribution). 
 
Anti-CD83 RA83 abrogated the TT specific IgG response to TT immunization but 
did not affect total circulating human IgG levels in human PBMC xenografted SCID mice 
(Figure 5-13). This result indicates that anti-CD83 did not deplete a high proportion of B-
cells when administered 3 days after PBMC transplant. In summary, anti-CD83 can inhibit 
antigen-specific IgG B cell recall responses without impacting total IgG levels nor depleting 
all B cells in this in vivo model. 
 
 
Figure 5-14: IgM and KLH specific serum IgM levels in xenografted mice immunized 
with KLH and treated with CD83 or negative control Ab. Data represent means (± 
SEM) (6/group). *p<0.05, **p<0.01. Statistical analysis: 2-tailed paired student’s t-test 
(passed normality test; Gaussian distribution).  
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Anti-CD83 significantly decreased antigen specific naïve B cell IgM responses to 
KLH immunization (Figure 5-14). However, this result is less clear cut than for the recall 
antigen (TT) data in Figure 5-13 above because total human IgM levels were also reduced 
by RA83 Ab treatment. Thus we have not proven that anti-CD83 can specifically down-
regulate naïve responses to immunization without impacting pre-existing IgM levels. 
 
5.4 Discussion 
 
 CD83 is well known as an activation marker for mature DC. Inflammatory and 
pathogenic stimuli induce maturation of DC, which in turn stimulate the differentiation and 
proliferation of naïve T cells [497, 498]. Our group has shown that anti-CD83 can deplete 
activated CD83+ DC and, to a lesser extent, activated human CD83dim CD4 T cells, by NK 
cell mediated ADCC lysis [83]. Although CD83 is also expressed on activated T and B 
cells, studies of CD83 on these cells, specifically B cells, are limited. The anti-CD20 
therapeutic mAb rituximab can deplete B-cells and is used to treat patients with RA and to 
prevent graft rejection/failure in transplant patients. However, as rituximab induces long-
term depletion of all B-cells including pathogen specific memory B-cells, immune defence 
may be compromised [372, 453]. In this chapter, I hypothesized that anti-CD83 would also 
deplete CD83+ activated B-cells and thereby inhibit B-cell immune responses, but spare 
resting B-cells and therefore may have therapeutic advantages over rituximab in 
autoimmunity and transplantation. 
 
5.4.1 Anti-CD83 mediated inhibition of B-cell responses to stimulation 
In Aim 1, I characterized anti-CD83 mediated inhibition of B-cell responses to 
stimulation in vitro. My results showed that anti-CD83 significantly inhibited CD4 T- and B-
cell proliferative responses to antigen-specific stimulation, leaving non-proliferated T and B 
cells untouched. The key feature here is that anti-CD83 targets only activated B cells, but 
not the resting B cells, which is an advantage over rituximab. A study which was done by a 
previous lab member had shown that CD83+ B cells can be lysed by 3C12.Ckif mediated 
NK/ADCC although with poorer efficacy than for other CD83+ cell types. In order to find out 
how our CD83 antibodies work, CD11c+ DC, CD19+ B cells and CD56+ NK cells were 
depleted from PBMC to determine the roles of these cells in this context.  
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 In my TT stimulation experiments, B cells did not function significantly as APC as 
they were not necessary for T cell proliferation in antigen-specific responses. This finding 
is consistent with various studies in B-cell deficient mice where it was demonstrated that B 
cells did not participate in T cell responses to model antigen KLH, schistosoma eggs, 
alloantigens [499], influenza virus [500] and human gamma globulins [501]. My data 
obtained from CD11c+ DC depleted PBMC cultures indicated that anti-CD83 did not target 
only CD83+ CD11c+ DC because inhibition of CD4 T-cell proliferation was no abrogated. 
APC other than primary CD83+ CD11c DC or B cells may play a role, for instance CD83+ 
APC arising from monocytes during the 6-day culture period, such as macrophages or DC 
[502, 503]. A recent study by Segura et al., 2013 reported that inflammatory DC represent 
a distinct human DC subset and proposed that they are derived from monocytes [504]. 
Also, anti-CD83 can inhibit CD4 T cell proliferation stimulated by CD83- APC as the 
activated T cells can be targeted directly although CD83 expression is relatively dim on 
these cells [83]. This needs to be validated in future experiments. As mentioned before, 
anti-CD83 requires NK cells to deplete CD83+ DC and CD4 T-cells [83] and purified 
activated B cells can be lysed by NK cell ADCC with anti-CD83 (manuscript in 
preparation). I wanted to ascertain whether NK cells also play a role in TT stimulated CD4 
T- and B-cell proliferation. Consistently, CD4 T-cell proliferation was not inhibited by anti-
CD83 in the absence of NK cells, which is consistent with the NK cell mediated ADCC 
mechanism of action. However, there was no increase in CD4 T cell proliferation between 
Nil and TT-stimulated cultures in the absent of NK cells (Figure 5-3 (A) (iv)), indicating that 
NK cells may also be required for CD4 T cell proliferation in antigen specific stimulation. 
One possible reason is that NK cell cytokines (IL-12, IFN-γ, IL-4) and direct cell to cell 
contact are required for DC to prime T cells [505].  
 
In contrast, B cell proliferation was increased by TT in NK depleted cultures (Figure 
5-3 (B) (iii)). Surprisingly, B-cell proliferation was suppressed by anti-CD83 despite the 
absence of NK cells. This indicated that inhibition of B-cell proliferation by anti-CD83 in this 
TT-stimulated culture is not entirely NK dependent. A possible additional mechanism may 
be direct apoptosis induction without any effector cell involvement, as is known for 
rituximab [506]. It will be interesting to further investigate the mechanism behind this effect 
of anti-CD83 on T and B cell proliferation. 
I further examined the effect of anti-CD83 on B cell responses and its mechanism of 
action, using the 2-way alloMLR. My results showed that anti-CD83 inhibited alloMLR 
stimulated immunoglobulin secretion. This inhibitory action of CD83 was abrogated by 
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blocking CD16a in the cultures. This is consistent with an NK cell mediated ADCC 
mechanism of action for CD83 inhibition of B cell immunoglobulin secretion. B cells may 
not be targeted directly however, as NK/ADCC depletion of allostimulatory DC and/or allo-
responding CD4 T helper cells would also inhibit B cell Ig expression in alloMLR. AlloMLR 
is a surrogate assay to study transplant rejection and GVHD, and therapeutic potential of 
anti-CD83 targeting activated DC to inhibit generation of pathogenic CD4 T cells has 
already been demonstrated for aGVHD [81]. My findings in this chapter regarding B cell 
stimulation and Ig expression suggest an additional potential therapeutic modality for anti-
CD83 in inhibiting or preventing Ab mediated transplant rejection and possibly also 
cGVHD [507-509].   
 
5.4.2 Anti-CD83 inhibits some of the pro-inflammatory cytokines 
 My results showed that anti-CD83 inhibited antigen specific CD4 T cell proliferation. 
CD4 T cells are considered major contributors of inflammatory cytokines, especially in 
autoimmune disease and transplantation [429, 510, 511]. This in turn drew my attention to 
investigate the effects of anti-CD83 on cytokine expression. In this experiment, specific 
antigen (TT) induced proliferation of presumably antigen-specific T- and B-cell proliferation 
was accompanied by significant increases in IL-2 and IFN-γ secretion. Although TT 
stimulation did not significantly increase levels of the other cytokines assayed in the 
supernatants, it is interesting that secretion of several pro-inflammatory cytokines such as 
GM-CSF and IL-17A were inhibited by anti-CD83 treatment. However, anti-CD83 also 
decreased the release of the anti-inflammatory cytokine IL-10. Consistent with my results, 
Lenaczyk et al., 2000 reported that TT stimulation of healthy donors did not significantly 
increase IL-10 and IL-17 compared to healthy controls [512]. Both CD83 antibodies 
significantly reduced secretion of these cytokines as well as of IL-17A, GM-CSF and IL-10. 
Cytokines occupy a central role in the orchestration of immune responses because they 
influence the development, differentiation and regulation of immune cells [469]. As a result, 
dysregulation of cytokine production may lead to destruction of immune balance and 
promote the pathogenesis of inflammatory and autoimmune disease [513-515]. 
Interestingly, my data showed that CD83 mAb 3C12.Ckif reduced intracellular expression 
of the pro-inflammatory cytokines IFN-γ, IL-17A and IL-21 (but not TNF-α) in proliferated 
(presumably antigen specific) CD4 T cells, as well as of IL-4 and IL-10. 
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IL-2 is well known for its ability to promote differentiation and proliferation of Th1 
responses, enhance Ab production and activation-induced cell death [255].  Reducing the 
secretion of IL-2 means the proliferation of Th1 cells was inhibited as well. This may 
explain the reduction of IFN-γ produced by Th1 CD4 T-cells. However, IL-2 also has anti-
inflammatory effects by inhibiting the Th17 differentiation. If IL-2 was the sole inhibitor of 
Th17 differentiation, we would see an increase in IL-17A expression. But the results did 
not reflect this. Anti-CD83 may have a direct effect on Th17 differentiation. IL-17A is a pro-
inflammatory cytokine that is increased in RA and graft rejection. But since autoimmune 
diseases are mainly Th1 and Th17 cytokine driven, inhibition of IL-2 expression by anti-
CD83 may be an advantage in treating these conditions. Human IL-2R mAb has been 
used in immunosuppressive regimens for transplantation [376, 516, 517]  and to treat 
autoimmune diseases, including uveitis and MS [518-520].  
 
IFN-γ has long been recognized as a signature pro-inflammatory cytokine of 
inflammation and autoimmune disease, although it may display anti-inflammatory and 
immunomodulatory activity under different conditions [515, 521-523]. Anti-IFN-γ had been 
described by Skurkovich et.al in 1989. It was used in combination with anti-TNF-α in 
treating autoimmune diseases [524, 525]. While everyone pointed to IFN-γ as a prime 
mover of autoimmunity over the past two decades, the discovery of IL-17/IL-23 produced 
by Th17 differentiated CD4 T cells has rapidly emerged as the new paradigm that has 
compelled us to critically re-examine the role of cytokines in the pathogenesis and 
treatment of autoimmune diseases. EAE, experimental autoimmune uveitis (EAU) and 
collagen-induced arthritis (CIA), formerly considered as Th1 conditions, are now seen as 
Th17-driven [526]. Cua et al. (2003) and Murphy et al. (2003) found that deficient 
production or action of IL-17 is associated with loss of susceptibility to these experimental 
autoimmune diseases [527, 528]. Thus, both IFN-γ and IL-17A contribute to autoimmune 
inflammation, and our anti-CD83 can inhibit the expression of both of these pro-
inflammatory cytokines.  
 
CD83 antibodies also reduced the secretion of GM-CSF in TT-stimulated cultures. 
As overexpression of GM-CSF leads to severe inflammation [529], CD83 may be useful in 
minimizing the inflammation of autoimmunity. In addition, two recent studies by Codarri et 
al. (2011) and El-Behi et al. (2011) suggested that GM-CSF produced by Th17 and Th1 
cells, and not IL-17A is the key pathogenic cytokine in EAE [340, 341]. In addition, arthritis 
was exacerbated following GM-CSF administration in two murine arthritis models [530, 
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531]. There were no significant changes in IL-6 induced by anti-CD83 in my TT stimulated 
cultures. Dienz et al, 2009 and Diehl et al., 2012 reported that IL-6 is necessary and 
sufficient for IL-21 production by memory and naïve CD4+ T cells, which in turn promote B 
cell differentiation and Ab production [276, 532].  My IL-21 ELISA results were below the 
detection limit, indicating that IL-21 secretion was very low in TT stimulated PBMC 
cultures. However, the percentage of proliferating IL-21+ CD4 T cells was significantly 
reduced by the 3C12.Ckif CD83 mAb. This suggests the possibility that anti-CD83 may 
inhibit IL-21 expression without inhibiting IL-6 production although more work would be 
required to show this. 
 
A modest but statistically significant reduction in secretion of IL-10 in anti-CD83 
treated cultures was linked with reduced IL-10+ CD4 T-cell proliferation. IL-10 is produced 
by several cell populations including CD4 Treg cells. IL-2 can increase the number of total 
CD4 T-cells including Treg cells during activation, so decreased IL-2 secretion in this study 
may bring down the number of Treg cells and hence reduced IL-10 levels. Even though IL-
10 is well known for its anti-inflammatory effects, overproduction of IL-10 can lead to a 
wide variety of diseases, including autoimmune diseases such as SLE [293]. Thus a 
reduction in IL-10 might be a benefit for us to consider if anti-CD83 was to be tested for 
treating SLE. Interestingly, TNF-α remained unchanged after treating with anti-CD83. 
Although TNF-α is a pro-inflammatory cytokine, it also plays a critical role in 
immunoregulation. TNF-α blockade is widely used in autoimmune disease, particularly RA. 
However, blocking TNF-α in patients can lead to an increased susceptibility to infection 
and also the formation of certain autoantibodies resulting in lupus-like syndrome [381]. 
Also, a significant proportion of RA patients do not respond to anti-TNF-α therapy [382]. 
These may be a good subpopulation of RA patients for anti-CD83 therapy.  
 
Among all cytokines, only a few, notably IFN-γ and IL-4 (and the related cytokine IL-
13), are central to both the stimulatory and inhibitory activities of a Th subset [254]. A few 
studies also found that the effect of IL-4 can be reversed by the addition of IFN-γ [533-
535].  My TT stimulation results showed that anti-CD83 reduced IFN-γ but IL-4 secretion 
was not affected which is consistent with my group’s previous GVHD related findings [81]. 
However, I found that CD83 mAb 3C12.Ckif induced a modest reduction in the percentage 
of proliferating IL-4+ CD4 T cells.  IL-4 is a Th2 cytokine and is key to the development of 
allergic inflammation, including asthma [536]. Th1 cytokines are major contributors to 
autoimmunity whereas Th2 cytokines are involved in allergy and asthma [214]. The role of 
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IL-4 in autoimmune disease is less studied, although there is evidence that IL-4 is involved 
in autoantibody production and lupus-like autoimmunity  [537-539]. In contrast, other 
reports have found no role for IL-4 in autoantibody production and lupus nephritis [540, 
541], and one study even found an inhibitory role for IL-4 on autoantibody production 
[542]. In conclusion, IL-4 was relatively unaffected by of anti-CD83 treatment and IFN-γ 
and IL-17A were strongly inhibited suggesting that anti-CD83 targets mainly Th1 and Th17 
rather than Th2 responses and might be more useful for treating patients with autoimmune 
disease rather than allergy. Also, as shown above, and previously reported for a GVHD 
model [81], anti-CD83 inhibition of the Th1 cytokines IL-2 and IFN-γ, supports a potential 
role for anti-CD83 in preventing transplant rejection. 
 
Activated B cells can secrete pro-inflammatory cytokines like IL-6, IFN-γ, IL-4 and 
immunosuppressive cytokines like TGF-β and IL-10 [364, 543, 544]. B cells can polarize to 
B effector cells just like T cells [545]. Activated Th cells can crosstalk with activated B cells 
to regulate their responses [546]. Hence, B effector cells adjust the polarized Th1 
response by producing IFN-γ [546]. Inhibition of B-cell proliferation with anti-CD83 may 
contribute to reduction of pro-inflammatory cytokines such as IFN-γ. This in turn could 
suppress the formation of activated CD4 T-cells and modulate CD4 T-cell immune 
responses.  
 
The increasing understanding that cytokines play a major role in autoimmune 
diseases has provided the pharmaceutical industry with a wide array of new targets for 
therapeutic intervention. Autoimmune diseases are mostly treated with conventional drugs 
such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and methotrexate, 
which have limited efficacy and inadequate safety profiles, and sometimes do not induce 
disease remission [547]. The current treatments for autoimmune disease mostly target 
only one cytokine (or in combination with MTX), such as IL-6 antagonism in RA [548, 549]; 
anti-TNF-α in RA, Crohn’s disease and type-1 diabetes [350, 547]; anti-IFN-γ in Crohn’s 
disease [550], RA [551], and MS [552]. Anti-CD83 is effective in inhibiting more than one 
pro-inflammatory cytokine, including IFN-γ, GM-CSF and IL-17A and did not affect IL-4 
and TNF-α expression which may be beneficial in the maintenance of immune protection 
from infection. The use of anti-TNF agents has shown to be associated with an increasing 
number of cases of autoimmune diseases, principally vasculitis, lupus-like syndrome, SLE 
and interstitial lung disease [383]. In addition, anti-cytokine biologicals are very expensive 
(~US$15,000-20,000 per year) [553], a major concern for cost-conscious healthcare 
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authorities. It is also advantageous to have alternative effective drug available for patients 
with severe or drug resistant disease. Taken together, my results strongly suggest that 
targeting CD83 may be a better approach to treat autoimmune disease and transplant 
rejection.  
 
Traditionally, autoimmune disorders were classified as T-cell mediated or 
autoantibody mediated. However, studies through the years have improved understanding 
of the complexity of the immune system and influenced the way we view the pathogenesis 
of autoimmune diseases. B-cells have become the focus in recent years as they can 
contribute to autoimmune diseases by autoantibody secretion, autoantigen presentation, 
inflammatory cytokine secretion, and generation of ectopic germinal centres [369]. 
Abnormalities in certain peripheral B-cell subsets such as B-1 cells in SLE compared with 
healthy subjects were reviewed recently [489, 554]. Griffin et al., 2011 [489] reported that 
B-1 cells express high level of MHCII and CD86, and Tze et al., 2011 [34] reported that 
CD83 stabilizes these molecules on the cell surface. This in turn induced us to 
hypothesize that CD83 would be elevated in B-1 cells. My results confirmed that CD11b+ 
and CD11b- B-1 cells make up less than 5% of total circulating B cells in man. 
Interestingly, CD11b+ B-1 cells had the highest expression of CD83 compared to other B-
cell subsets in unstimulated culture. As reported by Griffin et al. (2011), CD11b+ B-1 cells 
are expanded in SLE patients. Therefore, anti-CD83 targeting of CD83+ CD11b+ B-1 cells 
may be a potential therapeutic option for SLE patients [489]. As there are no other reports 
of CD11b+ B-1 cells involved in other autoimmune diseases, it is critical to further 
investigate the role of these cells in SLE and other autoimmune diseases, as well as the 
role of CD83 in these conditions. 
 
5.4.3 Kinetics of CD83 expression by B cells on stimulation 
 The expression of CD83 on B cells upon activation is not sustained. It is important 
to define the kinetics of CD83 expression by B cells on stimulation as it would influence the 
utility of anti-CD83 therapy. B cells that differentiated to plasma cells do not express CD83 
yet they express very high levels of Ig, including autoantibody [555-557]. I found that LPS, 
CD40L, anti-CD3/CD28 and polyclonal B cell activators such as anti-IgM/IgG, and αδ-dex 
each substantially upregulated CD83 expression within 6hrs and this was sustained 
another 6hrs before it started to drop. For some activators, including LPS, anti-IgG alone, 
and TT, CD83 expression on B cells had returned to baseline at 48hrs. CD83 expression 
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kinetics on B cells were shown to be similar in αCD40 and LPS treated mice [86]. αCD40 
and LPS stimulation rapidly increased CD83 expression within 4hrs and was sustained 
until 24hr. Contrary to human B cells, anti-IgM stimulation upregulated CD83 slowly until 
24hr in mice [86]. Overall, CD40L clearly induced a more sustained level of CD83 
expression. Therefore, anti-CD83 therapy can be expected to be most effective when 
resting B cells (eg. autoantigen specific memory B cells) are stimulated and CD4 T cell 
help is involved. Apart from this, stimulation of CD4 T cell help would also be abrogated by 
anti-CD83 mediated depletion of activated DC. 
  
5.4.4 Effects of anti-CD83 treatment on human B-cell responses in vivo 
 When I attempted to translate antigen-specific stimulation from in vitro to in vivo 
using Equivac® T immunization, the results were consistent. The engraftment data showed 
that B-cells were not completely depleted by anti-CD83 given 3 days post-transplant, even 
though the percentage was less than in controls. The reduction in B cells with anti-CD83 
was not large, approximately 35% in PC, and 45% in spleen. In contrast to B cells, CD4 T 
cells were increased in RA83 treated mice on day 13 post-transplant. This is different from 
the findings of Wilson et al. [81]. However, the timings and conditions were different 
between these studies; RA83 was given on day 0 and the mice received a higher dose of 
radiation (325 cGy) in the Wilson experiment. In my experiments, anti-CD83 significantly 
reduced antigen-specific Ig levels without affecting circulating total human IgG levels. Non-
specific depletion of B cells in anti-CD83 treated mice could account for the reduced 
antigen-specific IgG levels but it is not consistent with the unchanged total IgG. However, 
we cannot deny the fact that the human PBMC xenografted SCID mouse is a poor in vivo 
model of human B cell responses. This finding supports my hypothesis that anti-CD83 
would have advantages over rituximab in terms of maintenance of immune B cell memory. 
There is a lot of evidence showing that rituximab depletes all B cells including memory B 
cells [371-373, 377, 433, 435, 436, 558-562]. In conclusion, my in vitro (Figure 5-2 (D)) 
and in vivo results strongly suggest that anti-CD83 would not deplete all B cells (including 
memory B cells specific for other infectious organisms) in patients.  
 
Anti-CD83 acted differently in the context of KLH immunization, as it decreased 
both total human IgM and antigen-specific IgM production. Given that KLH immunization 
stimulates a naïve antibody response, anti-CD83 may be useful in this context. Krampera 
et al., 2003 showed that bone marrow derived mesenchymal stem cells have inhibitory 
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effects on naïve and memory T cell responses to transplant antigens, suggesting that 
inhibiting naïve responses may be useful in preventing host-versus-graft responses or 
GVHD [563]. These suggest that anti-CD83 may be able to be used as a prophylactic in 
naïve response relevant conditions, such as transplant rejection. CD28 and CTLA-4 
blockade which effectively inhibits both recall and naïve antigen-specific CD4+ T cell 
responses [564, 565], was developed in clinical trials for the treatment of autoimmunity, 
including RA and type-1 diabetes [566-570]. Although targeting co-stimulatory pathways 
may be able to inhibit naïve antigen-specific CD4+ T cell responses in autoimmune 
disease, and has been considered as treatment option, it is however not well studied to 
date. The role of anti-CD83 in inhibiting clinically relevant naïve responses requires more 
work. 
 
5.4.5 Conclusion 
In summary, I have shown for the first time that anti-CD83 inhibits specific antigen 
stimulated CD4 T- and B-cell proliferation and leaves resting CD4 T and B cells 
untouched. I demonstrated consequent reductions in inflammatory cytokine expression by 
CD4 T cells and, in MLR assays and confirmed that Ig expression is inhibited by a CD16 
FcγR mediated mechanism. The overall in vitro and in vivo findings strongly suggest that 
anti-CD83 is very promising for inhibiting Ab and inflammatory cytokine responses without 
impairing pre-existing humoral immunity to infection. Accordingly, anti-CD83 could 
potentially become a preferred choice over rituximab for treatment of patients with 
autoimmune diseases. Similarly, it may also be useful for treatment or prevention of other 
conditions such as antibody mediated transplant rejection.  
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Chapter 6: Anti-CD83 mediated stimulation of murine antibody 
responses 
 
6.1 Introduction 
Streptococcus pneumoniae often causes serious infections, such as pneumonia, 
septicaemia, and meningitis [571] in younger children, immunocompromised patients, and 
the elderly. Pneumovax-23 (23-valent pneumococcal polysaccharide (PPS) vaccine), is a 
non-conjugate capsular TI-2 antigen, which contains the 23 pneumococcal serotypes that 
cause up to 90% and 83% of the invasive pneumococcal disease in unvaccinated children 
less than 5 years of age in the United States [572] and Fiji [573] respectively. Pneumovax-
23 vaccine might provide wider serotype coverage than 7 or 13-valent conjugate 
pneumococcal vaccine (PCV7 or 13, Prevenar) but is reported to be weakly immunogenic 
in children less than 2 years-old [574]. Children younger than 2 years respond better to 
Prevenar than Pneumovax-23 as Prevenar is PPS conjugated to a protein carrier to 
generate TD responses [575, 576]. Nevertheless, conjugate vaccines are costly and 
invasive disease attributable to non-vaccine serotypes of S. pneumoniae has greatly 
increased [577]. 
 
Vaccine-induced protection from infection is usually mediated by antibodies [163, 
578]. Other potential effectors are cytotoxic CD8+ CTL that recognize and kill infected cells 
to limit the spread of infectious agents. Vaccines are normally optimized to induce B cell 
responses. DC and CD4 T cells have important roles in responses to vaccination. The 
generation and maintenance of both B and CD8+ T cell responses are supported by 
growth factors and signals provided by CD4+ Th cells. CD83 is upregulated on murine and 
human DC upon activation, but this is not restricted to DC. Other studies, mostly in mice 
but some in man, report that CD83 is also present on activated T and B cells [3, 10, 20, 
86, 579]. It is also reported for mice that CD83 is involved in the regulation of B cell 
maturation, homeostasis, and function [20, 21]. Therefore CD83 antibody treatment has 
the potential to seriously impact antibody responses to infection and to vaccination. My 
work to date in human models, in chapter 5 of this thesis, suggests that CD83 antibody 
treatment impairs humoral immune responses. In contrast, Kretschmer et al., 2009 
reported that B cells from CD83 mutant mice that lack functional CD83 secrete slightly 
enhanced amounts of Ig. They also found that CD83 antibody treatment of mice strongly 
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boosted TI-2 immune responses to 4-hydroxy-3-iodo-5-nitrophenyl-acetyl (NIP)-Ficoll but 
has no effect on TD responses [23], which I confirmed and extended in this chapter.  
 
B-1 and MZ B cells have been considered to be primarily responsible for the 
antibody response to TI-2 antigens [104, 580, 581]. Studies by Baumgarth et al., 2008 and 
Snapper, 2006 using model pathogens influenza and S. pneumoniae respectively 
suggested that protective humoral immune responses are comprised of a collection of 
antibodies derived from distinct B cell subsets [119, 123, 582]. Haas’s group demonstrated 
that murine B-1b cells are the major B cell subset involved in TI-2 immune responses [583, 
584]. In contrast, the response to the model TI-2 antigen NP-Ficoll has been characterized 
by the domination of IgM and IgG3 isotypes derived from MZ B cells [585, 586]. However, 
the division of labour among B cell subsets, including B-1a, B-1b cells, MZ B cells and 
even FO B cells [167], in antibody responses to TI-2 antigens is not completely clear. A 
recent study by Uhde and colleagues showed that CD83 is differentially regulated in 
murine FO and MZ B cell responses by modulating BCR and TLR signaling [24]. 
Therefore, targeting activated CD83+ B cell subsets with CD83 antibody may affect the 
antibody responses.  
 
I hypothesized that anti-CD83 antibody differentially affects antibody responses of 
the various B cell subsets in mice. I also specifically hypothesized that anti-CD83 antibody 
would stimulate IgG responses to the TI-2 vaccine Pneumovax in mice. 
  
 
6.2 Aims 
Aim 1: To characterize CD83 expression by murine B cell subsets and the effects of CD83 
deficiency on responses to TI-2 and TD immunization. 
Aim 2: To investigate the effect of anti-CD83 treatment on antigen specific antibody 
responses to TI and TD immunization of immunocompetent mice. 
Aim 3: To investigate in vitro TI-2 responses and class switching induced by anti-CD83 
treatment. 
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6.3 Results 
 
Aim 1: To characterize CD83 expression by murine B cell subsets and the effects of 
CD83 deficiency on responses to TI-2 and TD immunization 
 
6.3.1 CD83 expression by murine B cell subsets  
6.3.1.1 Rationale 
TI-2 responses have been attributed to both B-1 cells and to a subset of the major 
B2 subtype; MZ B cells [104, 124]. B-1 cells are found mostly in the peritoneal cavity of 
mice while B2 cells are found in the spleen, lymph nodes and circulation. Murine B-1a and 
B-1b cells are different in developmental requirements [123] and response to Ag receptor 
signalling [587], and perform unique functions in the immune system [100]. B-1a cells are 
well known as natural antibody-producing cells which are important for homeostasis and 
immune defence [100, 588] but they may also participate in antigen-specific antibody 
responses [589, 590]. Murine B-1b cells appear to serve a more critical function in 
producing antibodies in response to classical TI-2 antigens, such as PPS, α1,3 dextran, 
and haptenated Ficoll [123, 583, 591, 592] as well as other TI antigens [122, 593, 594]. 
Kretschmer et al., 2009 showed that CD83 expressed by B cells, not DC or T-cells, was 
required for the observed increase in TI-2 Ag specific IgG1 following anti-CD83 treatment 
[23]. There is increasing evidence for a primary role of B-1b and MZ B cells in producing 
antibodies in response to naïve PPS immunization in mice [123, 595] and a B-1b-like cell 
population similarly contributes to TI-2 antibody responses in non-human primates [596]. 
Consistent with this, human B-1-like cells have been reported to produce PPS-specific 
antibody following Pneumovax immunization [597]. My aim here was to characterize CD83 
expression by murine B cell subsets as this has not previously been reported at the subset 
level. Also, CD83 deficient mice have a CD4 T cell deficiency due to inhibition of 
thymocyte differentiation and hence reduced TD immune responsiveness attributed to 
limited CD4 T cell help [8]. I mentioned above, TI-2 responses are derived from B-1 and 
MZ B cells and IgG switching is enhanced by anti-CD83 in NIP-Ficoll immunized mice. 
Therefore I wanted to confirm the presence of the B cell subsets in CD83 deficient mice as 
well as test them functionally. I also investigated responses to TI-2 immunization in CD83 
deficient  mice, as only TD responses have been reported previously [8].  
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6.3.1.2. Experimental Design 
In this experiment, BALB/c strain mice were chosen. I used BALB/c mice to test anti-CD83 
on TI-2 responses to broaden knowledge beyond the Kretschmer group’s findings with the 
C57BL/6 strain. BALB/c are considered to produce predominantly Th2 responses (humoral 
immunity) [598] to infection, which I investigated in this chapter. BALB/c mouse peritoneal 
cavity (PC) cells and splenocytes were harvested. B cell subsets and CD83 expression 
were assessed by flow cytometry on day 0 (fresh isolated PC cells and splenocytes) and 
day 1 (overnight cultures) using fluorescently labeled rat anti-mouse antibodies using two 
different phenotyping panels: 
 
Based on Baumgarth (2011) : APC-CD83, PE-CD19, FITC-CD43, PE-Cy7-CD23, APC-
Cy7-CD21, and PB-CD5; Cell surface phenotype: Peritoneal cavity: B-1a (CD19+CD23-
CD5+), B-1b (CD19+CD23-CD5-), follicular B-2 (CD19+CD23+CD21-CD5-), marginal zone 
B-2 (CD19+CD23-CD21+CD5-); Spleen: B-1a (CD19+CD43+CD23-CD5+), B-1b 
(CD19+CD43+CD23-CD5-), follicular B-2 (CD19+CD43-CD23+CD5-), marginal zone B-2 
(CD19+CD43-CD23-CD21+CD5-), others (total CD19+ minus B1a, B1b, FO B2 and MZ B 
cells) [100]; freshly harvested cells were stained and analyzed at day 0. 
 
Based on Haas (2011) : PE-B220, PE-Cy7-CD11b, APC-CD83 and CD5-PB; Cell surface 
phenotype: B-1a (B220+CD11b+CD5+), B-1b (B220+CD11b+CD5-), B2 (B220+CD11b-CD5-) 
[583]. This phenoyping was adopted to minimize the unclassified “Others” subset that I 
found in Baumgarth (2011) phenotyping. Cells were stained and analysed on day 0 and 
after overnight cultures. 
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6.3.1.3 Results 
(A) B cell subsets and (B) CD83 expression by B cell subsets in PC and spleen on 
day 0 
 
 
 
Figure 6-1: (A) B cell subsets and (B) % CD83+ expression by B cell subsets in 
peritoneal cavity and splenocytes of freshly isolated untreated BALB/c mice, based 
on Baumgarth 2011. Data represent mean (± SEM) (n=3/group). Cell surface phenotype: 
Peritoneal cavity: B-1a (CD19+CD23-CD5+), B-1b (CD19+ CD23-CD5-), follicular B-2 
(CD19+CD23+CD21-CD5-), MZ B-2 (CD19+CD23-CD21+CD5-); Spleen: B-1a 
(CD19+CD43+CD23-CD5+), B-1b (CD19+CD43+CD23-CD5-), follicular B-2 (CD19+CD43-
CD23+CD5-), MZ B-2 (CD19+CD43-CD23-CD21+CD5-) [100], others (total CD19+ minus 
B1a, B1b, FO B2 and MZ B cells). 
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(A) B cell subsets in PC and Spleen 
 
 
(B) CD83 expressed by B cell subsets in PC and Spleen 
 
Figure 6-2: (A) B cell subsets and (B) % CD83+ expressed by B cell subsets in the 
peritoneal cavity and splenocytes of untreated BALB/c mice on day 0 and day 1 
cultures, based on Haas (2011). Data represent mean (± SEM) (n=4/group). Cell surface 
phenotype: B-1a (B220+CD11b+CD5+), B-1b (B220+CD11b+CD5-), B2 (B220+CD11b-CD5-) 
[583]. 
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I compared two different B cell subsets phenotyping panels: Baumgarth 2011 [100] 
(Figure 6-1 (A) and (B)) and Haas 2011[583] (Figure 6-2 (A) and (B)). Baumgarth 2011 
used phenotypic markers to separate B-2 cells into FO B and MZ B, whereas Haas et al., 
2011 classified both subsets under 1 roof, B-2 cell only. In PC, B-1a cells are the largest 
population in B cells (Figure 6-1 (A) and 6-2 (A)). The remaining unclassified B cells 
“Others” contributed the second largest populations in PC and SP (Figure 6-1). In contrast, 
the Haas phenotyping shows that B-1b cells are the second largest populations in PC and 
spleen. However, the “Others” populations overtook B-1a and B-1b in overnight cultures in 
spleen (Figure 6-2 (A)). As suggested by Baumgarth, “Others” may be regulatory B cells, 
which have phenotypical markers of both B-1 and B-2 cells. This may explain why the 
populations of “Others” are high in both PC and SP on day 0 and day 1 of cultures. As 
expected, B-2 cells including FO B, the key TD responders [599], are the most numerous 
of splenocyte B cells (Figure 6-1 (A) and 6-2 (A)). If the “Others” are excluded in splenic B 
cells, MZ B cells are the second largest population.  
  
CD83 expression is higher in B-1a than other B cell subsets in PC. B-2 cells 
expressed highest CD83 expression (~52%) in splenocytes followed by B-1b cells (~36%) 
before culture (Figure 6-2 (B)). B-1b cells in spleen expressed high CD83, although the 
population are less than 20% (Figure 6-2 (A)). However, using Baumgarth’s phenotypical 
markers [99], I showed that B-1b cells contribute less than 5% in PC (Figure 6-1 (A)) and 
only approximately 4% of these cells expressed CD83. Interestingly, CD83 expression on 
B-2 and B-1b cells in spleen had a big drop, especially B-1b cells has more than 50% 
decreased in CD83 expression. B-1a cells, of which only 5.8% expressed CD83 when 
freshly harvested had increased their expression to approximately 18% in overnight 
cultured splenocytes. A similar finding was observed in “Others”, in which CD83 expressed 
on these B cells had increased close to 5-fold in overnight cultures. Consistently, CD83 
expressed on B-1b cells was higher than B-1a cells in fresh isolated splenocytes  (Figure 
6-1 (B) and 6-2 (B)). Of all subsets, B-1a had the highest percentage of CD83+ cells in 
fresh and cultured PC (Figure 6-1 (B) and   6-2 (B)). Given that B-1 and MZ B cells are the 
key responders to TI immunization [189], B-1a and B-1b cells may be the significant target 
cells for anti-CD83 induced IgG class switching in TI-2 responses [23].  
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6.3.2 B cell subsets and antigen specific antibody responses in TI-2 and TD 
immunized C57BL/6 wild-type and CD83anu/anu  mice 
6.3.2.1 Rationale 
CD83 expression in the thymus is required for normal CD4+ T cell development in the 
thymus [8]. Fujimoto et al., 2002 reported that CD83-/- mice had lower antigen-specific 
antibody responses compared to WT mice after TD immunization [8]. To confirm their data 
and to further understand the role of CD83 in class/isotype switch responses to TI-2 
antigens, I immunized CD83 gene mutated mice (CD83anu/anu)   [34] that have the same 
CD4 T cell deficiency as CD83 knockout mice [8].  
6.3.2.2 Experimental design 
In this experiment, C57BL/6 mice were used and not the BALB/c I used in section 6.3.1 
because CD83anu/anu mice were not available in BALB/c strain. Also, Kretschmer 2009 [23] 
used C57BL/6 mice to investigate TI-2 and TD immune responses. C57BL/6 wild-type 
(WT) and CD83anu/anu  mice of the same strain at age 6-8 weeks were immunized i.p with 
25 μg of trinitrophenyl (TNP)-Ficoll (TI-2 antigen), in PBS or with 25 μg of alum-
precipitated TNP–KLH (TD antigen). All antigens were obtained from Biosearch 
Technologies. Serum samples were collected from the tail vein before immunizations and 
on day 7 and day 14 and were collected by cardiac puncture on day 21 after the 
immunization with TI-2 or TD antigen. TNP-specific antibodies were measured by ELISA. 
Peritoneal cavity and splenocyte B cell subsets of C57BL/6 WT and CD83anu/anu  naïve and 
immunized mice (TNP-Ficoll or TNP-KLH) were harvested 21 days post-immunization and 
analysed by flow cytometry. Cellular phenotype analysis was done using fluorescently 
labeled rat anti-mouse antibodies were as follows: B220-PE, CD11b-APC-Cy7, and CD5-
PB. Cellular phenotypes identified were: B-1a (B220+ CD11b+ CD5+), B-1b (B220+ CD11b+ 
CD5-), and B-2 (B220+ CD11b- CD5-) [583]. 
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6.3.2.3 Results 
 
 
Figure 6-3: TNP-specific serum IgM, IgG, IgG1, IgG2b, IgG2c, IgG3 and IgA levels in 
C57BL/6 WT and CD83anu/anu   mice immunized with 25 µg TNP-Ficoll. Data points 
represent means (± SEM) (n=3/group). *p<0.05, **p<0.01, C57BL/6 WT versus CD83anu/anu  
mice. Statistical analysis: 2-way ANOVA with Bonferroni post-tests. 
 
CD83anu/anu   mice had significantly reduced production of IgG switched TNP-specific 
antibodies after TNP-Ficoll immunization, whereas TNP-specific IgM and IgA were 
unaffected. IgG3 is the dominant IgG isotype produced in response to TNP-Ficoll in 
C57BL/6 WT mice and was significantly greater than in the CD83anu/anu mice on day 21, as 
were IgG1, IgG2b and IgG2c.  
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Figure 6-4: TNP-specific serum IgM, IgG, IgG1, IgG2b, IgG3 and IgA levels in 
C57BL/6 WT and CD83 anu/anu   mice immunized with 25 µg TNP-KLH. Data points 
represent means (± SEM) (n=3/group). *p<0.05, **p<0.01, ***p<0.001, C57BL/6 WT 
versus CD83 anu/anu   mice. Statistical analysis: 2 way ANOVA with Bonferroni 
post-tests. 
 
WT mice had strong isotype-switched TNP-specific IgG1, IgG3 and IgG2b 
responses within 7 days of TNP-KLH immunization. TNP-specific IgG1 and IgG2b 
produced in response to TNP-KLH in the C57BL/6 WT mice were significantly greater than 
in the CD83anu/anu mice on day 14 of immunization. CD83anu/anu   mice had delayed TNP 
specific responses but these had caught up to WT levels by day 21 for IgG1 and IgG3. 
TNP-specific IgM produced in WT mice was greater than in CD83anu/anu mice and remained 
high in TD in contrast to TI-2 immunized mice (compare Figures 6-3 and 6-4). TD IgA 
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responses were minimal in WT and CD83anu/anu mice. IgG2c responses were not 
determined in TD immunized mice due to insufficient of serum collected. 
 
Thus, acknowledging the strain difference between these mice and the results 
shown later in Figures 6-6 and 6-7 (BALB/c), we conclude that CD83 antibody treatment 
does not mimic the effects of CD83 deletion on TD and TI-2 immune responses. The major 
central immune effect of CD83 gene deletion is CD4 T cell deficiency. By definition CD4 T 
cell help is not required for TI-2 responses. However, it does not follow that the potent 
CD83 antibody induced stimulation of class switched TI-2 antigen specific antibody does 
not involve CD4 T cells. Further work is required to understand the mechanism of this 
phenomenon. 
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B cell subsets in naïve and immunized C57BL/6 WT and CD83anu/anu   mice 
 
 
 
Figure 6-5: B cell subsets in peritoneal cavity and splenocytes in naïve and 
immunized C57BL/6 WT and CD83anu/anu mice 21-day post-immunization (% of 
total B cells). Data represent mean (± SEM) (n=3/group). *p<0.05, ***p<0.001, C57BL/6 
versus CD83anu/anu mice. Cell surface phenotype: B-1a (B220+CD11b+CD5+), B-1b 
(B220+CD11b+CD5-), B2 (B220+CD11b-CD5-) [583]. Statistical analysis: the difference 
between C57BL/6 versus CD83anu/anu mice is analysed by 2 way ANOVA with Bonferroni 
post-tests. The difference between naïve and immunized mice in each group was 
analysed by 2-tailed Mann Whitney test.  
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B-1a and B-1b B cells were present in the peritoneal cavity of CD83anu/anu mice, 
although B-1a cells were reduced in frequency and B2 cells were increased. B2 cells were 
also increased in the spleen in CD83anu/anu mice. The percentage of B-1b B cells tended to 
increase upon immunization but it was not statistically significant in either C57BL/6 WT or 
CD83anu/anu mice. Haas reported a similar trend [583].  
 
 
Aim 2: To investigate the in vivo effect of anti-CD83 treatment on antigen specific 
antibody responses to TI and TD immunization of immunocompetent mice. 
 
6.3.3 Effect of anti-CD83 on TI-2 and TD antibody responses 
6.3.3.1 Experimental Design 
BALB/c mice at age 6-8 weeks were given 0.5 mg (200ul) of anti-CD83 antibody RAM83 
or control RANeg i.p one day before immunization. Mice were then immunized i.p with 25 
μg of trinitrophenyl (TNP)-Ficoll [TI-2 antigen), in PBS or 25 μg of alum-precipitated TNP–
KLH (TD antigen). All antigens were obtained from Biosearch Technologies. Serum 
samples were collected from the tail vein before immunizations and on day 7 and day 14 
and by cardiac puncture on day 21 after the immunization with TI or TD antigen. TNP-
specific class and subclass specific antibodies were measured by ELISA. 
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6.3.3.2 Results 
Effect of anti-CD83 on TI-2 immune response 
 
 
Figure 6-6: TNP-specific serum IgM, IgG, IgG1, IgG2a, IgG2b, IgG3 and IgA 
responses in BALB/c mice immunized with 25 µg TNP-Ficoll and administered anti-
CD83 (RAM83) or control antibody (RANeg). Data represent mean ELISA absorbance 
values for sera diluted as shown (± SEM) (n=3 mice per treatment group). *p<0.05, 
**p<0.01, ***p<0.001, RANeg versus RAM83. Statistical analysis: 2 way ANOVA with 
Bonferroni post-tests. 
 
Anti-CD83 treated BALB/c mice immunized with the model TI-2 antigen TNP-Ficoll 
significantly increased the production of IgG subclass-switched TNP specific antibody. 
Anti-CD83 significantly enhanced TNP-specific IgG levels particularly IgG1. In reducing 
order of magnitude, TNP-specific IgG3, IgG2b, IgG2a and IgA levels were also increased 
in anti-CD83 treated mice but IgM production was unaffected. IgG1 and IgG3 levels 
remained high for the 3 weeks of observation post-immunization in anti-CD83 treated 
mice. These results are broadly similar to those of Kretschmer et al., 2009 for anti-CD83 
mAb treated C57BL/6 mice immunized with NIP-Ficoll. They reported only IgG1 but not 
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IgG3, were significantly increased while I found IgG1 and IgG3 were significantly 
increased (Figure 6-6). 
 
Effect of anti-CD83 on TD immune response 
 
 
 
Figure 6-7: TNP-specific serum IgM and IgG levels in BALB/c mice immunized with 
25 µg TNP-KLH and treated with anti-CD83 (RAM83) or control antibody (RANeg). 
Data points represent means (± SEM) (n=3/group). *p<0.05, RANeg versus RAM83. 
Statistical analysis: 2-way ANOVA with Bonferroni post-tests. 
 
Anti-CD83 treatment of TNP-KLH immunized mice induced a small but significant 
decrease in TNP-specific IgM on day 7 post immunization. RAM83 induced a small but 
significant increase in TNP-specific IgG levels on day 14. However Kretschmer et al., 2009 
[23] found no change in TD antigen specific IgG in CD83 mAb treated C57BL/6 mice 
(Figure 6-7). In stark contrast to my data from human experimental models in chapter 5, 
there was no suggestion in these immunocompetent mouse experiments that anti-murine 
CD83 antibody treatment reduces antigen specific IgG responses to immunization.  
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6.3.4 Effect of anti-murine CD83 mAb Michel-19 on TI-2 antibody responses 
6.3.4.1 Rationale 
I have shown above that RAM83 exerts a potent IgG stimulatory effect in TNP-FIcoll 
immunized BALB/c mice. In contrast, Kretschmer et al. (2009) reported that anti-CD83 
mAb (Michel-19) induces a strongly increased IgG1 response to immunization with another 
TI-2 antigen, NIP-Ficoll [23]. Based on their findings, I also compared the efficacy of 
commercially available anti-CD83 mAb (Michel-19) with RAM83 and also its effect with 
another TI-2 antigen, TNP-Ficoll in BALB/c mice.  
6.3.4.2 Experimental design 
BALB/c mice at age 6-8 weeks were injected i.p with 12.5 µg (200 µl) of anti-CD83 mAb 
(clone: Michel-19) (Biolegend, USA) or rat IgG1 isotype one day prior to and one day post-
TNP-/NIP-Ficoll (Biosearch Technologies, USA) immunization. One day after the first 
antibody injection, mice were then immunized i.p with 50 μg of either TNP-Ficoll or NIP-
Ficoll, in 200 µl of PBS. Serum samples were collected from tail vein before immunizations 
and on day 7 and day 14 and by cardiac puncture on day 21 after immunization. TNP-
specific or NIP-specific antibodies were measured by ELISA. 
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6.3.4.3 Results 
 
 
Figure 6-8: TNP and NIP-specific serum IgM and IgG levels in BALB/c mice 
immunized with 25 µg TNP- or NIP-Ficoll and treated with anti-CD83 (Michel-19) or 
control antibody (Rat IgG1). Data points represent means (± SEM) (n=3/group). *p<0.05, 
**p<0.01, Michel-19 vs Rat IgG1. Statistical analysis: 2way ANOVA with Bonferroni post-
tests. 
 
 I found that Michel-19 induced a moderate, statistically significant increase in the 
NIP-Ficoll specific IgG response in BALB/c mice, but not as strong as that reported by 
Kretschmer et al. (2009) [23] in C57BL/6 mice. However, I found no effect of Michel-19 in 
TNP-Ficoll immunized BALB/c mice. It is uncertain why this phenomenon occurred. It 
could be due to different immunogenicities of the two model TI-2 antigens. Similarly, there 
were no differences in TI-2 antigen-specific IgM responses between Michel-19 and 
negative control treated mice. In my experiments, RAM83 was more potent than Michel-19 
in enhancing TNP-specific IgG responses to TNP-Ficoll immunization of BALB/c mice 
(supplementary data in Appendix I and J). 
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6.3.5 Effect of anti-CD83 in Pneumovax-23 vaccination 
6.3.5.1 Rationale 
My work above demonstrated that anti-CD83 antibody RAM83 strongly enhances TNP-
specific IgG antibody responses to immunization with the TI-2 antigen TNP-Ficoll. If anti-
CD83 can exert a similar effect in Pneumovax-23 immunization, it could be a promising 
candidate to consider for clinical use together with Pneumovax-23. In the experiment 
below, I tested for responses to pneumococcal polysaccharides 14 (PPS14) and 23F 
(PPS23F) in Pneumovax immunized mice treated with RAM83 vs RANeg. PPS14 and 
PPS23F are from twon of the many S. pneumoniae serotypes that are highly resistant to 
antibiotics [600-604]. Vaccinations which result in PPS-specific IgM and IgG 
opsonophagocytic antibodies are critical for bacterial clearance in man [191, 605-608]. 
6.3.5.2 Experimental design 
BALB/c mice at age 6-8 weeks were given 0.5 mg (200µl) of anti-CD83 antibody RAM83 
or control RANeg i.p one day before immunization. Mice were then immunized i.p with 200 
µl of diluted Pneumovax-23 (Merck) containing 0.125 µg of each of 23 different PPS 
serotypes. The mouse dose was determined based on Haas et al., (2014) [584]. Sera 
were obtained from tail vein one day before antibody injection, on day 7 and day 14 and by 
cardiac puncture on day 21 after the immunization with Pneumovax-23. For the anti-PPS 
ELISA, plates were coated with 23 µg/ml of Pneumovax-23, representing 1 µg of each 
PPS/ml (50 µl/well), PPS14 or PPS23F (5 µg/ml) (Staten Serum Institute, Denmark). 
Serum was treated at RT for a minimum of 30 min with Cell Wall Polysaccharide (CWPS 
Multi) (10 µg/ml) (Staten Serum Institute, Denmark) in PBS containing 2% goat serum to 
remove anti-C-polysaccharide antibodies and non-S. pneumoniae-specific antibodies. The 
plates were blocked with PBS containing 10% goat serum (37°C, 1hr), incubated with 100 
µl PBS, 1% BSA-diluted serum (37°C, 2hr), and incubated with HRP-conjugated goat anti–
mouse IgM/G (1:5000 dilution) in PBS, 1% BSA (37°C, 1.5hr). 
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6.3.5.3 Results 
 
 
Figure 6-9: Pneumovax/PPS14/PPS23F-specific serum IgM and IgG levels in BALB/c 
mice immunized with Pneumovax-23 and treated with anti-CD83 (RAM83) or control 
antibody (RANeg). Data points represent means (± SEM) (n=3/group). *p<0.05, RAM83 
vs RANeg IgG1. Statistical analysis: 2-way ANOVA with Bonferroni post-tests. 
 
 RAM83 induced a small but significantly increased Pneumovax-specific IgG 
response only on day 7 post-immunization. It also induced a small increase in PPS14-
specific but not PPS23Fspecific IgG on day 21 post-immunization (Figure 6-9). Again, 
there were no significance differences in any Pneumovax/PPS14/PPS23F-specific IgM 
responses between RAM83 and control treatments. 
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Aim 3: To investigate in vitro TI-2 responses and isotype switching induced by anti-
CD83 antibody treatment 
6.3.6 The in vitro effect of anti-CD83 on murine TI-2 antibody responses 
6.3.6.1 Rationale 
My previous results confirmed that anti-CD83 enhances antibody responses to TI-2 
antigen immunization in vivo. To assess the relative contributions from the peritoneal 
cavity (where B-1 cells predominate) and spleen (where B-2 cells predominate including 
MZ B cells), I investigated the effect of anti-CD83 in vitro. I used dextran-conjugated anti-
IgD antibody (αδ-dex) as a surrogate TI-2 antigen. αδ-dex cross-links multiple IgD+ BCRs 
in a manner analogous to that for TI-2, but it does this to all IgD+ B cells rather than just to 
a small antigen-specific population [177]. αδ-dex activated B cells undergo substantial Ig 
class switching and differentiation into Ig-secreting cells in the presence of various second 
signals, including cytokines and TLR ligands [609]. αδ-dex can also mimic antigen-specific 
stimuli encountered during immune responses to bacterial polysaccharides [610]. Thus, 
αδ-dex is an efficient and potent polyclonal B cell activator. 
6.3.6.2 Experimental Design 
CFSE-labelled PC and splenocytes from BALB/c mice were stimulated with αδ-dex 
(5ng/ml) and IL-5 (150 U/ml) in the presence of anti-CD83 (RAM83) or its control (RANeg) 
at 37°C in 5% CO2 for 6 days or 8 days. At day 6, cells were surfaced stained and 
proliferation assessed by CFSE dilution by flow cytometry. At day 8, culture supernatants 
were collected to analyse Ig expression and isotype switching by ELISA. ELISA plates 
were coated with goat anti-mouse IgG1, IgG3 or IgM (1:2000 dilution) (Sigma-Aldrich, 
USA). The plates were blocked with PBS containing 1% BSA (37°C, 1hr), incubated with 
200 µl PBS, 1% BSA-diluted serum (37°C, 1hr), and incubated with peroxidase-labelled 
goat anti-mouse IgG1, IgG3, or IgM (1:3000 dilution) in PBS, 1% BSA (37°C, 1hr). 
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6.3.6.3 Results 
 
(A) Proliferation of B cells stimulated with αδ-dex and IL-5 
 
 
 
Figure 6-10: RAM83 increased CD19 B-cell proliferation in αδ-dex+IL-5 stimulated 
cultured splenocytes but reduced it in peritoneal cavity cells (representative flow 
cytometry plots are shown in Appendix K). Data points represent means (± SEM 
obtained from at least 6 mice). *p<0.05, RAM83 versus RANeg, Statistical analysis: 2 –
tailed paired student’s t-test (passed normality test; Gaussian distribution) 
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(B) IgM/IgG expression: Isotype switching at day 8 of αδ-dex and IL-5 stimulation 
 
(i) Splenocytes 
 
 
 
Figure 6-11: RAM83 increases IgM, IgG1 and IgG3 expression in αδ-dex+IL-5 
stimulated splenocyte cultures. All results are representative of data obtained from at 
least 6 mice. Data represent mean (± SEM). *p<0.05, NIL versus NIL+ αδ-dex+IL-5, 
RAM83 versus RANeg. Statistical analysis: 2 –tailed paired student’s t-test (passed 
normality test; Gaussian distribution) 
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(ii) Peritoneal cavity 
 
 
 
Figure 6-12: RAM83 decreases IgM and IgG3 expression in αδ-dex+IL-5 stimulated 
peritoneal cell cultures. All results are representative of data obtained from at least 5 
experiments. Data represent means (± SEM). *p<0.05, NIL versus NIL+ αδ-dex+IL-5, 
RAM83 versus RANeg. Statistical analysis: 2 –tailed paired student’s t-test (passed 
normality test; Gaussian distribution) 
 
Anti-CD83 RAM83 significantly increased CD19 B cell proliferation in cultured 
splenocytes but decreased it in cultured peritoneal cavity cells  (Figure 6-10). The majority 
of B cells in spleen are FO- and MZ B cells, whereas in PC they are predominantly B-1 
cells. The B cell subsets primarily involved in TI responses are B-1 and MZ B cells. My in 
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vitro results suggest that, in vivo, splenic B cells (presumably MZ B cells) account for the 
enhanced response to TNP-Ficoll immunization in mice treated with anti-CD83 antibody. 
 
Anti-CD83 significantly increased IgM expression in αδ-dex+IL-5 stimulated 
splenocyte cultures, as were IgG1 and IgG3 (Figure 6-11). This observation is consistent 
with the increased proliferation of B cells observed on day 6 (Figure 6-10). In contrast, 
anti-CD83 significantly decreased IgM and IgG3 in similarly treated peritoneal cavity cell 
cultures (Figure 6-12), consistent with the reduction of B cell proliferation observed on day 
6 for these cells (Figure 6-10). 
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6.4 Discussion 
 B cell responses are classified as TD and TI based on the requirement for T cell 
help in antibody production [611]. Vaccines made from protein antigens (TD antigens) 
have been very successful in the induction of protective immune responses. In contrast, 
the development of protective vaccines against bacterial pathogens carrying 
polysaccharide capsules (TI-2 antigens), such as S. pneumoniae, H. influenzae or 
Neisseria meningitides, has encountered many difficulties in the past, including low 
immunogenicity in children under 2 years and poor induction of memory responses in the 
elderly [170]. Kretschmer et al. in 2009 showed in mice that anti-CD83 enhances IgG 
responses to the model TI-2 antigen NIP-Ficoll [23]. This stimulated our interest in 
investigating the potential use of anti-CD83 with TI-2 vaccines.  I further characterized the 
effect of anti-CD83 on murine TD and TI-2 humoral immune responses to model antigens 
and I tested its effect on the murine response to the clinically relevant TI-2 vaccine 
Pneumovax-23. 
 
6.4.1 Anti-CD83 greatly enhanced IgG responses to TNP-Ficoll immunization 
 My in vivo results demonstrated that RAM83 greatly enhanced all IgG isotype 
responses, especially IgG1 and IgG3 in immunocompetent BALB/c mice immunized with 
TNP-Ficoll. This is consistent with the findings reported by Kretschmer et al. in 2009, 
which showed that anti-CD83 mAb strongly boosted the IgG1 response to NIP-Ficoll 
immunization [23]. They concluded that the engagement of CD83 on B cells but not DC 
mediates the increased NIP-specific IgG1 response, because anti-CD83 mAb treatment 
had no effect in mice with CD83 deficient B cells but normal DC.  
 
As TNP-Ficoll is a model TI-2 antigen, I also tested in mice if anti-CD83 also boosts 
IgG immune responses to the clinically relevant TI-2 vaccine Pneumovax-23. I found that 
anti-CD83 only weakly enhanced IgG responses in Pneumovax-23 immunized mice, in 
contrast to the very strong enhancement I found for TNP-Ficoll immunization. The 
immunogens were the only difference in these two experiments as the same mouse strain 
and antibody (RAM83) were used.  A possible explanation is suggested by a study from 
the  Snapper laboratory in 2005 [612], in which they observed that immune responses to 
PPS are dependent on the presence of TLR ligands that co-purify with the PPS. 
Furthermore, according to a recent study, TLR agonists generated long-lasting anti-
pneumococcal humoral immunity in response to a plain polysaccharidic vaccine provided 
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administration was delayed until the second day after PPS vaccination [613]. TLR 
agonists, including Poly I:C (TLR3) and LPS (TLR4) upregulate CD83 expression on DC in 
mice [614]. LPS is also reported to increase CD83 expression on B cells [10, 24]. In 
chapter 4, my results showed that LPS treatment upregulated CD83 expression on DC 
and B cells in mice.  In conclusion, while TNP-Ficoll and Pneumovax-23 are both TI-2 
antigens, differences in composition, including presence of co-purifying TLR agonists, 
and/or structure which affect immunogenicity may account for the differential sensitivity to 
anti-CD83.  
 
 In immunization, experiments with the model TD antigen TNP-KLH I found that anti-
CD83 had only small effects on antibody responses in BALB/c mice, reducing TNP-
specific IgM on day 7 and increasing TNP-specific IgG on day 14. My data is similar to that 
of Kretschmer et al., who found that anti-CD83 mAb had no effect on the DNP-specific IgG 
response in C57BL/6 mice immunizaed with the TD antigen DNP-KLH (2,4-dinitrophenol-
conjugated KLH) [23]. These murine findings contrast strongly with my human data in 
chapter 5, which shows that anti-human CD83 reduced TT-specific IgG responses in TT 
(TD recall antigen) immunization in vivo (xenograft model). Also, in vitro, anti-CD83 
inhibited B- and CD4 T-cell responses in TT-stimulated cultures.  
 
I found that CD83anu/anu C57BL/6 mice had reduced antigen specific IgG responses 
to TI-2 and TD immunization. In TD, this may be explained by the reduced numbers of Th 
cells in these mice. Similar findings were also reported by Fujimoto et al. (2002), showing 
that CD83-/- mice had a reduced humoral immune response to challenge with a TD antigen 
(DNP-KLH) [8]. As noncognate T cell help has recently been suggested to be involved in 
TI-2 immune responses [167]  the reduced number of Th cells may affect the TI-2 immune 
responses in CD83anu/anu mice compared to WT mice. This is supported by my study, in 
which TI-2 immunized CD83anu/anu mice had reduced antigen specific IgM and IgG 
responses. Also, the reduction in response may be due to low MHCII and CD86 in the 
absence of CD83 [34]. Antigen-specific IgA was unaffected by anti-CD83 in both TI-2 and 
TD immunization. 
 
As I mentioned earlier in the Results section, anti-CD83 antibody treatment does 
not mimic the effects of CD83 deficiency on TD and TI-2 immune responses. Even though 
Th cells are classically not required in TI-2 immune responses, the potent anti-CD83 
antibody induced stimulation of class switched TI-2 antigen specific antibody may involve 
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CD4 Th cells. It has already been shown that TI-2 antigens do not bind MHCII molecules 
like TD antigens [178], excluding the possibility of a MHCII-T-cell receptor interaction. It is 
still largely unanswered how the T cell can influence B cell responses to TI-2 antigens. It 
has been proposed that CD1, including CD1d in mice and human, which shows striking 
similarities to MHCI proteins, can present carbohydrates such as α-galactoslyceramide (α-
GC) to T cells [179-182]. The BCR is specific for the carbohydrate antigen, but uptake of 
α-GC leads to CD1d-dependent natural killer T cell (NKT) activation [615]. A similar 
mechanism may be involved in anti-CD83 stimulated IgG responses to at least some TI-2 
antigens. The Lang group in 2006 observed that co-administration of NP-Ficoll and α-GC 
to C57BL/6 mice led to modest CD1d/NKT-cell dependent antibody class switching, 
whereby IgG1 was produced in addition to IgM and IgG3 [616]. In the same study, IgG1 
was not observed in CD1d-/- mice or in the absence of α-GC. More recently, Bai et al., 
2013 immunized mice with liposomes presenting S. pneumoniae-derived capsular 
polysaccharide and α-GC and observed isotype switching, antibody affinity maturation and 
B-cell memory. The responses was reversed with conditional ablation of CD1d+/+ B cells in 
the experiments [617]. Taken together, we could conclude that CD1d-dependent B cells or 
NKT cells may be involved in the TI-2 immune response in my anti-CD83 studies.  
 
Other candidates via which T cells could be activated in TI-2 immune responses are 
the TLRs (TLR2, TLR3, and TLR9) expressed by B cells which can induce expression of 
costimulatory molecules and production of cytokines by T cells [618, 619]. However, 
although TLR agonists may be involved in the Pneumovax-23 vaccine, there are no 
reports, and it seems unlikely, that they contaminate synthetic model antigens such as 
TNP-Ficoll. Therefore TLRs would not account for the strong response to TNP-Ficoll in the 
presence of anti-CD83 treatment.  Others have suggested T cells can be recruited directly 
by multivalent TI-2 antigens without the requirement of MHC-restricted antigen 
presentation or that B cells would recruit T cells without TCR triggering [129, 620, 621]. 
Apart from this, a possible mechanism might involve IFN-γ expression by NK cells or 
macrophages [609, 622] activated via CD16a or other FcR by anti-CD83 on target cells, as 
it has been shown that IgG switching is stimulated by IFN-γ [623].  
 
In summary, it is possible that the means by which anti-CD83 enhances TI-2 IgG 
responses may involve one or more factors, including the indirect involvement of Th cells, 
CD1d-dependent B/NKT cell interactions, TLRs and cytokine secretion by NK cells or 
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macrophages, or a direct effect (unknown mechanism) of anti-CD83 on the TI-2 antigen 
activated CD83+ B cells. 
 
6.4.2 In vitro effect of anti-CD83 on murine TI-2 antibody responses 
Antigen specific IgG, but not IgM, responses to immunization with the model TI-2 
antigen TNP-Ficoll were strongly enhanced by anti-CD83 treatment (Figure 6-6) and 
Kretschmer et al., 2009 [23]. However, in vitro, B cell proliferation stimulated with the 
surrogate polyclonal TI-2 antigen αδ-dex was inhibited in cultured PC cells but was 
increased in splenocytes treated with anti-CD83. In addition, in splenocytes, anti-CD83 
increased IgM expression as well as isotype switched IgG1 and IgG3. In contrast, in PC 
cell cultures, anti-CD83 reduced IgM and IgG3 expression, presumably due to the 
reduction in B cell proliferation caused by anti-CD83. 
 
B-1 and MZ B cells are the two major B cell subsets involved in TI-2 immune 
responses [189, 624]. In mice, the majority of B cells in PC are B-1 cells, while splenic B 
cells are mostly FO and MZ B-2 cells [169]. B-1a cells outnumber B-1b and B-2 subsets in 
the PC and I showed that a higher percentage of B-1a cells expressed CD83 than any 
other B cell subsets in unstimulated PC cell harvests (Figure 6-1 and 6-2). B-1b cells 
contributed 37% of B cells in PC, and the percentage expressing CD83 was low (Figure 6-
2 (A) and (B)). My in vitro culture experiments with αδ-dex (Figure 6-10, 6-11 and 6-12) 
suggest that TI-2 responsive B cells in the spleen rather than in the PC are stimulated by 
anti-CD83 to expand further and class switch to IgG. Haas concluded that antigen-specific 
B-1b cells are the major B cell population responding to TNP-Ficoll immunization [583]. 
However, in a review by Berland and Wortis, 2002 [169], they noted that B-1 cells 
expressed CD11b in PC but not in spleen. This suggests that CD11b, used by Haas as a 
marker for B-1 cells, may not be useful for phenotyping splenic B cells. Also, CD5, which is 
often used as a distinct B-1a cell marker, can be induced on B-2 cells after in vitro 
activation through the BCR [625] and is expressed by anergic B-2 cells [626]. This may 
further explain why the “Others” population is high in spleen in overnight cultures (Figure 
6-2 (A)). 
 
 Besides B-1b cells, the responding cells to TI-2 antigens in my anti-CD83 treated 
splenocyte cultures may be MZ B cells, although  B-1 B cells have been shown by others 
to confer TI-2 long lasting immunity [122, 583, 584, 596]. Martin et al., 2001 showed that 
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mouse MZ B cells in the spleen are required for immune responses to blood-borne TI 
antigens [104]. In addition to this, in 2008, Matto et al. also proposed that MZ B cells are 
important players in close cooperation with macrophages in the initiation and regulation of 
TI-2 immune responses [627]. This is further supported by Guinamard (2000) [585] and 
Shih (2002) [586], who showed that MZ B cells are the major B cells producing antigen-
specific IgM and IgG3 to TI-2 immunization Therefore, MZ B cell in spleen may share an 
important role with B-1b subsets in TI-2 immunization. Thus, the B cell subsets that 
respond to anti-CD83 in TI-2 immunization remains undetermined at this stage. It is 
important to identify the B cell subsets with more appropriate phenotypical markers in the 
future to confirm which B cell subsets are targeted by anti-CD83 to enhance TI-2 immune 
responses. It has been shown that advanced age contributes to alterations in the B-cell 
compartment [628, 629]. Haas et al., 2014 showed that there is an enhanced capacity for 
PPS-specific B-1b cells in aged mice to expand, class/isotype switch, and produce 
antibody in response to pneumovax vaccination [584]. Nonetheless, the impact of aging on 
the frequency and functionality of distinct B cell subsets, including antigen-specific B-cell 
responsiveness is unclear [584]. Overall, the role of TLR agonists and the mechanisms by 
which B cells regulate bacterial polysaccharide-induced responses are still largely 
unknown.  
 
In summary, my data in this chapter showed that CD83 antibody can have strong 
effects on TNP-Ficoll responses despite its weak effect on Pneumovax-23 vaccination. As 
my in vitro results demonstrated that αδ-dex stimulated B cells from spleen and PC 
respond very differently to anti-CD83, it is important to determine the contribution of the 
different B cell subsets to the TI-2 stimulatory effects of anti-CD83. Also, isolating specific 
B cell subsets and transplanting into B cell deficient mice should be done in future 
experiments. This will give us a better understanding of how TI-2 vaccine responses can 
be improved. 
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Chapter 7: Conclusions and Future Directions 
 
 Numerous studies in the past two decades have demonstrated that CD83 is an 
important modulator of the immune system and is likely to be a target for immunotherapy. 
Notwithstanding, CD83 remains a mystery molecule as no ligand has been confirmed to 
date, despite a number of reports, and its actions at the molecular level have barely been 
described. To uncover the potential for therapeutic targeting of CD83+DC, our laboratory 
developed anti-human and anti-mouse CD83 antibodies and investigated the effects and 
mechanisms of action of anti-CD83 Ab in mouse and human experimental systems. 
Previously, our laboratory had shown that anti-CD83 depletes CD83+ DC by NK cell-
mediated ADCC [83] and, in a xenograft model, limits the uncontrolled proliferative 
response that characterizes GVHD but preserves the donor T cell repertoire, especially 
potentially life-saving anti-viral memory T cells and anti-leukemic T cells [81]. Also, rabbit-
anti-mouse anti-CD83 conferred a survival advantage to allogeneic HSCT recipients in two 
murine models of GVHD (manuscript in preparation). However, we were unable to show 
that NK-mediated ADCC induced by anti-CD83 was involved in delaying acute GVHD in 
these models. This led me to investigate in chapter 4 of this thesis, another potential 
mechanism of action; one suggested by the work of Tze et al. [34], who showed that CD83 
impairs MHCII and CD86 ubiquitination and degradation on DC and B cells. 
 
I tested the hypothesis that anti-CD83 antibody, perhaps mimicking a CD83-ligand, 
enhances degradation of MHCII and CD86 on activated APC resulting in reduced T-cell 
activation and attenuated GVHD.  Based on the experimental approaches that I used in 
this study, however, I could not demonstrate that anti-CD83 increased MHCII 
ubiquitination. The transient transfections that I used could not provide sufficiently stable 
expression of CD83, and MHCII, and therefore did not allow quantitative assessment of 
the effect of anti-CD83 on MHCII ubiquitination. In order to perform a proper investigation, 
stable transfected cell lines are recommended in future experiments. Also, my experiments 
in this study did not show that anti-mouse CD83 induces a statistically significant  
reduction of CD4 T cell proliferation in an alloMLR and OVA stimulation assays, surrogates 
of alloHSCT- and antigen-specific T cell responses, respectively. Although I could not 
prove that the anti-CD83 induced downregulation of MHCII was linked to increased 
ubiquitination in the murine system, we cannot rule out this potential mechanism of action. 
Biological function is not required to be fully elucidated for a molecule such as CD83 to be 
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used as a therapeutic target, nor is drug mechanism of action, as exemplified by the CD52 
targeting mAb alemtuzumab and the CD20 targeting mAb rituximab [371, 506, 630, 631]. 
However, finding the mechanisms of action is important because we can use that 
information to design more effective drugs to improve alloHSCT which is already an 
indispensable approach to therapy.  
 
Over the last decade, T cells, DC and macrophages have been implicated as key 
regulatory cells of the innate and adaptive immune responses. B-cells have been almost 
forgotten in this discourse. However, the advent of B-cell depletion therapies, originally 
developed against B cell malignancies, has changed the way we see the role of the B-cell 
in the immune response.  Observations from the clinical use of agents such as anti-CD20, 
rituximab, have resulted in the recognition that B cells play extremely important effector 
and regulatory roles, such as antigen presentation on MHCII and cytokine expression, in 
addition to antibody production.  B-cell depletion using rituximab is useful for the treatment 
of autoimmune diseases such as RA and SLE and also to prevent antibody mediated 
transplant rejection. Nevertheless, the major side effects of this therapy are the risk of 
severe infections, infusion reactions, and hypogammaglobulinemia [369]. Therefore, there 
is an urgent need to develop new drugs that better target pathogenic B cells rather than all 
B cells to overcome the current drug shortcomings and provide better treatments for 
patients with these conditions.  
 
A previous group member had shown that anti-CD83 inhibits Ig expression by 
human PBMC and depletes purified activated CD83+ B cells by NK cell mediated ADCC, 
leaving resting B cells untouched;- which is a key advantage over rituximab. In chapter 5, I 
extended these preliminary observations. My most exciting in vitro findings, show for the 
first time that anti-CD83 antibodies, again in contrast to rituximab, simultaneously inhibit 
specific antigen stimulated CD4 T- and B-cell proliferation, leaving resting CD4 T and B 
cells untouched. In addition to this, I showed that anti-CD83, but not rituximab, reduced the 
expression of pro-inflammatory, autoimmune disease- and transplant rejection-associated 
cytokines, including IFN-g, GM-CSF and IL-17A. In vivo, in TT immunized hu-SCID mice, 
anti-CD83 inhibited TT-specific IgG production without impacting total circulating human 
IgG levels. Taken together, this strongly supports our contention that anti-CD83 depletes 
activated CD83+ B-cells in addition to activated CD4 T cells and DC, whilst sparing resting 
B cells. Activated B cells, activated CD4 T cells and activated DC all play key roles in 
autoimmunity and graft rejection. Therefore, anti-CD83 antibody may be a novel and 
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useful approach to treating or preventing these conditions with the added advantage of 
maintaining pre-existing immunity to infection. However, to demonstrate this, we need to 
do further testing using appropriate disease models and characterize outcomes in detail, 
particularly cytokine expression, effects on immunity to infection and effects on immune 
regulation.  
 
Overall in chapter 5, anti-CD83 may have immunosuppressive properties in which 
pre-existing immunity to infection is not impaired, potentially benefitting patients with some 
autoimmune diseases such as RA and SLE, or transplant patients at risk of antibody 
mediated rejection. The prime target cells of anti-CD83 co-express MHCII, therefore 
conditions mediated by activated DC and B cells and down-stream effector cells such as 
CD4 T cells can be expected to be targeted, including those conditions I have already 
discussed, but perhaps also chronic GVHD, allergy and myasthenia gravis.  Current 
immunosuppression strategies to prevent allograft rejection have substantial drawbacks, 
including chronic toxicities associated with calcineurin inhibitor-based regimens that 
increase morbidity and mortality, including increased cardiovascular disease [632-634] and 
allograft failure [635]. My studies in chapter 5 strongly support the contention that anti-
CD83 may be an alternative therapy for the discussed conditions. However, there are 
other potential new antibody drugs with effects that at least partially overlap with those of 
anti-CD83. For example, milatuzumab, the first humanized anti-CD74 antibody that is 
currently being developed for the treatment of relapsed or refractory B-cell malignancies 
[636-638]; an anti-HLA-DR mAb that prevents GVHD [639]; an anti-CD79 mAb that targets 
the B cell Ag receptor and ameliorates lupus-like syndrome [640, 641] and the nti-
BAFF/BLyS mAb belimumab that depletes activated and naive B cells as well as plasma 
cells but not memory B cells, recently approved to treat SLE patients [642-645]. Similar to 
anti-CD83, anti-CD74 and anti-HLA-DR also target all APC, which includes monocytes, 
macrophages, and DC, in addition to B cells [639, 646, 647]. More recent preclinical 
studies have demonstrated that anti-CD74 antibody is capable of modulating human B-cell 
proliferation, migration, and adhesion molecule expression [648, 649] suggesting that this 
antibody also may be effective in the therapy of autoimmune diseases. Soluble CD83, 
which has immunoinhibitory properties, is reported to improve colitis [650], EAE [17] and 
lupus [39] in experimental murine models. If anti-CD83 has any advantage over other 
APC-targeting antibodies it might be that it does not deplete non-activated DC [83] which 
have beneficial immunoregulatory functions nor resting B cells (chapter 5). 
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To generate vaccine-mediated protection is a complex challenge. Therefore, we 
need to continue to search for better approaches to make it successful. Studies using anti-
CD83 have been shown to enhance IgG responses to the model TI-2 antigen NIP-Ficoll in 
mice [23]. In Chapter 6, my hypothesis was that anti-CD83 would similarly stimulate IgG 
responses to the TI-2 vaccine Pneumovax-23 in mice. A key finding of this chapter is that 
anti-CD83 strongly enhanced antibody responses, in a different strain of mouse, to a 
different haptenated model TI-2 antigen (TNP-Ficoll) yet had a minimal effect in 
Pneumovax-23 immunization. My in vitro results in this study demonstrate that splenic 
rather than PC cells might be the target of anti-CD83 in TI-2 immune responses, even 
though TI-2 responding B-1 cells predominate in the PC. I also confirmed that CD83 
deficient (CD83anu/anu) mice had impaired TD antibody responses and showed for the first 
time that TI-2 responses were also impaired, compared to WT mice. Thus, anti-CD83 
antibody treatment does not mimic the effects of CD83 deletion on TD and TI-2 immune 
responses, which has not been shown before. As I mentioned in section 6.3.2.3, CD83 
gene deletion causes CD4 T cell deficiency. Classically, CD4 T cell help is not required for 
TI-2 responses. However, my results demonstrate that the potent anti-CD83 antibody 
enhanced stimulation of class switched TI-2 antigen specific antibody may involve CD4 T 
cells. Further work which involved the role of CD4 T cells is required to understand the 
mechanism of this phenomenon. 
 
Until we understand and confirm the mechanism by how anti-CD83 exerts its 
enhancing effects in antibody responses to TI-2 antigen, it is difficult to predict its future as 
a reliable antibody to enhance TI-2 vaccination. The main question lying behind this study 
is how to translate the TI-2 immune response to human. As reported in this thesis, anti-
human CD83 antibody inhibits TD, but anti-mouse CD83 stimulates TI-2 immune 
responses. However, I have to note that both anti-human and anti-mouse CD83 antibodies 
delay or prevent GVHD in xeno-human [81] and fully murine models (manuscript in 
preparation), respectively. This suggests that anti-CD83 may generate similar TI-2 
responses in humans, although I have not tested it in a human system. Therefore, future 
experiments, using anti-human αδ-dex as an in vitro model TI-2 antigen, may provide us 
with a preliminary indication on how anti-CD83 affects the TI-2 immune responses in man. 
Also, using a human PBMC engrafted xenogeneic SCID model, we can determine the 
effect of anti-human CD83 antibody to TI-2 antigens such as capsular polysaccharides in 
vivo [651-654]. However, it is obviously a big challenge ahead as there is significant 
difference between mouse and man. It is possible that any given response in a mouse 
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may not occur precisely the same way in humans. Mestas and Hughes highlight and 
emphasize the differences between mouse and human immunology and warn the 
researcher to take this into account when making assumptions if a drug works in mouse 
model [655], as many treatments that work in mice do not always translate into effective 
human therapies [656, 657]. It is therefore essential that further work be done using 
appropriate models to understand how anti-CD83 might be used to enhance clinically 
relevant TI-2 antibody responses in man.  
 
 In conclusion, we need to continue to investigate the mechanism of action of anti-
CD83 in the murine models, to provide additional insights into GVHD prevention where 
APC and T cells are involved. The data presented in chapters 5 and 6 of this thesis have 
provided valuable insights into how anti-CD83 can affect humoral immunity. The 
observations in this study highlight differences between mouse and man in terms of 
immune responses. Much more research is clearly necessary to elucidate the mechanism 
behind the inhibition and also stimulation of antibody responses in mice and humans. This 
project has taken the first step towards identifying the potential of anti-CD83 for 
manipulating humoral immunity, particularly for the treatment of autoimmune disease, 
transplant rejection, and possibly to enhance TI-2 vaccine responses. There are certainly 
significant opportunities for anti-CD83 to be developed as a novel immunosuppressive 
therapy and perhaps to boost TI-2 vaccine responses that would further improve the 
quality of life and reduce morbidity in relevant conditions.  
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Appendix D 
 
 
Figure D: Representative flow cytometry plots (for data summarized in Figure 5-2) of 
CD4 and CD19 cells gated from live cells. Proliferated cells = CFSEdim gated as 
shown. 
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Appendix E 
 
 
Figure E: Representative flow cytometry plots show the effect of anti-CD83 3C12.C 
IgG1, 3C12.C IgG4 and hIgG1 negative control on TT stimulated proliferation of CD4 
T-cells and CD19 B cells in PBMC from the same donor as described in Section 
5.3.1.3. 
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Appendix F 
 
Figure F: Representative flow cytometry plots (for data summarized in Figure 5-5) of 
TT stimulated CFSE labelled PBMC treated with anti-CD83 or negative control 
antibody for IFNγ, IL-17A, IL-10 and TNF-α expressing total CD4 T cells. The gates 
were defined by a matched isotype negative control fluorophore conjugated mAb 
for each cytokine (IgG2a-APC shown for IL-10).  
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Appendix G 
 
Figure G: Gating strategy and representative flow cytometry plots (for data 
summarized in Figure 5-6) showing CD83 expressed on B cell subsets in PBMC 
cultured for 24 hours in 10%FCS/RPMI. 
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Appendix H 
 
Figure H: Representative flow cytometry plots (for data summarized in Figure 5-8) 
showing CD83 expression by CD19 B cells in a freshly isolated human PBMC 
sample before culture. CD83 expression was determined relative to the FMO 
negative control. There were 6.71% CD19 B cells in the live cell gate and 0.67% of 
them expressed CD83. 
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Appendix I 
 
Figure I: TNP specific serum IgG levels in BALB/c mice immunized with 25 µg TNP-
Ficoll and treated with anti-CD83 (RAM83 or Michel-19) or control antibody (RANeg 
or Rat IgG1). Data points represent means (± SEM) (n=3/group, except RAM83, n=1).  
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Appendix J 
 
Figure J: TNP specific serum IgG levels in BALB/c and C57BL/6 mice immunized 
with 25 µg TNP-Ficoll and treated with anti-CD83 (RAM83 or Michel-19) or control 
antibody (Rat IgG1). Data points represent means (± SEM) (n=3/group, except 
RAM83, n=1).  This figure and Figure I contain data from two different experiments 
done at different times.  
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Appendix K 
 
 
 
 
Figure K: Representative flow cytometry plots (for data summarized in Figure 6-10) 
showing the effects of anti-CD83 (RAM83) compared to negative control antibody 
(RANeg) on proliferation of CD19 B cells in αδ-dex+IL-5 stimulated (6 days) CFSE 
labelled spleen (SP) and peritoneal cavity (PC) cells as described in Section 6.3.6. 
